Proteomic studies of human placentas reveal partnerships associated with
 preeclampsia, diabetes, gravidity, and labor

3

4 Shannon J. Ho<sup>1,10</sup>, Dale Chaput<sup>2,10</sup>, Rachel G. Sinkey<sup>1</sup>, Amanda H. Garces<sup>3</sup>, Erika P.

5 New<sup>1</sup>, Maja Okuka<sup>1</sup>, Peng Sang<sup>4</sup>, Sefa Arlier<sup>1</sup>, Nihan Semerci<sup>1</sup>, Thora S. Steffensen<sup>5</sup>,

6 Thomas J. Rutherford<sup>1,6</sup>, Angel E. Alsina<sup>7</sup>, Jianfeng Cai<sup>4</sup>, Matthew L. Anderson<sup>1,6</sup>,

7 Ronald R. Magness<sup>1</sup>, Vladimir N. Uversky<sup>8</sup>, Derek A. T. Cummings<sup>9</sup> & John C. M.

8 Tsibris<sup>1,8</sup> <sup>⊠</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, University of South Florida, Tampa, Florida,
 USA. <sup>2</sup>Department of Cell Biology, Microbiology and Molecular Biology, University of South

Florida, Tampa, Florida, USA. <sup>3</sup>Lisa Muma Weitz Microscopy Laboratory, University of
South Florida, USA. <sup>4</sup>Department of Chemistry, University of South Florida, Tampa,
Florida, USA. <sup>5</sup>Department of Pathology, Tampa General Hospital, Tampa, Florida, USA.
<sup>6</sup>Cancer Center, Tampa General Hospital, Tampa, Florida, USA. <sup>7</sup>Transplant Surgery
Center, Tampa General Hospital, Tampa, Florida, USA. <sup>8</sup>Department of Molecular
Medicine, University of South Florida, Tampa, Florida, USA. <sup>9</sup>Department of Biology and
Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA. <sup>10</sup>These authors

- 18 contributed equally. <sup>™</sup>e-mail: tsibris@usf.edu
- 19

20

21

23 Abstract

24

25 VEGFR2 is a central regulator of placental angiogenesis. The study of the VEGFR2 proteome of chorionic villi at term revealed its partners MDMX and PICALM. The 26 27 oxytocin receptor (OT-R) and vasopressin V1aR receptor were detected in MDMX and PICALM immunoprecipitations. Immunogold electron microscopy showed 28 29 VEGFR2 on endothelial cell (EC) nuclei, mitochondria, and Hofbauer cells (HC), the 30 tissue-resident macrophages. MDMX, PICALM, and V1aR were on EC plasma 31 membranes, nuclei, and HC nuclei. Unexpectedly, PICALM and OT-R were detected on EC projections into the fetal lumen and OT-R on 20-150 nm clusters therein, 32 33 prompting the hypothesis that placental exosomes transport OT-R to the fetus and across the blood-brain barrier. Insights on gestational complications were gained 34 35 by univariable and multivariable regression analyses associating preeclampsia with 36 lower MDMX protein levels in membrane extracts of chorionic villi, and lower MDMX. 37 PICALM, OT-R, and V1aR with spontaneous vaginal deliveries compared to cesarean deliveries before labor. We found select associations between higher 38 39 MDMX, PICALM, OT-R and either gravidity, diabetes, BMI, maternal age, or neonatal weight, and correlations between PICALM-OT-R (p<2.7x10<sup>-8</sup>), PICALM-V1aR 40 (p<0.006), and OT-R-V1aR (p<0.001). These results offer for exploration new 41 42 partnerships in metabolic networks, tissue-resident immunity, and labor, notably 43 for HC that predominantly express MDMX.

44

The placenta is a transient organ that performs the functions of major organs of the fetus, such as lungs, liver, and kidney<sup>1</sup>, supplies the fetus and in particular the fetal brain with oxygen and nutrients, and facilitates waste disposal and provides immune protection<sup>2,3</sup>. The genomes of placenta and fetus are identical except in cases of confined placental mosaicism. The vascular endothelial growth factor A (VEGF-A) is a key regulator of vasculogenesis, angiogenesis and placental growth that acts mainly through VEGFR1 and VEGFR2, two tyrosine kinase single-pass transmembrane receptors<sup>4-6</sup>.

53 Preeclampsia is a serious complication of human pregnancy occurring in 5-7% of 54 all gestations with newly-onset hypertension and proteinuria as its primary clinical 55 characteristics<sup>2,7</sup>. Preeclampsia is a multisystemic syndrome of different subtypes 56 associated with serious health problems to mother and child even after pregnancy<sup>8</sup>. Lipid 57 bilayer-enclosed extracellular vehicles (EV) transport extracellular nucleic acids, proteins, lipids, and metabolites<sup>9-12</sup>. Cancer cells deploy EV to activate VEGF signaling in 58 59 endothelial cells<sup>12</sup>. Exosomes are EV measuring 20–150 nm in diameter. Placental-60 derived exosomes released in the maternal circulation are associated with pregnancy 61 disorders and parturition<sup>11</sup>.

62 Tissue-based maps of the human proteome of many organs, including placentas, have been published,<sup>13-16</sup> but great challenges remain to discover which among the 63 64 hundreds of detected proteins regulate key metabolic networks, specifically, during normal 65 and complicated pregnancies and labor. To obtain such information, we chose to 66 immunoprecipitate VEGFR2, an ideal target as an extensively documented regulator of 67 placental angiogenesis. To deploy a wide net for the membrane partners of VEGFR2, we 68 analyzed the pellets obtained after high-speed centrifugation of chorionic villi 69 homogenates. Uterine blood in the maternal intervillous space exchanges substances with 70 fetal blood at the villous tree. Although the villi are physically separated from uterine 71 blood<sup>1,3</sup>, the pellets contain cells and EV from it. To preserve protein complexes, we 72 extracted the pellets with ASB-14 (amidosulfobetaine-14), an efficient non-denaturing 73 detergent. The extracts were immunoprecipitated with the bait antibody (Ab) charged on 74 magnetic beads knowing that extraction of membrane proteins from their native 75 environment could alter their structure and protein links. Mass spectrometry identified 76 proteins immunoprecipitated with VEGFR2, especially its newly discovered placental

partners, the multifunctional MDMX (Double minute 4 protein) and PICALM(Phosphatidylinositol-binding clathrin assembly protein).

79 MDMX, also known as MDM4 and HDMX, is a zinc-binding protein and a p53 80 inhibitor acting in coordination with MDM2, a zinc-dependent E3 ubiguitin ligase<sup>17</sup>. MDMX 81 and MDM2 have numerous p53-independent activities. In preeclampsia, p53 is 82 upregulated in villous trophoblasts<sup>18</sup>. PICALM is a nuclear and plasma membrane protein 83 that interacts with phosphatidylinositol to recruit clathrin and adaptor protein-2, initiates 84 endocytosis of clathrin-coated vesicles, internalizes ligand-receptor complexes, and participates in iron and cholesterol homeostasis<sup>19,20</sup>. PICALM is a genetic risk factor for 85 86 late-onset Alzheimer's disease that participates in amyloid-β transcytosis and processing 87 of amyloid precursor protein (APP). Human placentas express APP and APP-processing 88 enzymes which are increased in preeclampsia<sup>21</sup>. Oxytocin is a hydrophilic neuropeptide 89 and Pitocin, a synthetic oxytocin, is prescribed in the USA to induce labor and decrease 90 postpartum hemorrhage. The oxytocin receptor (OT-R, OXTR) is a magnesium-dependent 91 G protein-coupled receptor<sup>22</sup> that activates a phosphatidylinositol-calcium second 92 messenger system<sup>23</sup>. OT-R participates in numerous activities ranging from parturition to 93 lactation and mother-child bonding<sup>22,23</sup>. OT-R functions as a homodimer and in heterocomplexes with vasopressin receptors V1aR (AVPR1A)<sup>24</sup>, V2R, and other 94 95 receptors. V1aR is the most abundant among vasoactive receptors in human arteries<sup>25</sup>.

96 Here, among the newly detected partners of VEGFR2 we focused on MDMX and 97 PICLAM based on their documented biochemical functions, and their partners OT-R and 98 V1aR. Finding OT-R in exosome-size clusters in the fetal lumen led to the hypothesis that 99 placental OT-R is carried to the fetus in exosomes, potential transporters of future 100 therapeutic agents. MDMX, PICALM, OT-R, and V1aR protein levels, estimated by 101 western blots and relative to an internal control sample, were associated with clinical 102 characteristics of the 44 patients we studied. Potential insights on the molecular 103 mechanisms of placental MDMX and PICALM were gained, respectively, from the cancer 104 and Alzheimer's disease literature.


105

106 Results

107 **Immunoprecipitations (IP).** Key prerequisite for this study was that VEGFR2 protein 108 complexes withstood tissue freezing and extraction by ASB-14. Since Blue-Native 109 electrophoresis (BN) resolves protein mixtures under non-denaturing conditions, we 110 fractionated placental extracts by BN followed by VEGFR2 immunostaining which 111 revealed streaks extending up to 800 kDa. VEGFR2 monomers appear at 220 kDa in 112 western blots. Apparently, ASB-14 stabilized the extracted protein complexes of VEGFR2. 113 Several proteins described in this study were efficiently extracted by ASB-14 (see 114 Methods). New VEGFR2 partners, MDMX and PICALM, were also selected for IP.

115 Fig. 1 shows western blots of the fractions eluted from the magnetic beads and 116 used to select the fraction for mass spectrometric analysis. Representative fractions are 117 identified by the patient's assigned letter-number code shown on Table 1. Magnetic beads 118 retained all of the applied VEGFR2 (A) as none was detected in the flow-through fraction, 119 but the MDMX and PICALM antibodies charged on the beads retained only a fraction of 120 their target protein as shown, respectively, in **E** and **F**. All target proteins were greatly 121 enriched in the eluted fraction-E relative to the applied placental extract, fraction-X. OT-R 122 co-immunoprecipitated with MDMX (G, right side) and with PICALM (G, left side), but not 123 with VEGFR2 (D). V1aR co-immunoprecipitated with MDMX (H, left side) and with 124 PICALM (H, right side), but not with VEGFR2 (C). Eluted MDMX appeared smaller in the 125 VEGFR2 IP (B) and MDMX IP (E), whereas PICALM (F), OT-R (G) and V1aR (H) 126 appeared larger. The size of eluted VEGFR2 was the same as in the extracts (A).

- 127
- 128
- 129
- 130
- 131
- 132
- ...
- 133



134

135 Fig. 1. Protein elution profiles in VEGFR2, MDMX and PICALM IP. Detergent-extracted 136 villous sample X was incubated with magnetic bead suspension charged with the target 137 Ab (see Methods). E denotes eluted protein fractions. Western blots detected the target proteins eluted in the uniformly performed IP experiments. A. VEGFR2 in VEGFR2-IP. B. 138 MDMX in VEGFR2-IP. C. V1aR in VEGFR2-IP. D. OT-R in VEGFR2-IP. E. MDMX in 139 MDMX-IP. F. PICALM in PICALM-IP. G. Left-side, OT-R in samples from PICALM-IP, and 140 right-side OT-R in samples from MDMX-IP. H. Left-side, V1aR in samples from MDMX-IP, 141 142 and right-side samples from PICALM-IP. Panel C shows the membrane in B reprobed for 143 V1aR without stripping.

144

146 **Proteomic analysis.** Results of the immunoprecipitations of VEGFR2 (samples O4, O5, 147 07, U1), MDMX (samples 01, 04, 06, Q1, Q4, R4), and PICALM (samples N3, 01, R4, 148 Q1, Q4, U1) are listed in Tables 2-4. The peptide coverage was not consistent among the 149 placental extracts in each immunoprecipitation group due to different clinical 150 characteristics of the patients whose tissues we tested, and potential differences in post-151 translational modifications, such as acetylation, and ubiquitination. Soluble proteins in 152 villous homogenates having an affinity for membrane proteins would be retained on the 153 pellets obtained after centrifugation at 100,000g for 1h.

154 Select proteins that co-immunoprecipitated with VEGFR2 (Table 2). VEGFR2 was 155 retained on the beads by an Ab raised to the cytoplasmic tail of VEGFR2 exposing 156 extracted proteins to its extracellular, VEGF-binding, domain (see Methods). Therefore, 157 most VEGFR2 partners must have interacted, even after VEGFR2 internalization, with its 158 extracellular rather than its intracellular tyrosine kinase domain, and in binary associations 159 while fewer would bind via some intermediate protein partners. In principle, VEGFR2, 160 MDMX, and PICALM isoforms post-translationally modified at the target sequence of the 161 immunoprecipitating antibodies, are unlikely to be retained on the beads. Our experimental 162 design provided only an estimate of peptide levels in each placental sample. Very basic 163 proteins, such as VEGF-A (pl=9.2), were not detected due to excessive trypsin digestion 164 of these mostly intrinsically disordered proteins prior to mass spectrometric analysis. For 165 example, more than 65% of the VEGF-A residues are expected to be disordered. 166 Nevertheless, western blot analysis showed that VEGF-A co-immunoprecipitated in 167 VEGFR2 IP, and that OT-R (pl=9.6) and V1aR (pl=9.5) co-immunoprecipitated in MDMX 168 and PICALM IP. p53 and MDM2 were detected in IP eluates only by western blots. Under 169 our protocol, proteins larger than 220 kDa were, most likely, identified by peptides from 170 their smaller forms in the placenta.

The E3 ubiquitin ligase TRIM21 (tripartite motif-containing protein 21) coimmunoprecipitated with VEGFR2 and in MDMX and PICALM IP (Tables 2-4). TRIM21, a member of the large TRIM family, contains a zinc-binding as well as other motifs. TRIM21 is found in the cytosol and nucleus and is unique among all proteins as the highest-affinity Fc receptor in humans<sup>26</sup>. TRIM21 does not distinguish free from bound antibodies. Another VEGFR2 partner was PDC-E2 (*DLAT*), the E2 component of pyruvate dehydrogenase

(Table 2). The association of PDC-E2 with VEGFR2 probably occurs in the nuclei<sup>27</sup> and 177 178 mitochondria, as discussed later, and is shown in the vasculature of the villi (video). Other 179 VEGFR2 partners were complement components (Table 2) revealing complement 180 activation known to occur in placental dysfunctions<sup>28</sup>. Immunoglobulin heavy constant 181 alpha 1 (*IGHA1*), an autoantibody antigen and signature protein of plasma cells<sup>29</sup>, was 182 among the large amounts of immunoglobulins detected that are carried by placental 183 endothelial cells<sup>30</sup> and maternal blood cells. A smaller than 220 kDa form of the giant 184 protein titin was also detected in VEGFR2 and PICALM IP (Tables 2, 4).


185

186 Select proteins that co-immunoprecipitated with MDMX and PICALM (Tables 3, 4). 187 VEGFR2 was not detected in MDMX and PICALM IP, probably because of the limited 188 binding capacity of the MDMX and PICALM antibody charged on the beads. Among the 189 proteins that co-immunoprecipitated with MDMX were PICALM, annexins, arginase-1, RNA-binding protein HNPNPA2B1<sup>31</sup> and others that immunoprecipitated also in VEGFR2 190 191 and PICALM IP (Tables 2, 4). Protein-glutamine gamma-glutamyltransferase 2 (TGM2). 192 which co-immunoprecipitated with MDMX and PICALM (Tables 3, 4), catalyzes protein 193 cross-linking, is considered a bridge between inflammation and hypertension, and is 194 upregulated in preeclampsia<sup>32</sup>. We indicated in Table 3 the few proteins common in 195 VEGFR2, MDMX and PICALM immunoprecipitations, and many more that co-196 immunoprecipitated only with MDMX, likely members of the HC proteome. After an initial 197 statistical analysis associated MDMX with the mode of delivery, we were prompted to study the OT-R, which is activated in the myometrium causing uterine contractions<sup>22</sup>, and 198 199 its partner V1aR, after validating two commercial antibodies (Figure 10).

200

Immunohistochemistry and whole mount immunofluorescence. VEGFR2 strongly stained the endothelium of the villous capillaries (Fig. 2A). TRIM21 staining is seen in the cytoplasm of villous trophoblasts and stronger staining in intervillous maternal leukocytes (Fig. 2B, arrows). MDMX is predominantly expressed (Fig. 2, C and D) on Hofbauer cells (HC)<sup>33-37</sup> that are targets of Zika and other viruses<sup>38</sup>. Strong MDMX staining was limited to the cytoplasm of HC, easily identified within the villous stroma, some within stromal channels (Fig. 2C). CD163<sup>33,39</sup>, a marker for placental macrophages<sup>40</sup>, stained the

cytoplasm of the HC (Fig. 2D). PICALM showed strong staining of trophoblasts and
syncytiotrophoblasts (Fig. 2E) and on higher power images (Fig. 2F) positive cytoplasmic
staining of the villous capillary endothelial cells was also seen.



211


212 Fig. 2. Immunohistochemical staining of placental sections. A. VEGFR2 213 immunostaining is strongly positive in villous endothelial cells (patient Q3). B. TRIM21 is uniformly positive in villous trophoblast (patient N4). Very strong staining is seen of 214 215 maternal leukocytes (arrows). C. MDMX is strongly positive in the cytoplasm of HC and 216 moderately positive in endothelial cells (patient W2). D. CD163 is strongly positive in the 217 cytoplasm of the HC (patient U1). E. PICALM is strongly positive in the trophoblast (patient 218 R4). F. PICALM positivity seen in the villous endothelial cells and fetal blood leukocytes 219 (patient R4). Magnifications in A-F were 10x, 20x and 40x.

220

The co-localization of VEGFR2 (red) and PDC-E2 (green) in endothelial cells of the villous vasculature of a normotensive patient is shown on the video obtained from reconstructed stacked images of whole mount immunofluorescence. Nuclei were stained blue with DAPI.

224


225 **Immunogold electron microscopy (IGEM).** VEGFR2 was localized along segments of 226 endoplasmic reticulum, and in mitochondria (Fig. 3). MDMX was localized diffusely within 227 the cytoplasm of an HC and was seen clustering in the nucleus and cytosol. Clusters ran 228 along the nuclear membrane and appeared associated with mitochondrial and 229 endoplasmic reticulum membranes (Fig. 4). PICALM was localized to endothelial cell 230 junctions, along endothelial cell plasma membrane, in cytoplasmic projection into the 231 lumen and adjacent stroma and fetal blood (Fig. 5). OT-R was detected in endoplasmic 232 reticulum and cytoplasmic "peninsulas" of endothelial cells extending into the lumen and 233 on clusters (Fig. 6). V1aR was localized to endothelial cell membrane, nucleus, and 234 stroma. V1aR was also seen on a fetal RBC (Fig. 7). Details are seen in Figures 3-7.



#### 235


Fig. 3. Detection of VEGFR2 by IGEM in chorionic villi of placenta Ho-73 236 237 (preeclamptic). A. Top left micrograph shows a villous capillary. P: pericyte, E: RBC, SC: 238 stromal cells. Bottom image details area outlined on the top micrograph and shows 239 endothelial cell (EC) cytoplasm, pericyte (P), tight junction (\*), collagen fibers in villous 240 stroma (VS), and capillary lumen (L). Image at right: Enlargement of area outlined on the 241 bottom left shows VEGFR2 in mitochondria (arrows). B. Micrograph on top left shows 242 villous capillary, stroma (S), luminal RBC (E), and Hofbauer cell (HC). Enlargement of 243 rectangle at bottom shows prominent nucleolus, mitochondria, and endoplasmic reticulum 244 of HC. Micrographs on the right show enlargement of areas outlined on the bottom left


245 micrograph that detail clusters of VEGFR2 (arrows) in the cytosol (C), along segments of 246 endoplasmic reticulum (ER), and mitochondria (M). Enlargement of image at bottom right 247 shows diffuse localization of VEGFR2 clusters throughout the nucleoplasm (arrows). C. 248 Top left micrograph: Villus stroma depicting a fibroblast (Fb), and a pericyte (P) associated 249 with fetal capillary in partial profile, RBC (E), and EC cytoplasm. Bottom left is enlargement 250 of area outlined on the top graph and shows fibroblast cytosol, mitochondria (M), and 251 villous stroma (S). To the right, enlargement of two areas show VEGFR2 in cytoplasm and 252 in partial profiles of mitochondrial matrix (white arrow heads). **D.** A TEM micrograph after 253 osmication provided a better outline of mitochondria in an EC, compared to A, B and C 254 panels. E. Fetal capillaries with luminal RBC (E) are shown in the top left image, IS: 255 intervillous space; mE: maternal RBC. Bottom: enlargement of outlined area shows a fetal 256 macrophage in greater detail; a syncytiotrophoblast (SCT) is also present. Right 257 micrograph: enlargement of area in bottom left micrograph, points to VEGFR2 labelling in 258 an incomplete profile of a mitochondrion. Dashed arrows outline the outer double 259 membrane of the labeled and unlabeled mitochondria. The gold particle diameter is 6 nm.




260

Fig. 4. Detection of MDMX by IGEM in chorionic villi of placentas Ho-71 (normotensive) and Ho-73 (preeclamptic). A. Left micrograph: Nucleus (N) of endothelial cell (EC) from Ho-73. Arrow heads point to small MDMX clusters, parallel to the inner aspect of the EC plasma membrane. Area outlined, top left: EC junction; P: pericyte process; E: RBC in capillary lumen, S: stroma. This area is enlarged on the top right graph and shows MDMX clusters along the junction (Ju), and endoplasmic reticulum 267 (ER). Bottom right: enlargement of outlined area shows diffuse pattern of MDMX clusters 268 throughout the nucleoplasm. B. Top left micrograph shows an outline of apoptotic 269 macrophage in the lumen of fetal capillary (cap) from Ho-71. P: pericyte, F: partial profile 270 of fibroblast (F) and HC partially marked by a white outline. Enlargement on the top right 271 image shows diffuse MDMX localization in the vacuolated cytoplasm of luminal 272 macrophage. Image at bottom left is enlargement of area outlined in white and shows 273 MDMX clustering in the nucleus (N) and cytosol of the HC. Clusters, averaging 50-100 nm 274 in diameter, run along the nuclear membrane and appear to be associated with mitochondrial and endoplasmic reticulum membranes. Bottom right: enlarged area shows 275 276 MDMX clusters of approximately 100 nm. The gold particle diameter is 6 nm.






285 nucleoplasm near chromatin, on EC cytoplasmic membrane (white arrows) and in luminal 286 space (black arrow). C. Top micrograph: HC in stroma of Ho-73. E: RBC in capillary. At 287 bottom: enlargement shows PICALM in HC nucleus (arrows). D. Top micrograph: HC cell 288 in the stroma of placenta Ho-71. Bottom image: enlargement shows PICALM in 289 nucleoplasm in association with chromatin. E. PICALM is shown (arrows) at the junction 290 (Ju), and plasma membrane of EC and in adjacent stroma (S) of fetal capillary from Ho-291 73. F. PICALM is shown (arrows) in cytoplasm and plasma membrane of EC of capillary 292 from Ho-71, and in basal lamina (BL), stroma (S) and capillary lumen. The gold particle 293 diameter is 10 nm.



295


296

Fig. 6. Detection of Oxytocin Receptor (OT-R) in chorionic villi of placentas of 297 normotensive Ho-71, and preeclamptic Ho-73 patients. A. Top IGEM micrograph: 298 299 Villus capillary from Ho-71. P: pericyte adjacent to the endothelial cell (EC); L: lumen. White arrow shows cluster of PICALM on P. Bottom: enlargement shows OT-R in 300 301 endoplasmic reticulum (ER) and cytoplasm projections of EC into the lumen. (arrows). B. 302 Top micrograph: Partial view of villus capillary from Ho73, E: RBC; S: stroma. Bottom 303 graph shows EC junction (J) and OT-R clusters on J, EC cytoplasm, and lumen (arrow). 304 **C.** OT-R is seen in the nucleus of an EC from Ho-73. The gold particle diameter is 10 nm.



305

306 Fig. 7. Detection of Vasopressin Receptor V1aR in chorionic villus of placenta Ho-307 72 (diabetic). A. Composite IGEM image shows nucleus of HC in stroma on the left and enlargements of three demarcated regions of its nucleus on the right. V1aR clusters, 20-308 309 100 nm, in the nucleus are indicated by arrows. **B.** Top micrograph shows EC aspect of a villus capillary. Bottom image is enlargement that shows V1aR on EC membrane, nucleus, 310 311 and stroma (arrows). C. Top micrograph shows aspect of EC of villus capillary; an RBC is 312 seen in the lumen. Bottom image is enlargement that shows several 20-100 nm clusters 313 of V1aR on surface of the RBC (arrows). The gold particle diameter is 10 nm.




314

315 Fig. 8. Transmission electron microscopy of osmicated chorionic villus from 316 placenta Ho-73 (preeclamptic). A. An  $exosome^9$  is shown in the lumen with the 317 characteristic lipid bilayer adjacent to RBC (E). B. A dense particle with a lipid bilayer, 318 perhaps an exomere<sup>12</sup>, is shown in the lumen next to an RBC (E). Scale in A and B is 50 319 µm.

#### 320

321 Statistical analysis of protein levels in placental extracts. To estimate the protein 322 levels of MDMX, PICALM, OT-R and V1aR, we analyzed by western blots 25 µg protein 323 from each of the 44 placental extracts (Table 1). The intensity of the native-protein band, 324 shown at the top of the representative western blots in Fig. 9, is relative to an internal 325 control sample (Q1 or V1) taken as 100% (Table 5). Violin plots show the analysis of the 326 mean protein levels (Fig. 9) among different clinical conditions. Precluded from the 327 statistical analysis were VEGFR2, since its protein levels did not differ significantly among 328 the 44 placentas analyzed in this study, and TRIM21 due to extensive degradation of its 329 native 50-kDa form in our placental extracts.



331

Fig. 9. Representative western blots (A) of MDMX, PICALM, OT-R, and V1aR, and violin plots of their relative protein levels associated with diabetes, gravidity, labor, neonatal weight, preeclampsia, BMI, or maternal age, as indicated in B-E. Western blots show the molecular mass (kDa) and the placental extracts identified by a letternumber code shown in Table 1. Internal control for MDMX and PICALM was sample Q1, and sample V1 for OT-R and V1aR.

Next, we performed univariable and multivariable analyses, shown in Tables 6-12, to test whether the mean protein levels of MDMX, PICALM, OT-R and V1aR, represented by western blot band intensity of placental extracts and relative to an internal reference sample Q1 or T1, varied as a function of maternal age, gravidity, gestational age, body mass index, race, preeclampsia, diabetic status, delivery mode, neonatal sex, and neonatal weight. Preeclamptic patients were compared to non-preeclamptic, and diabetic to non-diabetic patients.

345 Univariable analysis of protein levels. Protein expression units are the percent values
346 relative to an internal control sample taken as 100% (Table 5).

347 MDMX protein levels were associated with diabetes with an increase of 47.63 units 348 (95% CI 14.27, 90.00) among those with Type II diabetes and 47.91 (95% CI 5.51, 90.32) 349 among those with gestational diabetes mellitus (GDM) compared to those without 350 diabetes, and gravidity with an increase of 9.66 (95% CI 3.59, 15.70) with each unit 351 increase in gravidity, neonatal weight (an increase of 0.03 (95% CI 0.01, 0.06) for each 352 increase in grams), and preeclampsia (-44.13 (95% CI -71.63, -16.64). Regarding the 353 mode of delivery, cesarean delivery, CD, prior to the onset of labor was associated with 354 an increase of 56.16 (95% CI 24.13, 88.18) compared to those with SVD. See Table 6 for 355 full results. Recently, CD163 expression in Hofbauer cells was associated with BMI, 356 gravidity, and fetal birthweight<sup>41</sup>.

357 Increased PICALM levels were associated with maternal age with an increase of 358 3.68 (95% CI 0.28, 7.08) in intensity for each year increase, and body mass index with an 359 increase of 2.06 (95% CI 0.66, 3.45) for each unit increase. Regarding the mode of 360 delivery, CD prior to the onset of labor had an increase of 59.96 (19.24, 100.68) compared 361 to those with SVD. See Table 7 for full results.

OT-R protein levels were associated with maternal age, an increase of 1.56 (95% CI 0.13, 2.99) for each year of age, and diabetes with an increase of 24.16 (95% CI 5.47, 42.85) among those with Type II diabetes compared to those without diabetes. Neonatal weight was associated with an increase of 0.01 (95% CI 8.36x10<sup>-4</sup>, 0.03) for each increase in grams. See Table 8 for full results.

367 V1aR protein levels were statistically significantly associated with mode of delivery,
368 CD prior to onset of labor 20.36 (95% CI 10.58, 30.13) compared to SVD. See Table 9 for

full results. No associations were found for race, neonatal sex, or gestational age between35-42 weeks for any outcome.

371

Multivariable analysis of protein levels. A multivariable model considered simultaneously all variables that were statistically significant in univariable analysis. MDMX protein levels showed a statistically significantly association with gravidity 7.19 (95% CI 1.24, 13.14), and preeclampsia -40.61 (95% CI -66.18, -15.04) as shown on Table 10. There were no significant associations for PICALM or OT-R as shown in Tables 11-12. The best fit model for V1aR included only an intercept (no covariate).

To account for the spread in the replicate measurements of MDMX, PICALM, OTand V1aR (Table 5), we carried out the bootstrapping analysis shown in Tables 14-19. The statistical results were robust to bootstrapped resampling (n=1000) of data points included in the analyses.

We also looked at the correlation of MDMX, PICALM, OT-R and V1aR protein levels with each other and found significant correlations between PICALM and OT-R (0.72 95% CI 0.54, 0.84, p<2.7x10<sup>-8</sup>), PICALM and V1aR (0.41 95% CI 0.12, 0.63, p<0.006), and OT-R and V1aR (0.47 95% CI 0.20, 0.67, p<0.001). MDMX was not correlated with PICALM, OT-R or V1aR.

387

### 388 Discussion

389 Mass spectrometry placed VEGFR2, MDMX and PICALM and their partners in the 390 molecular landscape of chorionic villi of placentas at term. The co-immunoprecipitated 391 proteins represent the most prevalent and stable complexes. IGEM provided a detailed 392 map of VEGFR2, MDMX, PICALM, OT-R and V1aR in the villi, and hints about protein 393 traffic, specifically, of placental exosomes transporting OT-R to the fetus. In future studies, 394 IGEM can show if two proteins are within 10-20 Å of each other, with secondary antibodies 395 labeled with gold particles of different size<sup>42</sup>, such as 6 nm and 12 nm, even though larger 396 particles may occasionally eclipse the smaller ones.

A comprehensive statistical analysis of 44 placental extracts associated MDMX,
 PICALM, OT-R and V1aR protein levels with labor at term and a number of clinical
 parameters and gestational complications. Further studies may assign their binary protein

interactions into networks of signaling partnerships among patient groups with normal gestation and gestational complications.<sup>43</sup> The predominant expression of MDMX on fetal macrophages (HC)<sup>37</sup> and the association of MDMX levels in the villi with most of the clinical characteristics we tested, suggest that MDMX has a central role in comorbidities, that originate from deficient trophoblast proliferation,<sup>44</sup> and are linked to pre-existing conditions and environmental exposures.<sup>45</sup>

406

407 **MDMX immunoprecipitations.** We were puzzled that the immunoprecipitated MDMX had 408 a molecular mass of 50 kDa, instead of 75 kDa in the placental extracts (Fig. 1, B and E). A possible explanation was offered by the discovery<sup>46</sup> that MDMX interacts with TRPM7. 409 410 a bi-functional cation channel protein fused with a kinase domain. TRPM7 is a master 411 regulator of the cellular balance of divalent cations, that mediates the uptake of Zn<sup>2+</sup>, Mg<sup>2+</sup> and Ca<sup>2+</sup>,<sup>47</sup> and senses oxidative stress to release Zn<sup>2+</sup> from intracellular vesicles<sup>48</sup>. 412 413 TRPM7 regulates MDMX levels by modulating Zn<sup>2+</sup> concentration, and induces the 414 formation of faster moving forms of MDMX on SDS-PAGE gels<sup>46</sup>. These forms depend on 415 the channel function of TRPM7 and proteasomal degradation. We hypothesize that 416 placental TRPM7, which is downregulated in preeclampsia,<sup>49</sup> interacted with MDMX during the overnight incubation with the immunoprecipitation beads stripping MDMX of Zn<sup>2+</sup>. 417 418 Proteasomal degradation was prevented by including MG-132 in our tissue-extraction and 419 IP buffer. We missed detecting TRPM7 because it did not enter the top section of the 4-420 12% Bis-Tris NuPAGE gels we used to fractionate the IP proteins with and submit the 25-421 220 kDa strips for proteomic analysis (see Methods). TRPM7 has a theoretical mass of 422 213 kDa and pl 8.1, but on SDS-PAGE gels it is shown at 230 kDa and was reported at 423 245 kDa in BN electrophoresis.

424

425 **Autoantibody antigens and TRIM21.** Although our patients did not show symptoms of 426 autoimmune diseases, a few of the immunoprecipitated proteins listed on Table 20 were 427 also among the autoantigens detected by Neiman *et al.* in healthy adults<sup>50</sup>, such as the 428 extensively studied autoantigens TRIM21/Ro(SS-A) and PDC-E2, also an autoantigen in 429 primary biliary cholangitis and other autoimmune diseases. PDC-E2 would be held on the 430 beads as a partner of VEGFR2. TRIM21 is also extracted from intervillous maternal

431 leucocytes based on their staining with TRIM21 (Fig. 2B). Maternal autoantigen-432 autoantibody complexes, with an affinity for proteins in the villous membrane fraction, 433 would be trapped on the beads by Fc-receptor TRIM21 based on its high affinity for IgG<sup>26</sup>. 434 Since TRIM21 has broad species specificity, it could bind to the sheep anti-rabbit Ab on 435 the Dynabeads and the IP-bait, the anti-rabbit Ab the beads were charged with. If TRIM21 436 clusters on the beads remain catalytically active, they could, in principle, retain VEGFR2, 437 MDMX and PICALM, as substrates of ubiquitin ligases, along with other proteins, many 438 not *in vivo* TRIM21 substrates, detected by mass spectrometry. Consequently, TRIM21 439 can confound immunoprecipitations, performed according to our protocol, by retaining 440 proteins unrelated to the bait-Ab. Based on the extensive TRIM21 literature, placental TRIM21 could participate in metabolic pathways as an E3 ubiquitin ligase,<sup>51,52</sup> and as Fc 441 442 receptor defending against infections.

443

444 **Immunohistochemistry and immunogold electron microscopy.** The distribution of 445 VEGFR2, MDMX and PICALM in the villi was shown by IHC (Fig. 2) and by IGEM which 446 also showed the distribution of OT-R and V1aR (Figures 3-7). VEGFR2 was detected in 447 the nucleus, as previously reported<sup>27,53</sup>, and in mitochondria, a novel observation to the 448 best of our knowledge (Fig. 3, panels A, B and C). Translocation in the other direction, 449 mitochondria to the nucleus, was shown for the entire pyruvate dehydrogenase complex to supply acetyl-CoA for histone acetylation<sup>54</sup>. VEGFR2 is distributed through relay 450 451 networks in lipid rafts and endosomal trafficking<sup>55</sup> and SUMOylation holds VEGFR2 at the 452 traffic control Golgi apparatus<sup>56</sup>. Gradients in receptor concentration may exist along the 453 placental vascular tree, as was shown for the purinergic P2Y<sub>2</sub> receptor (pl=9.7)<sup>57</sup>. 454 Distortion of receptor gradients in preeclampsia and diabetes could affect protein traffic 455 and even expose proteins to degradation. Regarding the latter, it may be pertinent to 456 consider the mechanism of action of estrogen receptor antagonists that decreased the 457 estrogen receptor intra-nuclear mobility and subsequently induced its turnover<sup>58</sup>.

458 MDMX appeared in nuclear clusters (Fig. 4, A and B). PICALM was detected in 459 nuclei (Fig. 5, B and C). The very basic OT-R and V1aR were also detected (Figures 6 460 and 7). Surprisingly, clusters of V1aR became clearly visible on a fetal RBC after 461 increasing gamma (Fig. 7, C). Since vasopressin receptors participate in erythropoiesis<sup>59</sup>

their presence on RBC was not very surprising. We hypothesize that in addition to nontraditional functions, such as critical immune sensors,<sup>60</sup> RBC transport V1aR to the endothelial cells of the villi<sup>25</sup>.

465 PICALM and OT-R were detected on endothelial cell projections into the fetal lumen 466 (Figures 5A, 6A) where OT-R clusters were also observed (Fig. 6, A and B) matching the 467 dimensions of microvesicles-exosomes<sup>10,11</sup>. Although we cannot prove that OT-R clusters 468 are inside exosomes with the characteristic bi-lipid membranes, as seen in standard EM 469 cellular morphology, we propose that fetal exosomes carry to the fetus the OT-R and other 470 proteins produced in the placenta. A limitation of IGEM, from the exosome perspective, is 471 that bi-lipid layers are greatly impaired during the processing of tissues because OsO<sub>4</sub> is 472 omitted in a post-fixation step used to increase the visualization of such membranes. OsO4 473 reacts strongly with lipid complexes, and while it enhances contrast for standard EM cell 474 morphological imaging, it can oxidize many antigen epitopes in IGEM. Fig. 8 shows 475 representative intraluminal vesicles<sup>9</sup> seen in the fetal capillary of the placenta sample that 476 was processed with the OsO<sub>4</sub> post-fixational step included. Membranes are more clearly 477 defined here, compared to the IGEM sample, representing exosomes or microvesicles<sup>9</sup> in 478 the fetal lumen (Fig. 8, A and B). We noticed similarities between our IGEM Figures 5 and 479 6 and transmission electron microscopy images in a study at two polluted cities in Mexico 480 showing that environmental nanoparticles of Fe, Ti, Cu, Hg and Sn accumulated in HC 481 and endothelial cells of chorionic villi sampled at term<sup>61</sup>.

482

483 Statistical analysis of protein levels and clinical presentations. Our search for the 484 function of the newly detected placental membrane proteins MDMX, PICALM, and of OT-485 R and V1aR, was accelerated by a statistical analysis of their protein levels, which 486 revealed numerous associations with clinical characteristics of the 44 patients. MDMX, 487 located predominantly in HC (Fig. 2C), took center stage based on its association with 488 most of the clinical characteristics we tested. Although many of our statistical associations 489 from 44 placentas are highly unlikely to be observed by chance, our conclusions could 490 change by testing a larger number of placenta samples and integrating, after further 491 research, protein isoforms and post-translational modifications of the newly detected 492 proteins. But to what extent did proteins from intervillous blood, reflecting also the maternal

immune system,<sup>45</sup> contribute to the observed clinical associations? An initial answer was
 provided for MDMX by the statistical analyses showing that tissue-resident HC contributed
 most extensively since they predominantly express MDMX (Fig. 2).

496

497 **Diabetes.** In diabetic patients, higher MDMX levels (Table 6) seem to correspond to the 498 higher number of cells stained with CD163<sup>62</sup>, a marker of HC<sup>39</sup>. It is not known if MDMX 499 upregulation and higher HC numbers mark a metabolic shift towards diabetes. A diabetic 500 atherosclerosis rat model showed upregulation of MDMX mRNA and protein levels<sup>63</sup>. 501 MDMX was shown in cell cultures to serve as a nutrient sensor by inhibiting mTORC1<sup>64</sup>. HC could facilitate nutrient transportation in the villous stroma<sup>34</sup> linking placental MDMX to 502 503 nutrient levels and metabolic networks. OT-R levels are higher in Type 2 diabetes (Table 504 8), and there is an association of OXTR variants with insulin sensitivity and Type 2 diabetes<sup>65</sup>. 505

506

507 **Preeclampsia.** Villous trophoblasts in pregnancies complicated by preeclampsia had 508 higher p53 and lower MDM2 levels <sup>18</sup>. Although MDMX was not measured, we believe it 509 would have been decreased also. Lower MDMX levels (Tables 6, 10) could reflect the decreased numbers of HC in preeclampsia<sup>40,41</sup>. What can cause the decrease of HC? In 510 cancer, abnormal vascularity disrupts the penetration of immune cells,<sup>66</sup> and their function 511 512 is hindered by the tumor microenvironment<sup>67,68</sup>. Here, defective placental vascularity and 513 increased placental stiffness<sup>69</sup>, both changing the architecture of the villi, could have an 514 adverse effect on HC levels. In preeclampsia, placental stiffness could be increased by 515 higher levels of tissue transglutaminase/TGM2 (Tables 3, 4) which catalyzes protein 516 crosslinking<sup>32</sup>. MDMX could be involved in the reprogramming of fetal macrophages (HC) 517 during preeclampsia and other gestational complications and labor. Drawing from the 518 breast cancer literature<sup>70</sup>, downregulation of placental MDMX in preeclampsia could be linked to estrogen receptor- $\alpha^{71}$  and lower estrogen levels<sup>72,73</sup>. 519

520 In preeclampsia large quantities of magnesium sulfate are prescribed to prevent 521 seizures. A potentially relevant study of a blood-brain barrier (BBB) model of primary 522 endothelial cells from human brain<sup>74</sup>, showed that TRPM7 mediated the entry of 523 extracellular Mg<sup>2+</sup> into cells and that high Mg<sup>2+</sup> levels speeded up the clearance of A $\beta$  to

524 the blood side via BBB transcytosis and upregulation of PICALM and LRP-1 that is also 525 expressed in HC<sup>75</sup>. It was shown recently that TRPM7 kinase activity induces amyloid- $\beta$ 526 degradation and clearance<sup>76</sup>. Among other mechanisms, the accumulation of placental 527 A $\beta^{21}$  could be related to TRPM7 and limiting PICALM-dependent transcytosis.

528

529 Gravidity. Univariable and multivariable regression analysis found a significant 530 association of gravidity with MDMX levels (Tables 6, 10). Gravidity was recently associated 531 with HC levels determined by CD163 immunostaining<sup>41</sup>. While multigravida women have 532 shorter telomeres and increased DNA methylation age,<sup>77</sup> a role of p53 and MDMX on 533 telomere length is not established in normal human tissues, to the best of our knowledge. 534 DNA methylation age is associated with MDMX and prenatal smoke exposure<sup>78</sup>. The 535 gravidity-MDMX association, which registers in the villi, could reflect the cost of multiple pregnancies to the mother<sup>79</sup>. 536

537

**PICALM, OT-R and V1aR.** The association of placental PICALM levels with BMI (Table
7) is intriguing because the placenta functions in the absence of adipocytes. A potential
precedent for such association was provided by a study on gastric bypass surgery where
PICALM mRNA levels in the blood were decreased after a significant drop of BMI<sup>80</sup>.
Furthermore, among the Alzheimer's risk nucleotide polymorphisms (SNP), a PICALM
SNP is associated with obesity<sup>81</sup>.

544 The strong correlation of protein levels of PICALM with OT-R (p<2.7x10<sup>-8</sup>), PICALM 545 with V1aR (p<0.006), and OT-R with V1aR (p<0.001) point to fundamental interactions by 546 yet unknown mechanisms. MDMX was not correlated with PICALM, OT-R or V1aR.

547 Downregulation of OT-R in spontaneous vaginal deliveries (SVD) relative to CD 548 prior to the onset of labor (Table 8), would be consistent with the higher oxytocin levels in 549 SVD than CD. It is not known to what extend extravillous blood cells and exosomes may 550 have supplied OT-R, and V1aR, detected in placental membrane extracts. Nevertheless, 551 IGEM images of the chorionic villi support the hypothesis that the lipid-covered exosomes 552 carry a cargo of the very basic, magnesium-dependent OT-R across the blood-brain 553 barrier to interact also with fetal microglia<sup>82-84</sup>, the resident immune cells of the brain<sup>85</sup>. OT-554 R protein levels in venous and arterial blood from the umbilical cord may reveal differences

555 in bi-directional OT-R traffic in normal, preterm and postterm deliveries. In that case, OT-556 R protein levels and epigenetic modifications<sup>86</sup> may lead to therapeutic interventions with 557 exosomes<sup>87</sup> prepared, ideally, with the transmembrane orientation<sup>12</sup> of OT-R in villous 558 exosomes.

559

560 Labor. The decrease of MDMX in the membrane fraction of chorionic villi in SVD vs. CD 561 prior to the onset of labor (Table 6), could be related to the decrease of immune cells in 562 peripheral maternal blood with approaching labor<sup>88</sup>, and the molecular signature of the 563 "immune clock".<sup>45,89</sup> Lower MDMX levels could also indicate a molecular switch in late 564 gestation, locally, to energy-preserving measures or other mechanisms involving uterine 565 macrophages<sup>90</sup>. MDMX, PICALM, OT-R and V1aR could be components of the fetal and 566 maternal immune system during pregnancy and as the fetus develops immunity in preparation for birth.<sup>91,92</sup> Concomitant downregulation of MDMX, PICALM, OT-R and 567 568 V1aR occurred only in SVD compared to CD prior to the onset of labor (Tables 6-9) 569 signifying a potential convergence of metabolic networks to prepare the uterus for the final 570 act in pregnancy, delivery of the fetus.

571

### 572 Materials and methods

573

574 Human Subjects. All patients signed consent forms prior to their inclusion in the study 575 according to the protocol approved by the Institutional Review Board of the University of 576 South Florida and Tampa General Hospital. Placental samples were obtained from 44 577 patients with singleton pregnancies, aged 19-40 and gestational ages ranging from 35-42 578 weeks based on the dating criteria from the American College of Obstetricians and 579 Gynecologists (ACOG) (https://pubmed.ncbi.nlm.nih.gov/28426621/) for women who 580 delivered vaginally or by cesarean delivery (CD), between 7 AM to 4 PM, based on 581 obstetric indications (Table 1). Patients were excluded if they had active viral infections or 582 fetal growth restriction, defined as estimated fetal weight of <10<sup>th</sup>% per the Hadlock growth 583 curve. Preeclampsia was diagnosed according to the criteria established in 2013 by ACOG 584 (DOI: 10.1097/01.AOG.0000437382.03963.88). Low risk pregnancy was defined by the 585 absence of maternal co-morbidities including chronic hypertension defined as

586 hypertension prior to pregnancy or systolic blood pressure  $\geq$ 140 mm Hg or diastolic blood 587 pressure  $\geq$ 90 mm Hg prior to 20 weeks' gestation, pregestational or gestational diabetes, 588 smoking, renal disease, and autoimmune disease. Patients with preeclampsia with severe 589 features defined by the 2013 ACOG Guidelines received magnesium sulfate for seizure 590 prophylaxis during induction of labor or CD through 24h postpartum. The demographic 591 Table 21 shows that 91% of study participants were 18-34 years old and 75% were 592 multiparous. Most participants (91%) were  $\geq$ 37 weeks' gestation. There was no risk of 593 bias in the selection of placentas which was at random. Sample/patient IDs (e.g., H-1, 594 J-1, etc.) are not known to anyone outside the research group, and are assigned 595 identifiers not using any personally identifiable information.

596

597 **Reagents.** Most of the reagents were purchased from Thermo Fisher Scientific 598 (Waltham, MA, USA), MMP-200 metalloprotease inhibitor III, proteasome inhibitor 599 MG-132, protease inhibitor cocktail III, marimastat, Hammarsten-grade casein, detergent 600 ASB-14, Novagen S-protein HRP conjugate 69047-3, Novex 4-12% BT SDS-PAGE 601 gels, CL-XPosure film, magnetic Dynabeads M-280 charged with sheep anti-rabbit 602 antibodies, Maxisorp Nunc C-bottom 8-well strips, protein assay Pierce BCA 562 nm kit 603 23225 (Pierce, Rockford, IL), and Protein Perfect HRP MW markers 69079-3/ 604 Millipore-Calbiochem (Billerica, MA). Additional reagents are provided in the sections 605 below.

606

Antibodies (Protein target/vendor). VEGFR2 (55B11) no. 2479/Cell Signaling 607 608 (Danvers, MA), MDMX A300-287A/Bethyl Laboratories (Montgomery, TX), 609 PDC-E2 SC-365276/Santa Cruz Biotechnology (Santa Cruz, CA), PICALM 610 Sigma Prestige HPA019053, OT-R ABN1735/Millipore (Temecula, CA), V1aR 611 MBS176788/MyBiosource (San Diego, CA), CD163 MA5-33091/InVitrogen-Thermo 612 Fisher Scientific, TRIM21 Novus NBP1-33548 (Centennial, CO), Alexa-488 (green) 613 and Alexa-64 (red) goat anti-rabbit/mouse conjugated secondary antibodies/Life 614 Technologies (Eugene, OR), immunogold donkey-anti-rabbit secondary antibodies 615 25702 (6 nm) and 25705 (10 nm) (Electron Microscopy Sciences (Hatfield, PA).


616

**Placenta tissue collection, homogenization, and protein extraction with ASB-14** Within 15 min of the delivery of the placenta, samples were obtained from the fetal side of the placental bed at 4-5 cm from the umbilical cord and were placed on dry ice and then

617 stored at -80°C. Tissues were also fixed in formalin for IHC or in paraformaldehyde-tannic 618 acid for IGEM. Frozen tissue samples were finely cut and placed, at 150 mg per mL, in 619 homogenization buffer containing 50 mM sodium phosphate pH 7.6, 50 mM NaCl, 50 µM 620 sodium o-vanadate, 10 mM NaF, 20 µM proteasome inhibitor MG-132, 10 µM marimastat 621 and 6 µL protease inhibitor cocktail-III per mL. After homogenization at 4<sup>o</sup>C by three 15s 622 bursts of a homogenizer with one-minute cooling in between, the homogenates were 623 centrifuged for 1h at 100,000g. On top of the pellets was a thin pink fluffy layer, presumably 624 of RBC membranes, which was included when the pellets were suspended in 625 homogenization buffer containing 1% ASB-14 and then extracted overnight, due to 626 logistical reasons, at 6-8°C by end-over-end rotation. The zwitterionic detergent ASB-14 627 was superior in solubilizing membrane proteins to CHAPSO or n-octyl β-D-maltoside. After 628 centrifugation at 100,000g for 1h, the supernatant solution was used in 629 immunoprecipitations and western blots. We refrained from washing the membrane pellets 630 in order to capture weak protein complexes. Protein levels of the membrane extracts were 631 determined in guadruplicate at two dilutions with the Pierce BCA 562 nm kit. Final yield: 632 10-15 mg of detergent-extracted proteins per g wet tissue. To determine the efficiency of 633 protein extraction by ASB-14, the post-ASB-14 100,000g pellets were solubilized in SDS-634 DTT at 95°C and then probed in western blots. Extraction yield was 100% for VEGFR2, 635 MDMX and PICALM, 86% for PDC-E2 and 64% for TOMM20, a marker for inner 636 mitochondrial membranes.

637

Peptide synthesis to validate the OT-R and V1aR antibodies. Fig. 10 shows OT-R peptides EGNRTAGPPRRNEA (within the OT-R immunogen range given for this antibody), AEAPEGAAAGDGGRVA (outside the OT-R immunogen range) and V1aR immunogen peptide HPLKTLQQPARRSRLMIAA to validate the OT-R Millipore ABN1735 (0.5  $\mu$ g/ $\mu$ L) and V1aR MyBioSourse MBS176788 (0.5  $\mu$ g/ $\mu$ L) antibodies. The peptides were synthesized on 100 mg Rink Amide-MBHA resin (0.65 mmol/g) at room temperature under air using standard solid phase peptide synthesis protocol.



646

Fig. 10. Validation of OT-R and V1aR antibodies. The synthesized peptides and their pl
are shown next to the scans of the coated Nunc C-bottom strips probed with the antibodies
being validated.

650 Validation method for OT-R and V1aR antibodies. Maxisorp Nunc C-bottom strips were 651 coated overnight at 4°C with the indicated amounts of synthetic peptides (Fig. 10) dissolved in sodium carbonate buffer pH 9.693. After blocking, as in western blot 652 653 experiments, the OT-R and V1aR antibodies were added for 2h at room temperature at 654 the indicated dilution followed by the secondary anti-rabbit antibody conjugated with 655 horseradish peroxidase. Detection of bound OT-R or V1aR antibodies was conducted by 656 ECL on films exposed for the indicated times. The OT-R and V1aR antibodies bound only 657 to peptide sequences used to raise them.

658

Immunoprecipitations. Each immunoprecipitation of the 4-6 placental extracts, shown in Table 3-5, was carried out in one batch. Half mL of pellicular support M-280 Dynabeads was washed in homogenization buffer containing 1% ASB-14 and charged separately at room temperature for 2h with 0.9 μg VEGFR2, 15 μg MDMX or 7.5 μg PICALM antibody. Three mg of ASB14-extracted placental membranes from each placenta were mixed separately with the beads, overnight for logistical reasons, at 6-8°C. Most proteins adhering to the beads were removed by washing four times with homogenization buffer

containing 1% ASB-14 and once with detergent-free buffer. Bound proteins were eluted at
95°C with 100 mM Tris-HCl pH 7.6, 4% SDS (w/v) and 100 mM DTT. Eluted proteins were
fractionated on 4-12% Bis-Tris NuPAGE gels. After Coomassie blue staining, gel strips
from 25-220 kDa were submitted for mass spectrometric analysis.

670

671 **Mass spectrometry.** Samples were submitted and analyzed in a double-blinded fashion. 672 Immunoprecipitated proteins were digested with Trypsin/Lys-C overnight at 37° C as 673 described<sup>94</sup>. Each group of immunoprecipitated samples was analyzed with a new trap 674 and HPLC column. Peptides were dried in a vacuum concentrator and resuspended in 675 0.1% formic acid for LC-MS/MS analysis. Peptides were separated with a C18 reversed-676 phase-HPLC column on an Ultimate3000 UHPLC with a 60-min gradient and analyzed on 677 a Q-Exactive Plus using data-dependent acquisition. Raw data files were processed in 678 MaxQuant (www.maxquant.org) and searched against the UniprotKB human protein 679 sequence database. Search parameters included constant modification of cysteine by 680 carbamidomethylation and the variable modification, methionine oxidation. Proteins were 681 identified using the filtering criteria of 1% protein and peptide false discovery rate.

682

683 Western blot analysis. 25 µg of protein from placental extracts were resolved on 4-12% 684 Bis-Tris NuPAGE gels, transferred to PVDF membranes and blocked overnight at room 685 temperature in 1% Hammarsten-grade casein or 5% Difco skimmed milk powder. MDMX, 686 PICALM, OT-R or V1aR primary antibody dilutions ranged from 1:800 to 1:10000. PVDF 687 membranes incubated with ECL reagents were exposed to film for 1-20s. Films were 688 scanned in the transmittance mode (Epson Perfection 3200 Photo, Epson America, Los 689 Alamitos, CA, USA). The intensity of the top band (Fig. 9) was measured with Li-Cor Image 690 Studio Lite software (Lincoln, Nebraska, USA) and chosen from a film exposed at the linear 691 portion of the correlation between band intensity and film exposure time before films were 692 overexposed. In the statistical analyses we used the mean intensity from 3.6 blots, on the 693 average, and relative to an internal control sample Q1 or V1 (Table 5).

694

Immunohistochemistry. 4 μm formalin-fixed paraffin embedded tissue sections were
 processed for IHC and stained with VEGFR2 (1:50), MDMX (1:500) or PICALM (1:1000)

antibodies. Slides were exposed with diaminobenzidine tetrahydrochloride dehydrate as a
 chromogen and counterstained with hematoxylin before permanent mounting.

699

700 **Immunogold electron microscopy.** Tissue samples were promptly fixed in buffered 4% 701 paraformaldehyde and kept overnight at 4°C and then immersed in 0.75% buffered 702 solution of tannic acid for 2h at room temperature. Samples were rinsed in filtered glass-703 distilled water, dehydrated through a series of increasing ethanol concentration, infiltrated, 704 and embedded in LRW acrylic resin. Selected blocks were sectioned at 90-100 nm and 705 mounted on formvar coated copper grids. The immunogold reaction was performed by 706 incubating grids in standard blocking solution for 30 min at room temperature and 707 transferring to either 1:100 MDMX rabbit Ab, 1:400 PICALM rabbit Ab, 1:100 VEGFR2 708 rabbit Ab or 1:600 OT-R or V1aR rabbit Ab for an overnight incubation at 4°C. After 709 washing in PBS, gold-conjugated donkey anti-rabbit Ab 25703 (Electron Microscopy 710 Sciences, Hatfield, PA), was applied at 1:50 dilution for 90 min at room temperature. The 711 diameter of the gold particles (Electron Microscopy Sciences, Hatfield, PA) was 6 nm in 712 VEGFR2 and MDMX and 10 nm in PICALM and OT-R experiments. Excess secondary 713 antibody was removed by washing with glass-distilled water and the grids were further 714 treated with 2% aqueous uranyl acetate added for contrast. In control experiments 715 excluding the primary antibody, 1-2 gold particles were detected throughout the grids. In 716 morphological analysis by transmission electron microscopy, tissues were fixed in 2% 717 OsO4, after 2.5% glutaraldehyde fixation and prior to the dehydration and resin infiltration 718 steps. Images were obtained with a JEM-1400 transmission electron microscope (JEOL, 719 Peabody, MA) and Orius-832 camera (Gatan Inc., Pleasanton, CA).

720

Whole mount immunofluorescence (WMIF). Small samples (2x2x2 mm) of placental tissues ,were fixed in 1 mL 90% methanol for 2*h* at 4°C according to Bushway et al.<sup>95</sup> with modifications. After washing with PBS, the samples were blocked for 2h at 4°C with 1% Hammarsten-grade casein in PBS containing 0.02% Thimerosal. After washing with 0.5% Casein in PBS, antibodies to VEGFR2 and PDC-E2 were added at 1:400 dilution and incubated overnight at 4°C, followed by washing with 0.5% Casein-PBS containing 0.3% Triton-X and incubation with the secondary antibodies at 1:100 dilutions. WMIF slides were

728 observed with a Leica TCS SP5 AOBS laser scanning confocal microscope through a 729 40X/1.3NA Plan Apochromat oil immersion objective lens (Leica Microsystems CMS) 730 GmbH, Germany). 405 Diode, Argon 488 and He-Ne 647 laser lines were applied to excite 731 the samples and tunable emissions were used to minimize crosstalk between 732 fluorochromes. Images were captured with photomultiplier detectors and prepared with the 733 LAS AF software version 2.7 (Leica Microsystems CMS GmbH, Germany). A 3D projected 734 image was created by Z-stack of images taken at 1.0-0.5-micron intervals to create a 735 movie by Imaris version 7.6 (Bitplane AG, Switzerland) (video).

736

737 Statistical analysis. The protein levels of MDMX, PICALM, OT-R and V1aR were 738 analyzed for univariable and multivariable associations by linear regression using the R 739 statistical program (https://www.r-project.org, 4.1.3). Parsimonious multivariable models 740 were selected using Akaike's Information Criteria with a stepwise selection procedure 741 (StepAIC in the MASS package of R) and were run with covariates that were identified as 742 statistically significant in univariable analysis. A p-value of less than 0.05 was considered 743 statistically significant. Violin plots were made by R statistical program, and data Figures 744 and graphs were assembled using Fiji ImageJ, GraphPad Prism 9.4.0, Adobe Illustrator 745 and Windows Office365 software. To test the robustness of results to the specific 746 datapoints included in the analysis, bootstrapped resampling (with replacement) was used 747 to generate 1000 replicate datasets, upon which regression analyses were redone. 748 Results of bootstrapped resampled analyses were summarized and compared to the full 749 dataset to characterize consistency of point estimates and patterns of statistical 750 significance. Pearson correlation coefficients were used to characterize correlation of 751 protein measurements with each other.

752

### 753 Acknowledgements

This study was supported by the Department of Obstetrics and Gynecology at the University of South Florida and research funds from Tampa General Hospital (AEA) and the Teasley Foundation (TJR). The WMIF images were obtained by the Analytic Microscopy Core Facility at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). We thank Umit A. Kayisli for

advice on IHC, and Santo V. Nicosia and Greg Arsenis for reading the manuscript andcomments.

761

# 762 Author contributions

763 JCMT conceived the study, performed most wet chemistry experiments, and wrote the first 764 draft of the manuscript in consultation with VNU and RRM. SJH, RGS, and EPN recruited 765 patients, collected, and interpreted clinical data in consultation with TSS, TJR, AEA, and 766 MLA. DC performed proteomic analyses. MO assisted in the analysis of western blot data 767 and confocal and WMIF experiments. SA and NS performed IHC experiments. AG 768 performed and interpreted IGEM. PS and JC synthesized OT-R and V1aR peptides. DATC 769 performed analyses and statistical data presentation. All authors critically read and 770 approved the manuscript.

771

# 772 Competing interests

773 DATC declares a grant from Merck for research unrelated to this manuscript. The774 remaining authors declare no competing interests.

775

### 776 Data availability

777 The video of the chorionic villi is deposited at

- 778 https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fzenodo.org%2Frecord%2
- 779 F8160169%3Ftoken%3DeyJhbGciOiJIUzUxMiIsImV4cCI6MTY5MjMwOTU5OSwiaWF0IjoxNjg5
- 780 Njk3NDQzfQ.eyJkYXRhljp7InJIY2lkljo4MTYwMTY5fSwiaWQiOjM10DEzLCJybmQiOiJjMTlkOT
- 781 M2NCJ9.2OSYKMRxBpqO7afBKem\_S8HdQJgmbtnahLFTgJ\_5hoiK3wxcbB2fvuyqEPJ0PeTtF\_r
- 782 9f9Zuocr6LcfXPs2-
- 783 gw&data=05%7C01%7Ctsibris%40usf.edu%7C02564875fb61480dab4f08db87ae6fdb%7C741bf
- 784 7dee2e546df8d6782607df9deaa%7C0%7C0%7C638252955485880125%7CUnknown%7CTWF
- 785 pbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7
- 786 C3000%7C%7C%7C&sdata=iukZjlFOvoliQAdfd566alnMH33jLMz3TV%2BDqPv5Trk%3D&reser
- 787 ved=0.
- All MS raw files and corresponding results files will be deposited to the ProteomeXchange
- 789 Consortium via the PRIDE partner repository.
- 790

791		
792		REFERENCES
793		
794	1	Burton, G. J. & Fowden, A. L. The placenta: a multifaceted, transient organ. Philos Trans R Soc Lond
795		<i>B Biol Sci</i> <b>370</b> , 20140066 (2015). <u>https://doi.org:10.1098/rstb.2014.0066</u>
796	2	Burton, G. J., Redman, C. W., Roberts, J. M. & Moffett, A. Pre-eclampsia: pathophysiology and
797		clinical implications. BMJ 366, I2381 (2019). https://doi.org:10.1136/bmj.I2381
798	3	Aplin, J. D., Myers, J. E., Timms, K. & Westwood, M. Tracking placental development in health and
799		disease. Nat Rev Endocrinol 16, 479-494 (2020). <u>https://doi.org:10.1038/s41574-020-0372-6</u>
800	4	Shibuya, M. VEGFR and type-V RTK activation and signaling. Cold Spring Harbor perspectives in
801		biology 5, a009092 (2013). <u>https://doi.org:10.1101/cshperspect.a009092</u>
802	5	Peach, C. J. et al. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.
803		Int J Mol Sci 19 (2018). https://doi.org:10.3390/ijms19041264
804	6	Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF
805		receptor signalling. Nature reviews. Molecular cell biology 17, 611-625 (2016).
806		https://doi.org:10.1038/nrm.2016.87
807	7	Qu, H. & Khalil, R. A. Vascular mechanisms and molecular targets in hypertensive pregnancy and
808		preeclampsia. Am J Physiol Heart Circ Physiol <b>319</b> , H661-H681 (2020).
809	•	https://doi.org:10.1152/ajpheart.00202.2020
810	8	Roberts, J. M. <i>et al.</i> Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness.
811	0	Hypertension <b>77</b> , 1430-1441 (2021). <u>https://doi.org:10.1161/HYPERTENSIONAHA.120.14781</u>
812 813	9	Mincheva-Nilsson, L. Immunosuppressive Protein Signatures Carried by Syncytiotrophoblast-
814		Derived Exosomes and Their Role in Human Pregnancy. Front Immunol <b>12</b> , 717884 (2021).
815	10	https://doi.org:10.3389/fimmu.2021.717884
816	10	Ormazabal, V., Nair, S., Carrion, F., McIntyre, H. D. & Salomon, C. The link between gestational diabetes and cardiovascular diseases: potential role of extracellular vesicles. <i>Cardiovasc Diabetol</i>
817		<b>21</b> , 174 (2022). https://doi.org:10.1186/s12933-022-01597-3
818	11	Morelli, A. E. & Sadovsky, Y. Extracellular vesicles and immune response during pregnancy: A
819	11	balancing act. <i>Immunol Rev</i> (2022). https://doi.org:10.1111/imr.13074
820	12	Kugeratski, F. G., Santi, A. & Zanivan, S. Extracellular vesicles as central regulators of blood vessel
821		function in cancer. <i>Science signaling</i> <b>15</b> , eaaz4742 (2022).
822		https://doi.org:10.1126/scisignal.aaz4742
823	13	Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science <b>347</b> , 1260419
824		(2015). https://doi.org:10.1126/science.1260419
825	14	Wang, D. <i>et al.</i> A deep proteome and transcriptome abundance atlas of 29 healthy human tissues.
826		Mol Syst Biol 15, e8503 (2019). https://doi.org:10.15252/msb.20188503
827	15	Di Meo, A. et al. Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. J Proteome
828		Res 20, 444-452 (2021). <u>https://doi.org:10.1021/acs.jproteome.0c00502</u>
829	16	Manna, S. et al. A proteomic profile of the healthy human placenta. Clin Proteomics 20, 1 (2023).
830		https://doi.org:10.1186/s12014-022-09388-4
831	17	Klein, A. M., de Queiroz, R. M., Venkatesh, D. & Prives, C. The roles and regulation of MDM2 and
832		MDMX: it is not just about p53. <i>Genes Dev</i> (2021). <u>https://doi.org:10.1101/gad.347872.120</u>
833	18	Sharp, A. N. et al. Preeclampsia is associated with alterations in the p53-pathway in villous
834		trophoblast. PLoS One 9, e87621 (2014). <u>https://doi.org:10.1371/journal.pone.0087621</u>
835	19	Tebar, F., Bohlander, S. K. & Sorkin, A. Clathrin assembly lymphoid myeloid leukemia (CALM)
836		protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of

837 overexpression on clathrin-mediated traffic. *Mol Biol Cell* **10**, 2687-2702 (1999). 838 https://doi.org:10.1091/mbc.10.8.2687

- Ando, K. *et al.* PICALM and Alzheimer's Disease: An Update and Perspectives. *Cells* 11 (2022).
   <u>https://doi.org:10.3390/cells11243994</u>
- 841 21 Buhimschi, I. A. *et al.* Protein misfolding, congophilia, oligomerization, and defective amyloid
  842 processing in preeclampsia. *Science translational medicine* 6, 245ra292 (2014).
  843 <u>https://doi.org:10.1126/scitranslmed.3008808</u>
- 84422Meyerowitz, J. G. *et al.* The oxytocin signaling complex reveals a molecular switch for cation845dependence. Nat Struct Mol Biol (2022). <a href="https://doi.org/10.1038/s41594-022-00728-4">https://doi.org/10.1038/s41594-022-00728-4</a>
- Jurek, B. & Neumann, I. D. The Oxytocin Receptor: From Intracellular Signaling to Behavior. *Physiol Rev* 98, 1805-1908 (2018). <u>https://doi.org:10.1152/physrev.00031.2017</u>
- 84824Dekan, Z. et al. Nature-inspired dimerization as a strategy to modulate neuropeptide849pharmacology exemplified with vasopressin and oxytocin. Chem Sci 12, 4057-4062 (2021).850https://doi.org:10.1039/d0sc05501h
- Liu, X., Luo, D., Zhang, J. & Du, L. Distribution and relative expression of vasoactive receptors on arteries. *Sci Rep* 10, 15383 (2020). <u>https://doi.org:10.1038/s41598-020-72352-5</u>
- 85326Zeng, J. *et al.* Target-induced clustering activates Trim-Away of pathogens and proteins. Nat Struct854Mol Biol 28, 278-289 (2021). <a href="https://doi.org/10.1038/s41594-021-00560-2">https://doi.org/10.1038/s41594-021-00560-2</a>
- 855 27 Domingues, I., Rino, J., Demmers, J. A., de Lanerolle, P. & Santos, S. C. VEGFR2 translocates to the 856 nucleus to regulate its own transcription. PLoS One 6, e25668 (2011). 857 https://doi.org:10.1371/journal.pone.0025668
- 85828Collier, A. Y., Smith, L. A. & Karumanchi, S. A. Review of the immune mechanisms of preeclampsia859and the potential of immune modulating therapy. Hum Immunol 82, 362-370 (2021).860https://doi.org:10.1016/j.humimm.2021.01.004
- Streicher, K. *et al.* The plasma cell signature in autoimmune disease. *Arthritis & rheumatology*(Hoboken, N.J.) 66, 173-184 (2014). <u>https://doi.org:10.1002/art.38194</u>
- 30 Gafencu, A., Heltianu, C., Burlacu, A., Hunziker, W. & Simionescu, M. Investigation of IgG receptors
   864 expressed on the surface of human placental endothelial cells. *Placenta* 24, 664-676 (2003).
   865 <u>https://doi.org:10.1016/s0143-4004(03)00041-9</u>
- 866 31 Hu, L. *et al.* Identification of a novel heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1)
  867 ligand that disrupts HnRNPA2B1/nucleic acid interactions to inhibit the MDMX-p53 axis in gastric
  868 cancer. *Pharmacol Res* 189, 106696 (2023). https://doi.org:10.1016/j.phrs.2023.106696
- 86932Liu, C., Kellems, R. E. & Xia, Y. Inflammation, Autoimmunity, and Hypertension: The Essential Role870ofTissueTransglutaminase.AmJHypertens**30**, 756-764 (2017).871https://doi.org:10.1093/ajh/hpx027
- 872 33 Reyes, L. & Golos, T. G. Hofbauer Cells: Their Role in Healthy and Complicated Pregnancy. *Front Immunol* 9, 2628 (2018). <u>https://doi.org:10.3389/fimmu.2018.02628</u>
- 34 Zulu, M. Z., Martinez, F. O., Gordon, S. & Gray, C. M. The Elusive Role of Placental Macrophages:
  875 The Hofbauer Cell. *J Innate Immun* **11**, 447-456 (2019). <u>https://doi.org:10.1159/000497416</u>
- 87635Semmes, E. C. & Coyne, C. B. Innate immune defenses at the maternal-fetal interface. Curr Opin877Immunol 74, 60-67 (2021). https://doi.org:10.1016/j.coi.2021.10.007
- 878 36 Fakonti, G., Pantazi, P., Bokun, V. & Holder, B. Placental Macrophage (Hofbauer Cell) Responses to
  879 Infection During Pregnancy: A Systematic Scoping Review. *Front Immunol* 12, 756035 (2021).
  880 <u>https://doi.org:10.3389/fimmu.2021.756035</u>
- Ning, J., Zhang, M., Cui, D. & Yang, H. The pathologic changes of human placental macrophages in women with hyperglycemia in pregnancy. *Placenta* 130, 60-66 (2022).
   <u>https://doi.org:10.1016/j.placenta.2022.11.004</u>

- 88438Girsch, J. H. *et al.* Host-Viral Interactions at the Maternal-Fetal Interface. What We Know and What885We Need to Know. Frontiers (Boulder) 2 (2022). <a href="https://doi.org:10.3389/fviro.2022.833106">https://doi.org:10.3389/fviro.2022.833106</a>
- Lasch, M. *et al.* Isolation of Decidual Macrophages and Hofbauer Cells from Term Placenta-Comparison of the Expression of CD163 and CD80. *Int J Mol Sci* 23 (2022).
  https://doi.org:10.3390/ijms23116113
- Mercnik, M. H., Schliefsteiner, C., Fluhr, H. & Wadsack, C. Placental macrophages present distinct
   polarization pattern and effector functions depending on clinical onset of preeclampsia. *Front Immunol* 13, 1095879 (2022). <u>https://doi.org:10.3389/fimmu.2022.1095879</u>
- Mittelberger, J. *et al.* The programmed cell death protein 1 (PD1) and the programmed cell death ligand 1 (PD-L1) are significantly downregulated on macrophages and Hofbauer cells in the placenta of preeclampsia patients. *Journal of reproductive immunology* 157, 103949 (2023).
   https://doi.org:10.1016/j.jri.2023.103949
- Zinn, V. Z., Khatri, A., Mednieks, M. I. & Hand, A. R. Localization of cystic fibrosis transmembrane
  conductance regulator signaling complexes in human salivary gland striated duct cells. *Eur J Oral Sci* 123, 140-148 (2015). <u>https://doi.org:10.1111/eos.12184</u>
- Maron, B. A. *et al.* Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. *Nat Commun* **12**, 873 (2021). <u>https://doi.org:10.1038/s41467-021-21146-y</u>
- 90244Burton, G. J. & Jauniaux, E. The human placenta: new perspectives on its formation and function903during early pregnancy. Proc Biol Sci 290, 20230191 (2023).904https://doi.org:10.1098/rspb.2023.0191
- 90545Ozen, M. *et al.* Omics approaches: interactions at the maternal-fetal interface and origins of child906health and disease. *Pediatr Res*, 1-10 (2022). <a href="https://doi.org:10.1038/s41390-022-02335-x">https://doi.org:10.1038/s41390-022-02335-x</a>
- 90746Wang, H. et al. The ion channel TRPM7 regulates zinc depletion-induced MDMX degradation. J Biol908Chem, 101292 (2021). <a href="https://doi.org:10.1016/j.jbc.2021.101292">https://doi.org:10.1016/j.jbc.2021.101292</a>
- 90947Nadezhdin, K. D. *et al.* Structural mechanisms of TRPM7 activation and inhibition. *Nat Commun* 14,9102639 (2023). <a href="https://doi.org:10.1038/s41467-023-38362-3">https://doi.org:10.1038/s41467-023-38362-3</a>
- 91148Abiria, S. A. et al. TRPM7 senses oxidative stress to release Zn(2+) from unique intracellular vesicles.912Proc Natl Acad Sci U S A 114, E6079-E6088 (2017). <a href="https://doi.org:10.1073/pnas.1707380114">https://doi.org:10.1073/pnas.1707380114</a>
- 91349Yang, H., Kim, T. H., Lee, G. S., Hong, E. J. & Jeung, E. B. Comparing the expression patterns of914placental magnesium/phosphorus-transporting channels between healthy and preeclamptic915pregnancies. Mol Reprod Dev 81, 851-860 (2014). https://doi.org:10.1002/mrd.22353
- 91650Neiman, M. et al. Individual and stable autoantibody repertoires in healthy individuals.917Autoimmunity 52, 1-11 (2019). <a href="https://doi.org:10.1080/08916934.2019.1581774">https://doi.org:10.1080/08916934.2019.1581774</a>
- 91851Cheng, J. et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT919pathway and PPP metabolism. Nat Commun 11, 1880 (2020). <a href="https://doi.org:10.1038/s41467-020-15819-3">https://doi.org:10.1038/s41467-020-</a>92015819-3
- 92152Park, J. S. *et al.* Mechanical regulation of glycolysis via cytoskeleton architecture. *Nature* 578, 621-922626 (2020). <a href="https://doi.org:10.1038/s41586-020-1998-1">https://doi.org:10.1038/s41586-020-1998-1</a>
- 92353Silva, J. A. F., Qi, X., Grant, M. B. & Boulton, M. E. Spatial and temporal VEGF receptor intracellular924trafficking in microvascular and macrovascular endothelial cells. Sci Rep 11, 17400 (2021).925https://doi.org:10.1038/s41598-021-96964-7
- 92654Sutendra, G. *et al.* A nuclear pyruvate dehydrogenase complex is important for the generation of927acetyl-CoA and histone acetylation.*Cell***158**, 84-97 (2014).928https://doi.org:10.1016/j.cell.2014.04.046
- 92955Kofler, N. *et al.* The Rab-effector protein RABEP2 regulates endosomal trafficking to mediate930vascular endothelial growth factor receptor-2 (VEGFR2)-dependent signaling. *J Biol Chem* 293,9314805-4817 (2018). <a href="https://doi.org:10.1074/jbc.M117.812172">https://doi.org:10.1074/jbc.M117.812172</a>

- 93256Zhou, H. J. *et al.* SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological<br/>angiogenesis. *Nat Commun* **9**, 3303 (2018). <a href="https://doi.org:10.1038/s41467-018-05812-2">https://doi.org:10.1038/s41467-018-05812-2</a>
- 934 57 Buvinic, S. *et al.* P2Y1 and P2Y2 receptor distribution varies along the human placental vascular
   935 tree: role of nucleotides in vascular tone regulation. *The Journal of physiology* 573, 427-443 (2006).
   936 <u>https://doi.org:10.1113/jphysiol.2006.105882</u>
- 93758Guan, J. et al. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its938Mobility. Cell 178, 949-963 e918 (2019). <a href="https://doi.org/10.1016/j.cell.2019.06.026">https://doi.org/10.1016/j.cell.2019.06.026</a>
- 93959Mayer, B. et al. Vasopressin stimulates the proliferation and differentiation of red blood cell940precursors and improves recovery from anemia. Science translational medicine 9 (2017).941https://doi.org:10.1126/scitranslmed.aao1632
- 94260Lam, L. K. M. et al. DNA binding to TLR9 expressed by red blood cells promotes innate immune943activation and anemia. Science translational medicine13, eabj1008 (2021).944https://doi.org:10.1126/scitranslmed.abj1008
- 94561Calderon-Garciduenas, L. *et al.* Environmental Nanoparticles Reach Human Fetal Brains.946Biomedicines 10 (2022). <a href="https://doi.org:10.3390/biomedicines10020410">https://doi.org:10.3390/biomedicines10020410</a>
- 94762Kerby, A. et al. Placental Morphology and Cellular Characteristics in Stillbirths in Women With948Diabetes and Unexplained Stillbirths. Arch Pathol Lab Med 145, 82-89 (2021).949https://doi.org:10.5858/arpa.2019-0524-OA
- Biggin Biggin
- 95264Mancini, F. et al. MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability.953Mol Cancer 16, 55 (2017). <a href="https://doi.org:10.1186/s12943-017-0626-7">https://doi.org:10.1186/s12943-017-0626-7</a>
- 95465Amin, M., Wu, R. & Gragnoli, C. Novel Risk Variants in the Oxytocin Receptor Gene (OXTR) Possibly955Linked to and Associated with Familial Type 2 Diabetes. Int J Mol Sci 24 (2023).956https://doi.org:10.3390/ijms24076282
- 95766Huang, Y. *et al.* Improving immune-vascular crosstalk for cancer immunotherapy. *Nat Rev Immunol*95818, 195-203 (2018). <a href="https://doi.org/10.1038/nri.2017.145">https://doi.org/10.1038/nri.2017.145</a>
- 959
   67
   Kao, K. C., Vilbois, S., Tsai, C. H. & Ho, P. C. Metabolic communication in the tumour-immune 960
   microenvironment. Nat Cell Biol 24, 1574-1583 (2022). <a href="https://doi.org/10.1038/s41556-022-01002-x">https://doi.org/10.1038/s41556-022-961
- 96268Zheng, W. et al. Manipulation of the crosstalk between tumor angiogenesis and963immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-<br/>angiogenesis and immune checkpoint blockade. Front Immunol 13, 1035323 (2022).965https://doi.org:10.3389/fimmu.2022.1035323
- 96669Spiliopoulos, M. et al. Characterizing placental stiffness using ultrasound shear-wave elastography967in healthy and preeclamptic pregnancies. Arch Gynecol Obstet **302**, 1103-1112 (2020).968https://doi.org:10.1007/s00404-020-05697-x
- 96970Mancini, F., Giorgini, L., Teveroni, E., Pontecorvi, A. & Moretti, F. Role of Sex in the Therapeutic970Targeting of p53 Circuitry. Front Oncol 11, 698946 (2021).971https://doi.org:10.3389/fonc.2021.698946
- 972 71 Swetzig, W. M., Wang, J. & Das, G. M. Estrogen receptor alpha (ERalpha/ESR1) mediates the p53973 independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. *Oncotarget* 7, 16049-16069 (2016). <a href="https://doi.org:10.18632/oncotarget.7533">https://doi.org:10.18632/oncotarget.7533</a>
- 97572Berkane, N. *et al.* From Pregnancy to Preeclampsia: A Key Role for Estrogens. *Endocr Rev* 38, 123-976144 (2017). <a href="https://doi.org:10.1210/er.2016-1065">https://doi.org:10.1210/er.2016-1065</a>
- 97773Jobe, S. O., Tyler, C. T. & Magness, R. R. Aberrant synthesis, metabolism, and plasma accumulation978of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular

979		dysfunction.	Hypertension	61,	480-487	(2013).
980		•	161/HYPERTENSIONAHA.1	-		( /
981	74	Zhu, D., Su, Y., Fu, B	8. & Xu, H. Magnesium Red	uces Blood-Brain	Barrier Permeability	and Regulates
982		Amyloid-beta Trans	cytosis. Mol Neurobiol 55,	7118-7131 (201	8). <u>https://doi.org:10.</u>	1007/s12035-
983		<u>018-0896-0</u>				
984	75	Hentschke, M. R. <i>et</i>	t al. Is the atherosclerotic p	henotype of pre	eeclamptic placentas o	due to altered
985		lipoprotein concent	rations and placental lipop	rotein receptors	? Role of a small-for-ge	estational-age
986		phenotype. J Lipid F	Res <b>54</b> , 2658-2664 (2013). <u>†</u>	https://doi.org:1	0.1194/jlr.M036699	
987	76	Zhang, S., Cao, F., L	i, W. & Abumaria, N. TRPN	17 kinase activity	y induces amyloid-bet	a degradation
988		to reverse synaptic	and cognitive deficits in mo	use models of A	lzheimer's disease. Sci	ence signaling
989		<b>16</b> , eade6325 (2023	3). <u>https://doi.org:10.1126/</u>	scisignal.ade632	<u>25</u>	
990	77	Ryan, C. P. <i>et al.</i> Re	production predicts shorte	r telomeres and	epigenetic age accele	ration among
991		young adult womer	n. <i>Sci Rep</i> <b>8</b> , 11100 (2018).	<u> https://doi.org:1</u>	.0.1038/s41598-018-2	9486-4
992	78	Richmond, R. C., Su	derman, M., Langdon, R., R	elton, C. L. & Da	vey Smith, G. DNA me	thylation as a
993		marker for prena	tal smoke exposure in	adults. Int J	Epidemiol <b>47</b> , 1120-	1130 (2018).
994		https://doi.org:10.1	<u>1093/ije/dyy091</u>			
995	79	Ryan, C. P. <i>et al.</i> Im	mune cell type and DNA m	ethylation vary	with reproductive stat	us in women:
996		possible pathways	for costs of reproducti	on. Evol Med	Public Health 10, 4	17-58 (2022).
997		https://doi.org:10.1	1093/emph/eoac003			
998	80	Ghanim, H. <i>et al.</i> Re	eduction in inflammation a	nd the expressio	on of amyloid precurso	or protein and
999		other proteins rela	ted to Alzheimer's disease	following gastr	ic bypass surgery. J C	lin Endocrinol
1000		Metab <b>97</b> , E1197-12	201 (2012). <u>https://doi.org</u>	:10.1210/jc.2011	<u>1-3284</u>	
1001	81	Hinney, A. <i>et al.</i> Ge	netic variation at the CELF	1 (CUGBP, elav-	like family member 1	gene) locus is
1002		genome-wide assoc	ciated with Alzheimer's dise	ease and obesity	. Am J Med Genet B N	europsychiatr
1003		Genet <b>165B</b> , 283-29	93 (2014). <u>https://doi.org:1</u>	0.1002/ajmg.b.3	32234	
1004	82	Behura, S. K. <i>et a</i>	<i>l.</i> The brain-placental axi	s: Therapeutic	and pharmacological	relevancy to
1005		pregnancy. Pharma	col Res <b>149</b> , 104468 (2019)	. https://doi.org	<u>;:10.1016/j.phrs.2019.</u>	104468
1006	83	Mairesse, J. <i>et al.</i> Ox	xytocin receptor agonist rec	duces perinatal b	orain damage by target	ting microglia.
1007		Glia <b>67</b> , 345-359 (20	019). <u>https://doi.org:10.10</u>	02/glia.23546		
1008	84	Shook, L. L., Sullivar	n, E. L., Lo, J. O., Perlis, R. H.	& Edlow, A. G. C	COVID-19 in pregnancy	: implications
1009		for fetal brai	in development. <i>Tre</i>	ends Mol	Med 28, 319-3	30 (2022).
1010		https://doi.org:10.1	1016/j.molmed.2022.02.00	<u>4</u>		
1011	85	Lazarov, T., Juarez-(	Carreno, S., Cox, N. & Geiss	mann, F. Physio	logy and diseases of ti	issue-resident
1012		macrophages. Natu	re <b>618</b> , 698-707 (2023). <u>ht</u> i	tps://doi.org:10.	1038/s41586-023-060	<u>002-x</u>
1013	86	Erickson, E. N., My	yatt, L., Danoff, J. S., Kro	l, K. M. & Con	nelly, J. J. Oxytocin r	eceptor DNA
1014		methylation is asso	ociated with exogenous o	xytocin needs o	during parturition and	d postpartum
1015		hemorrhage. Comm	nun Med (Lond) <b>3</b> , 11 (2023	). https://doi.or	g:10.1038/s43856-023	<u>3-00244-6</u>
1016	87	Liang, Y., Duan, L., L	u, J. & Xia, J. Engineering ex	osomes for targ	eted drug delivery. Th	eranostics <b>11</b> ,
1017		3183-3195 (2021).	https://doi.org:10.7150/th	<u>10.52570</u>		
1018	88	Stelzer, I. A. <i>et al.</i> In	tegrated trajectories of the	e maternal meta	bolome, proteome, an	id immunome
1019		predict labor	onset. Science	translational	medicine 1	<b>3</b> (2021).
1020		https://doi.org:10.1	126/scitranslmed.abd9898	<u>3</u>		
1021	89	Aghaeepour, N. e	et al. An immune clock	of human pr	egnancy. Sci Immun	ol <b>2</b> (2017).
1022		https://doi.org:10.1	126/sciimmunol.aan2946			
1023	90	Gomez-Lopez, N. e	t al. Macrophages exert he	omeostatic actic	ons in pregnancy to p	rotect against
1024		preterm birth	and fetal inflamn	natory injury	. JCI Insight	<b>6</b> (2021).
1025		https://doi.org:10.1	172/jci.insight.146089			

- 102691Rackaityte, E. & Halkias, J. Mechanisms of Fetal T Cell Tolerance and Immune Regulation. Front1027Immunol 11, 588 (2020). <a href="https://doi.org/10.3389/fimmu.2020.00588">https://doi.org/10.3389/fimmu.2020.00588</a>
- 102892Miller, D. et al. Single-Cell Immunobiology of the Maternal-Fetal Interface. J Immunol 209, 1450-10291464 (2022). <a href="https://doi.org:10.4049/jimmunol.2200433">https://doi.org:10.4049/jimmunol.2200433</a>
- 103093Braitbard, O., Glickstein, H., Bishara-Shieban, J., Pace, U. & Stein, W. D. Competition between1031bound and free peptides in an ELISA-based procedure that assays peptides derived from protein1032digests. Proteome Sci 4, 12 (2006). <a href="https://doi.org:10.1186/1477-5956-4-12">https://doi.org:10.1186/1477-5956-4-12</a>
- 103394Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. & Mann, M. In-gel digestion for mass1034spectrometric characterization of proteins and proteomes. Nat Protoc 1, 2856-2860 (2006).1035https://doi.org:10.1038/nprot.2006.468
- 103695Bushway, M. E. *et al.* Morphological and phenotypic analyses of the human placenta using whole1037mount immunofluorescence.*BiolReprod***90**,110 (2014).1038https://doi.org:10.1095/biolreprod.113.115915

#### Table 1.

#### Clinical characteristics of 47 patients in the study group.

**A.** Patient samples were labelled with a code consisting of a letter and 1, 2, 5, 6, 7 for non-preeclamptic, 3, 4 for preeclamptic patients or a Ho-number. **B**. Patients Ho-71, Ho-72 and Ho-73 provided placental samples for immunogold electron microscopy.

A												
Patient	Age Range	Gravida	Gestational Age (weeks)	BMI in L&D	Race	cHTN	Preeclampsia	DM	Delivery Mode	Pitocin pre-delivery	Sex F=1	Neonatal weight (g)
H1	21-25	1	38.0	30.0	6	0	0	0	1	1	1	2,940
H2	21-25	2	37.0	24.0	8	0	0	0	1	NA	2	2,590
H3	31-35	2	37.0	32.0	8	0	1	0	1	NA	1	3,040
I-1	21-25	3	38.0	34.0	2	0	0	0	3	1	2	2,631
I-2	21-25	1	42.0	30.0	1	0	0	0	1	1	2	3,759
I-3	26-30	8	35.0	34.0	2	0	1	2	2	0	2	3,195
I-4	18-20	1	36.6	41.0	8	0	1	0	3	0	1	3,335
J-1	26-30	2	39.0	25.0	8	0	0	0	3	0	2	3,300
J-2	36-40	2	37.4	22.0	1	0	0	0	1	1	1	3,460
J-3	26-30	3	38.5	28.0	1	0	1	3	3	<u>1</u>	2	3,630
L1	21-25	1	39.0	24.0	3	0	0	0	3	0	1	3,147
L2	18-20	1	39.0	29.0	6	0	0	0	1	1	1	2,920
L3	21-25	3	35.0	30.0	2	0	1	0	2	0	2	2,235
L4	26-30	3	40.0	29.0	8	0	1	0	1	NA	1	3,010
M1	21-25	3	40.1	55.0	2	0	0	0	2	0	1	3,795
M3	18-20	2	37.0	31.3	8	0	1	0	2	0	1	3,490
M4	26-30	1	40.1	39.8	8	0	1	0	1	1	2	3,380
N1	31-35	4	39.1	30.0	8	0	0	2	2	0	2	3,800
N2	31-35	2	39.3	32.8	8	0	0	0	2	0	1	3,180
N3	31-35	2	39.0	35.5	8	0	1	0	2	0	2	3,390
N4	18-20	2	36.4	29.5	1	0	1	0	3	1	2	3,510
01	21-25	2	39.3	26.2	1	0	0	0	4	1	1	2,960
02	21-25	1	38.4	34.8	1	0	0	0	1	1	1	2,940
03	26-30	1	37.1	29.5	1	0	1	0	1	1	1	2,800
04	21-25	3	40.3	52.5	1	0	1	0	3	1	2	3,575
O5	36-40	4	39.1	50.4	8	0	0	3	2	0	2	4,295
07	32-35	12	39.3	35.2	2	0	0	0	2	0	1	3,780
Q1	21-25	2	37.0	47.8	1	0	0	3	2	0	1	3,885
Q2	31-35	4	39.1	35.8	2	0	0	3	2	0	1	3,390
Q3	26-30	2	37.2	66.7	1	1	1	0	3	1	2	3,375
Q4	31-35	4	39.1	77.2	2	0	1	3	2	0	2	3,835
R3	21-25	1	37.6	49.5	1	1	1	0	1	1	2	2,560
R4	26-30	4	39.1	29.8	2	0	1	2	3	1	1	3,960
R5	21-25	6	39.0	30.9	2	0	0	0	2	0	1	3,205
S1	26-30	2	37.4	46.2	8	0	0	2	2	0	2	4,675
S2	26-30	3 5	37.5	42.2	1	0	0	2	2	0	1	4,600
T1 T2	26-30	5 1	38.0 39.1	41.9	1	0	0	2	2	0	1	3,090
	26-30			53.3	2	1	-			0		3,960
U1 U2	31-35 26-30	3	37.1 37.1	62.6 52.7	2	1	0	2	2	0	2	4,440 5,020
V1		5	37.1		2	1	0	2	2	0	2	2,720
V1 V2	36-40 36-40	2	37.1	35.5 26.1	2	0	0	0	2	0	2	4,150
V2 W1	18-20	1	39.2	30.5	1	0	0	0	2	0	2	3,470
W2	26-30	8	39.2	51.7	2	1	0	0	2	0	 1	3,000
B	20-30	0	57.0	51.7	2		U	U	۷	0	1	3,000
Ho-71	31-35	6	37.1	N/A	2	0	0	0	2	0	1	3,195
H0-71 H0-72	26-30	1	39.3	29.4	2	0	0	3	2	NA	1	3,195
H0-72 H0-73	26-30	1	39.3	29.4	2	0	1	3	1	1 1	2	2,780
10-73	20-30		37.0	<u>ک</u> ۳.۱	0	U		U	I		2	2,100

Abbreviations: *Race*: White 1, Black 2, Asian 3, Hispanic 8, unknown 6. *Chronic hypertension*: cHTN 1. *Preeclampsia* 1. *Diabetes (DM)*: Type-1 1, Type-2 2, Gestational 3. *Delivery mode*: Spontaneous vaginal delivery (SVD) 1, Cesarean delivery (CD) prior to the onset of labor 2, CD after the onset of labor 3, Vaginal birth after CD (VBAC) 4. Pitocin pre-delivery 1. *Fetal sex*: Female 1, Male 2. *L&D*: Labor and delivery suite. *NA*, not available. The number of patients in each category were as follows: Diabetes: 30 no, Type-2 9, Gestational 5. Preeclampsia: 28 no, 16 yes. Delivery Mode: SVD 12; CD prior to the onset of labor 23; CD after the onset of labor 9; VBAC 1.

#### Table 2

Proteins identified in VEGFR2 immunoprecipitations.

Placental extracts O4, O5, U1, and O7 were immunoprecipitated in one experiment.

Majority Protein ID	Protein	Gene	Total Intensity	Intensity VEGFR2 O4	Intensity VEGFR2 05	Intensity VEGFR2 U1	Intensity VEGFR2 07	Peptides
P01857	lg gamma-1 chain C region	IGHG1	24,993,000,000			4,017,600,000		16
O15151-5	Protein Mdm4	MDM4	14,682,000,000	14,638,000,000	0	21,714,000	22,289,000	14
P01834	Ig kappa chain C region	IGKC	11,450,000,000	1,978,700,000	1,363,300,000	2,438,900,000	5,668,800,000	7
A0A0B4J231	Immunoglobulin lambda-like polypeptide 5;Ig lam	IGLL5	10,336,000,000			2,053,600,000	4,291,800,000	4
P01871	Ig mu chain C region	IGHM	4,544,300,000	2,132,500,000	923,280,000	706,680,000	781,900,000	16
P20073-2	Annexin A7	ANXA7	3,045,300,000	1,631,900,000	402,390,000	522,590,000	488,400,000	19
P01624	Ig kappa chain V-III region POM	IGKV3D-15	2,885,700,000	707,630,000	775,800,000		1,381,500,000	2
A0A286YES1	lg gamma-3 chain C region	IGHG3	2,266,900,000	1,322,900,000	493,150,000	239,480,000	211,400,000	14
Q9Y6R7	IgGFc-binding protein	FCGBP	1,815,700,000	1,201,900,000	310,570,000	246,590,000	56,630,000	50
J3KT55	Protein-tyrosine-phosphatase;Receptor-type tyro	PTPRM	1,604,700,000	511,350,000	129,960,000	380,380,000	582,970,000	1
P01701	Ig lambda chain V-I region NEW	IGLV1-51	1,311,400,000	193,890,000	242,130,000	234,850,000	640,570,000	3
P50995-2	Annexin A11	ANXA11	984,170,000	401,780,000	125,800,000	283,580,000	173,010,000	18
P01583 P01709	Ig kappa chain V-I region AU	IGKV1D-33 IGLV2-8	948,420,000	223,440,000	220,510,000	138,140,000	366,330,000	2 2
P01709 P05783	lg lambda chain V-II region MGC; Keratin, type I cytoskeletal 18	KRT18	640,270,000 610,030,000	48,724,000 342,270,000	120,690,000 114,070,000	169,210,000 75,571,000	301,660,000 78,111,000	2 19
P35968	Vascular endothelial growth factor receptor 2	KDR	571,130,000	132,550,000	167,190,000	146,080,000	125,310,000	28
A0A286YEY4	Ig gamma-2 chain C region	IGHG2	460,180,000	213,440,000	63,593,000	99,658,000	83,492,000	13
A0A286YEY1	lg alpha-1 chain C region	IGHA1	403,780,000	211,760,000	52,913,000	85,992,000	53,116,000	6
Q8WZ42	Titin	TTN	396,070,000	215,440,000	31,243,000	97,005,000	52,381,000	2
A0A075B6K4	lg lambda chain V-IV region Bau	IGLV3-10	353,630,000	0	105,060,000	0	248,570,000	1
P01602	lg kappa chain V-I region HK102	IGKV1-5	352,740,000	23,518,000	98,394,000	83,336,000	147,490,000	1
P07355	Annexin A2;Annexin;Putative annexin A2-like pro	ANXA2	310,810,000	50,471,000	50,738,000	48,427,000	161,170,000	9
P0DP08	Ig heavy chain V-II region NEWM;Ig heavy chain	IGHV4-61	304,360,000	139,200,000	44,252,000	64,988,000	55,917,000	2
A0A4W8ZXM2	Immunoglobulin heavy variable 3-72	IGHV3-72	293,310,000	149,140,000	29,272,000	50,152,000	64,749,000	3
A0A140T8W4	Ras/Rap GTPase-activating protein SynGAP	SYNGAP1	288,030,000	44,004,000	63,931,000	66,499,000	113,600,000	1
P01619	lg kappa chain V-III region B6	IGKV3D-20	270,720,000	61,855,000	116,270,000	75,359,000	17,241,000	3
A0A0C4DH42	Ig heavy chain V-III region BUT;Ig heavy chain V	IGHV3-66	262,750,000	165,010,000	39,894,000	44,120,000	13,734,000	3
A0A087WW87	Ig kappa chain V-II region FR;Ig kappa chain V-II	IGKV2-40	253,710,000	36,751,000	64,720,000	43,474,000	108,760,000	3
P59666	Neutrophil defensin 3;HP 3-56;Neutrophil defens	DEFA3	216,520,000	69,150,000	64,470,000	3,576,200	79,326,000	3
P69905	Hemoglobin subunit alpha	HBA1	215,170,000	0	0	7,679,400	207,490,000	3
P68871	Hemoglobin subunit beta;LVV-hemorphin-7;Spin	HBB	212,010,000	31,855,000	0	8,761,200	171,400,000	5
A0A2R8Y804	Catenin beta-1	CTNNB1	209,290,000	166,480,000	20,293,000	22,516,000	0	1
H0Y2X5 P0DOY3	Aldehyde dehydrogenase family 1 member A3	ALDH1A3	208,040,000	81,161,000 71,942,000	28,288,000 14,393,000	92,767,000	5,824,900	1
P0D013 P17931	Ig lambda-6 chain C region;Ig lambda-7 chain C	IGLC6 LGALS3	206,310,000	8,812,900		49,459,000	70,513,000	3 4
P60709	Galectin-3;Galectin Actin, cytoplasmic 1;Actin, cytoplasmic 1, N-term	ACTB	177,750,000 169,720,000	77,252,000	12,846,000 11,135,000	37,357,000 41,447,000	118,730,000 39,882,000	4 7
P0DP03	Ig heavy chain V-III region CAM;Ig heavy chain V	IGHV3-23	161,210,000	84,420,000	37,310,000	16,539,000	22,945,000	3
P08670	Vimentin	VIM	138,160,000	72,126,000	18,191,000	31,138,000	16,707,000	14
A0A0A0MRZ8	lg kappa chain V-III region VG	IGKV3D-11	111,170,000	34,909,000	76,260,000	01,100,000	0	1
A0A075B6K5	lg lambda chain V-III region LOI	IGLV3-9	96,087,000	25,060,000	23,281,000	14,993,000	32,753,000	1
A0A286YFJ8	lg gamma-4 chain C region	IGHG4	87,485,000	47,260,000	30,192,000	1,565,900	8,467,600	9
A0A075B6Z5	T cell receptor alpha joining 4	TRAJ4	81,903,000	16,074,000	21,003,000	0	44,826,000	1
Q96Q89-4	Kinesin-like protein KIF20B	KIF20B	80,885,000	35,045,000	8,063,900	37,776,000	0	1
P31942-3	Heterogeneous nuclear ribonucleoprotein H3	HNRNPH3	80,200,000	14,536,000	9,591,700	10,848,000	45,224,000	4
P0DP01	Ig heavy chain V-I region HG3;Ig heavy chain V-I	IGHV1-3	75,366,000	33,904,000	12,319,000	16,686,000	12,457,000	1
C9JA05	Immunoglobulin J chain	JCHAIN	74,956,000	6,239,800	24,681,000	8,971,600	35,063,000	1
A6NJ08	Putative methyl-CpG-binding domain protein 3-lik	MBD3L5	72,585,000	0	0	72,585,000	0	1
O43866	CD5 antigen-like	CD5L	67,251,000	6,765,200	12,049,000	0	48,437,000	3
A0A075B6H9	Immunoglobulin lambda variable 4-69	IGLV4-69	66,271,000	0	23,139,000	15,467,000	27,664,000	1
A0A0C4DH31	Ig heavy chain V-I region V35	IGHV1-18	66,003,000	33,480,000	6,768,000	14,275,000	11,480,000	2
Q8IZ41	Ras and EF-hand domain-containing protein	RASEF	63,614,000	0	0	0	63,614,000	1
Q5JTQ6	Alpha-catulin	CTNNAL1	57,823,000	0	0	0	57,823,000	1
S4R460	Immunoglobulin heavy variable 3/OR16-9	IGHV3OR16-9	55,031,000	38,287,000	3,882,000	8,163,400	4,697,800	3
P31943	Heterogeneous nuclear ribonucleoprotein H;Hete	HNRNPH1	53,003,000	27,450,000	6,928,200	12,581,000	6,044,000	8
P01700 P69892	lg lambda chain V-I region HA Hemoglobin subunit gamma-2;Hemoglobin subur	IGLV1-47 HBG2	52,593,000 51,210,000	4,428,100 4,832,700	9,274,400 6,432,400	10,578,000 4,039,100	28,313,000 35,906,000	2 2
Q01469	Fatty acid-binding protein, epidermal	FABP5	49,218,000	9,923,200	8,054,700	6,476,700	24,764,000	1
A0A0C4DH38	Immunoglobulin heavy variable 5-51	IGHV5-51	47,777,000	21,306,000	9,176,600	9,526,200	7,768,200	2
P06312	lg kappa chain V-IV region	IGKV4-1	45,342,000	3,210,900	8,777,500	9,179,900	24,174,000	2
A0A075B7B8	0 11	IGHV30R16-12	42,463,000	23,390,000	6,964,700	8,836,000	3,272,300	2
D6RF44	Heterogeneous nuclear ribonucleoprotein D0	HNRNPD	42,167,000	25,423,000	6,531,800	3,981,200	6,231,100	2
P12314	High affinity immunoglobulin gamma Fc receptor	FCGR1A	41,035,000	21,744,000	3,306,900	13,766,000	2,217,200	4
A0A075B6I0	Immunoglobulin lambda variable 8-61	IGLV8-61	36,318,000	0	15,369,000	0	20,949,000	1
P01023	Alpha-2-macroglobulin	A2M	34,428,000	24,712,000	0	5,408,900	4,307,000	9
M0R1R1	Serine/threonine-protein kinase PAK 4	PAK4	33,472,000	0	0	33,472,000	0	1
A0A1C7CYZ1	Mitogen-activated protein kinase 15	MAPK15	33,062,000	6,944,400	14,185,000	7,347,000	4,586,000	1
A0A0C4DGL8	Haptoglobin;Haptoglobin alpha chain;Haptoglobi	HP	32,080,000	0	0	0	32,080,000	2
P05109	Protein S100-A8;Protein S100-A8, N-terminally p	S100A8	29,241,000	14,931,000	0	10,002,000	4,308,000	2
Q03135	Caveolin-1;Caveolin	CAV1	28,128,000	0	0	0	28,128,000	2
P01714	Ig lambda chain V-III region SH	IGLV3-19	26,041,000	4,373,400	0	0	21,668,000	1
P19474	E3 ubiquitin-protein ligase TRIM21	TRIM21	25,255,000	18,886,000	4,813,800	1,555,300	0	4
P62979	Ubiquitin-40S ribosomal protein S27a;Ubiquitin;4	RPS27A	25,055,000	1,656,300	2,801,700	7,174,300	13,423,000	2
P81605	Dermcidin;Survival-promoting peptide;DCD-1	DCD	22,842,000	12,716,000	3,502,900	0	6,623,700	2
P52594-2	Arf-GAP domain and FG repeat-containing protei	AGFG1	22,167,000	16,991,000	2,315,700	2,860,400	0	1
A0A0C4DH35	Probable non-functional immunoglobulin	IGHV3-35	20,964,000	12,648,000	3,344,000	2,850,000	2,122,100	1
Q86VF2-5	Isoform 5 of Immunoglobulin-like	IGFN1	20,453,000	4 268 800	0	0 0	20,453,000	1
K7EJT5 A0A0A0MSV6	60S ribosomal protein L22 Complement C1q subcomponent subunit B	RPL22 C1QB	18,553,000 18,258,000	4,268,800 0	0 6,523,400	0	14,284,000 11,734,000	2 2
A0A075B6K0	Ig lambda chain V-IV region Hil;Ig lambda chain \	IGLV3-16	18,172,000	0	4,095,500	3,407,600	10,669,000	2
P06702	Protein S100-A9	S100A9	17,656,000	10,525,000	4,095,500	7,131,300	10,009,000	2
F8W0I9	Microspherule protein 1	MCRS1	16,973,000	16,973,000	0	7,131,500	0	1
P48741	Putative heat shock 70 kDa protein 7;Heat shock	HSPA7	15,835,000	7,272,600	1,230,000	4,196,900	3,135,800	2
			,	.,212,000	.,200,000	.,100,000	0,100,000	-

P04430	lg kappa chain V-I region BAN	IGKV1-16	15,155,000	0	1,349,600	3,349,700	10,456,000	1
O75594	Peptidoglycan recognition protein 1	PGLYRP1	14,595,000	2,156,900	2,885,000	0	9,552,700	1
P01599	lg kappa chain V-I region Gal	IGKV1-17	14,133,000	1,638,200	1,801,900	5,586,300	5,106,400	1
A0A6Q8PHQ9	Prelamin-A/C;Lamin-A/C	LMNA	13,477,000	10,473,000	0	990,760	2,014,100	3
F8WCU1	Coiled-coil domain-containing protein 150	CCDC150	13,165,000	13,165,000	0	0	0	1
P11021	78 kDa glucose-regulated protein	HSPA5	12,097,000	12,097,000	0	0	0	3
P10515	Dihydrolipoyllysine-residue acetyltransferase cor	DLAT	11,577,000	0	0	0	11,577,000	2
A0A0C4DH73	lg kappa chain V-I region Daudi;lg kappa chain ∖	IGKV1-12	11,157,000	4,228,600	3,358,000	0	3,570,100	1
Q02413	Desmoglein-1	DSG1	11,044,000	6,539,700	4,504,100	0	0	4
A0A2R8Y851	40S ribosomal protein S29	RPS29	10,819,000	0	0	0	10,819,000	1
E9PHT9	Annexin;Annexin A5	ANXA5	10,757,000	0	0	0	10,757,000	2
P01766	Ig heavy chain V-III region BRO	IGHV3-13	9,742,100	6,872,500	2,869,600	0	0	3
I3L0Q1	CREB-binding protein;Histone acetyltransferase	CREBBP	9,408,100	9,408,100	0	0	0	2
A0A0A0MT36	Immunoglobulin kappa variable 6D-21	IGKV6D-21	9,327,900	0	0	0	9,327,900	1
P35030-5	Trypsin-3	PRSS3	8,538,700	4,010,200	0	0	4,528,500	1
P02747	Complement C1q subcomponent subunit C	C1QC	8,466,800	0	6,587,500	1,879,200	0	2
A0A0B4J1V0	Immunoglobulin heavy variable 3-15	IGHV3-15	8,461,900	2,460,400	6,001,500	0	0	2
C9JD14	Guanine nucleotide-binding protein G(I)/G(S)/G(	GNB4	8,022,200	0	0	0	8,022,200	1
A0A0C4DH68	Immunoglobulin kappa variable 2-24	IGKV2-24	7,515,800	7,515,800	0	0	0	2
Q5T3N1	Annexin;Annexin A1	ANXA1	7,426,700	1,331,300	0	803,800	5,291,600	2
A0A0A0MRA5	Heterogeneous nuclear ribonucleoprotein U-like	HNRNPUL1	6,653,000	6,653,000	0	0	0	3
P0DP04	Ig heavy chain V-III region DOB	IGHV3-43D	6,600,800	0	3,028,100	3,572,700	0	3
P02675	Fibrinogen beta chain;Fibrinopeptide B;Fibrinoge	FGB	6,128,300	6,128,300	0	0	0	2
Q9NZT1	Calmodulin-like protein 5	CALML5	6,023,300	1.202.800	0	4.408.400	412.040	3
A0A0C4DH67	Immunoglobulin kappa variable 1-8	IGKV1-8	5,877,100	2,421,000	3,456,100	0	0	1
A0A2R8YD12	Serpin B6	SERPINB6	5,710,400	5,710,400	0	0	0	1
A0A0A0MRQ5	Peroxiredoxin-2;Peroxiredoxin-1	PRDX1	5,706,700	0	0	2.361.100	3,345,600	1
Q5VVL7	Lipoamide acyltransferase component of branche	DBT	5.612.200	3,395,200	0	2.217.000	0	1
P06310	lg kappa chain V-II region RPMI 6410	IGKV2-30	5,336,000	0,000,200	0 0	2,017,100	3,318,900	2
P50991	T-complex protein 1 subunit delta	CCT4	4,474,800	0	0	2,011,100	4,474,800	1
A0A0C4DH36	Probable non-functional immunoglobulin heavy v	IGHV3-38	4,238,600	0	4,238,600	0 0	0	2
P47929	Galectin-7	LGALS7	4,195,800	0	0	1.755.800	2.440.000	3
B4E1S2	Annexin;Annexin A4	ANXA4	4,022,500	0	õ	0	4,022,500	1
E7ETU5	RNA-binding motif, single-stranded-interacting pr	RBMS1	3,858,200	2.150.500	Ő	1,707,700	4,022,000	2
I3L1P8	Mitochondrial 2-oxoglutarate/malate carrier prote	SLC25A11	3,820,000	2,130,300	0	1,707,700	3,820,000	1
Q71U36-2	Tubulin alpha-1A chain;Tubulin alpha-1B chain;T	TUBA1A	3,782,000	3,782,000	Ő	Ő	0,020,000	2
D6R9P3	Heterogeneous nuclear ribonucleoprotein A/B	HNRNPAB	3,571,200	3,120,400	0	450,800	0	2
E9PJT1	Phosphatidylinositol-binding clathrin assembly pr	PICALM	3,561,800	3.561.800	0	430,000	0	1
A0A0B4J1V6	Immunoglobulin heavy variable 3-73	IGHV3-73	3,460,100	3,301,800	1.501.600	1,958,600	0	3
P14923	Junction plakoglobin	JUP	3,261,700	2,178,900	1,501,000	1,938,000	1,082,900	3
Q5T749	Keratinocyte proline-rich protein	KPRP	3,196,400	3,196,400	0	0	1,002,900	2
P15924	Desmoplakin	DSP		3,190,400	2.479.300	0	497,000	2
E9PKD2	Nuclear pore complex protein Nup214	NUP214	2,976,300 2,854,500	1,488,400	2,479,300 1,366,100	0	497,000	3 1
		KDM5B		1,400,400		0	0	1
B3KV94	Lysine-specific demethylase 5B	RAE1	2,598,600	-	2,598,600 0	0	0	1
P78406	mRNA export factor		2,408,100	2,408,100		-	-	
P17661	Desmin	DES	2,140,500	0	0	1,047,300	1,093,200	4
P31994-5	Low affinity immunoglobulin gamma Fc	FCGR2B	2,042,300	0	2,042,300	0	0	1
A0A087WT15	N-acetylglucosaminyldiphosphodolichol	ALG13	1,878,000	0	1,878,000	0	0	1
P31944	Caspase-14;Caspase-14 subunit p17, mature for	CASP14	880,720	0	880,720	0	0	1
A0A3B3ISA6	Complement C4-A;Complement C4 beta chain;C	C4B	664,880	0	0	0	664,880	1

 Table 3

 Proteins identified in MDMX immunoprecipitations (IP).

 Protein extracts 01, 04, 06, Q1, Q4, and R4 were immunoprecipitated in one experiment.

			rea were initiality explated in one experiment.			Intensity	Intensity	Intensity	Intensity	Intensity	Intensity	
Unique to MDMX IP	Common to all IP	Majority protein ID	Protein	Gene	Total Intensity	MDMX 01	MDMX 04	MDMX 06	MDMX Q1	MDMX Q4	MDMX R4	Peptides
		P01857	lg gamma-1 chain C region	IGHG1	172,120,000,000	22,238,000,000	2,879,300,000	4,953,400,000	85,828,000,000	8,388,500,000	47,830,000,000	17
	Yes Yes	P68871 P69905	Hemoglobin subunit beta Hemoglobin subunit alpha	HBB HBA1	49,360,000,000 46,601,000,000			924,450,000 1,616,500,000	1,416,300,000		3,293,300,000 7,128,000,000	14 15
	Yes	P20073-2 Q9Y6R7	Annexin A7 IgGFc-binding protein	ANXA7 FCGBP	25,375,000,000 19,471,000,000	5,386,800,000 6,976,500,000	1,897,400,000 5,284,100,000	6,836,600,000 2,450,000,000	2,658,100,000 1,183,900,000	3,368,800,000 470,780,000	5,226,900,000 3,105,900,000	31 75
Ves		P81605	Dermcidin;Survival-promoting peptide;DCD-1 Annexin A11	DCD	11,575,000,000 11,312,000,000	2,289,500,000	1,337,700,000	2,158,100,000	2,832,500,000	985,260,000	1,971,800,000	9
Yes	Yes	P50995 P01871	Ig mu chain C region	ANXA11 IGHM	10,253,000,000	478,090,000 2,115,600,000	3,548,100,000	1,675,600,000 788,140,000		1,253,200,000	2,827,400,000 1,620,700,000	22 18
	Yes	P63261 P69892	Actin, cytoplasmic 2 Hemoglobin subunit gamma-2	ACTG1 HBG2	7,787,800,000 7,148,400,000	669,640,000 1,386,800,000	2,068,500,000 780,010,000	955,900,000 795,220,000	645,430,000 661,950,000	2,563,700,000 460,580,000	884,630,000 3.063.800.000	16 12
Yes		P55072 P07355	Transitional endoplasmic reticulum ATPase	VCP ANXA2	4,620,000,000	185,550,000	758,330,000	1,565,000,000	411,970,000	553,090,000	1,146,000,000	39
Yes	Yes	P15924	Annexin A2;Annexin;Putative annexin A2-like Desmoplakin	DSP	4,497,800,000 4,032,200,000	586,000,000 470,760,000	417,330,000 397,430,000	1,170,600,000 777,640,000	722,980,000 503,940,000	573,440,000 1,011,000,000	1,027,400,000 871,340,000	24 71
	Yes Yes	Q02413 P01834	Desmoglein-1 Ig kappa chain C region	DSG1 IGKC	3,842,500,000 3,261,700,000	671,480,000 842,260,000	532,380,000 1,005,100,000	484,300,000 115,500,000	578,340,000 198,480,000	684,390,000 706,400,000	891,590,000 393,970,000	23 8
Yes		P08670 A0A0C4DH90	Vimentin Ig kappa chain V-III region POM	VIM IGKV3OR2-268	3,157,700,000 2,570,200,000	489,550,000 1,897,100,000	337,990,000 0	734,410,000 13,227,000	251,720,000 0	392,940,000 225,870,000	951,130,000 434,010,000	25 1
Yes		V9HW 50	Alcohol dehydrogenase 1B	HEL-S-117	2,525,500,000	0	2,445,000,000	0	0	80,447,000	0	17
Yes	Yes	P17931 Q08554-2	Galectin-3;Galectin Desmocollin-1	LGALS3 DSC1	2,429,700,000 2,289,200,000	1,214,100,000 409,040,000	169,570,000 260,520,000	378,710,000 496,130,000	177,170,000 269,620,000	77,588,000 267,980,000	412,490,000 585,960,000	8 11
	Yes Yes	P0DOY3 P14923	lg lambda-1 chain C regions Junction plakoglobin	IGLC1 JUP	2,060,500,000 1,729,100,000	902,940,000 212,940,000	302,390,000 113,640,000	106,470,000 343,050,000	55,564,000 269,710,000	332,740,000 404,730,000	360,390,000 385,000,000	6 15
Yes		Q8N5G2-2	Macoilin	MACO1 KPRP	1,581,700,000	99,294,000	476,890,000	430,010,000	308,790,000	0	266,730,000	2
	Yes	Q5T749 P19474	Keratinocyte proline-rich protein E3 ubiquitin-protein ligase TRIM21	TRIM21	1,575,500,000 1,493,600,000	330,330,000 373,480,000	141,660,000 221,830,000	226,220,000 137,660,000	285,640,000 252,360,000	313,090,000 260,040,000	278,590,000 248,270,000	12 10
	Yes	Q9NZT1 P04083	Calmodulin-like protein 5 Annexin A1;Annexin	CALML5 ANXA1	1,415,300,000 1,402,800,000	243,820,000 51,347,000	182,070,000 99,256,000	222,180,000 209,080,000	153,060,000 80,360,000	70,118,000 733,430,000	544,030,000 229,300,000	5 12
Yes Yes		P02647 A0A3B3IS80	Apolipoprotein A-I;Proapolipoprotein A-I Fructose-bisphosphate aldolase B	APOA1 ALDOB	1,331,000,000 1,149,700,000	11,399,000 0	117,700,000 1.053.900.000	5,319,000 0	16,475,000 0	1,162,800,000 95.806.000	17,217,000 0	15 15
100		P04406	Glyceraldehyde-3-phosphate dehydrogenase	GAPDH	1,024,600,000	45,228,000	381,510,000	144,970,000	70,343,000	219,600,000	162,960,000	13
	Yes Yes	A0A286YES1 P02675	lg gamma-3 chain C region Fibrinogen beta chain	IGHG3 FGB	1,009,000,000 987,840,000	138,810,000 3,484,400	318,110,000 109,660,000	154,420,000 9,669,900	99,280,000 0	160,810,000 843,190,000	137,620,000 21,839,000	15 8
		A0A5F9ZH78 P04040	Arginase-1 Catalase	ARG1 CAT	985,040,000 883,310,000	29,882,000 55,685,000	296,130,000 377,410,000	165,080,000 124,610,000	133,750,000 80,278,000	191,750,000 132,340,000	168,450,000 112,980,000	7 10
		A0A286YEY1	Ig alpha-1 chain C region	IGHA1	816,250,000	19,070,000 22,095,000	323,900,000	34,146,000	95,177,000	136,490,000	207,470,000	11
Yes	Yes	P01023 Q2L6G8	Alpha-2-macroglobulin Corneodesmosin	A2M CDSN	764,980,000 755,530,000	85,379,000	427,860,000 142,160,000	9,797,400 258,560,000	18,372,000 81,346,000	162,150,000 84,291,000	124,700,000 103,800,000	19 5
Yes	Yes	P11021 Q14103-3	78 kDa glucose-regulated protein Heterogeneous nuclear ribonucleoprotein D0	HSPA5 HNRNPD	754,080,000 743,760,000	73,659,000 190,940,000	267,450,000 159,680,000	111,330,000 172,750,000	14,914,000 62,051,000	122,090,000 75,439,000	164,640,000 82,904,000	19 7
Yes	Yes	S4R460 Q8N257	Ig heavy chain V-III region BRO Histone H2B type 3-B	IGHV3OR16-9 HIST3H2BB	737,650,000 735,150,000	77,631,000 68,866,000	167,330,000 97,720,000	68,300,000 133,440,000	164,380,000 90,551,000	145,600,000 222,990,000	114,400,000 121,590,000	2 4
		P02671	Fibrinogen alpha chain; Fibrinopeptide A	FGA	727,500,000	0	39,906,000	0	0	687,600,000	0	20
Yes		H0Y9N0 A0A6Q8PFJ0	Alcohol dehydrogenase 4 Prelamin-A/C;Lamin-A/C	ADH4 LMNA	720,950,000 692,900,000	0 124,240,000	690,910,000 137,300,000	0 102,670,000	0 16,496,000	30,039,000 157,450,000	0 154,750,000	13 15
Yes		P31327 P02787	Carbamoyl-phosphate synthase [ammonia], mitochondrial Serotransferrin	CPS1 TF	684,130,000 652,910,000	0	639,470,000 470,270,000	0	0	44,655,000 146,010,000	0 36,628,000	22 17
	Yes	Q01469	Fatty acid-binding protein, epidermal	FABP5	620,650,000	95,889,000	59,613,000	208,230,000	97,652,000	68,443,000	90,819,000	6
Yes Yes		Q9BTM1 P02042	Histone H2A.J Hemoglobin subunit delta	H2AFJ HBD	616,220,000 608,730,000	134,230,000 5,412,700	164,340,000 569,100,000	41,711,000 0	94,091,000 0	86,576,000 34,217,000	95,268,000 0	3 11
Yes	Yes	P31943 Q15007	Heterogeneous nuclear ribonucleoprotein H Pre-mRNA-splicing regulator WTAP	HNRNPH1 WTAP	586,320,000 583,670,000	235,200,000 146,160,000	40,807,000 79,564,000	91,509,000 83,145,000	52,962,000 52,450,000	116,480,000 83,328,000	49,360,000 139,020,000	10 11
		E7ETU5 F8VZY9	RNA-binding motif, single-stranded-interacting protein 1 Keratin, type I cytoskeletal 18	RBMS1 KRT18	582,990,000 508,470,000	101,720,000 182,680,000	109,470,000 57,886,000	87,943,000 98,079,000	47,975,000 48,183,000	117,990,000 67,435,000	117,880,000 54,210,000	4 11
Yes		P01024	Complement C3;Complement C3 beta chain	C3	484,020,000	0	112,750,000	0	0	371,270,000	0	18
Yes Yes		F5H5D3 C9JEU5	Tubulin alpha-1C chain;Tubulin alpha-1B chain Fibrinogen gamma chain	TUBA1C FGG	478,170,000 455,740,000	54,611,000 0	141,340,000 79,865,000	66,825,000 2,023,400	35,734,000 0	118,870,000 368,680,000	60,793,000 5,169,500	7 8
Yes	Yes	P31942-2 A0A286YEY4	Heterogeneous nuclear ribonucleoprotein H3 Ig gamma-2 chain C region	HNRNPH3 IGHG2	453,350,000 432,350,000	48,222,000 114,780,000	34,002,000 109,100,000	131,920,000 83,334,000	77,527,000 18,798,000	103,460,000 68,437,000	58,216,000 37,904,000	7 10
Yes	100	P06733	Alpha-enolase	ENO1	410,010,000	29,654,000	202,800,000	42,689,000	15,683,000	119,190,000	0	12
Yes		E9PGY2 E5RHP7	Dynein assembly factor 5, axonemal Carbonic anhydrase 1	DNAAF5 CA1	404,800,000 401,260,000	19,772,000 0	183,310,000 391,980,000	67,144,000 0	0	69,246,000 9,284,600	65,333,000 0	1 8
		O43866 O14979-3	CD5 antigen-like Heterogeneous nuclear ribonucleoprotein D-like	CD5L HNRNPDL	377,830,000 365,710,000	69,239,000 19,376,000	55,821,000 5,685,600	96,818,000 198,730,000	44,043,000 94,806,000	63,341,000 32,417,000	48,571,000 14,696,000	7 8
Yes		Q9UNZ2 P01767	NSFL1 cofactor p47 Ig heavy chain V-III region BUT	NSFL1C IGHV3-66	347,920,000 341,860,000	35,893,000 194,310,000	47,043,000 62,905,000	106,430,000 0	50,500,000 45,120,000	26,935,000 39,526,000	81,121,000 0	8
		P06702	Protein S100-A9	S100A9	328,250,000	18,939,000	0	0	0	309,310,000	0	5
		E7EQB2 J3QSA3	Lactotransferrin;Lactoferricin-H Ubiquitin-40S ribosomal protein S27a	LTF UBB	327,250,000 324,440,000	38,827,000 21,637,000	139,660,000 77,494,000	27,766,000 57,113,000	5,594,100 32,248,000	60,142,000 60,277,000	55,260,000 75,668,000	7
Yes Yes		P35579 P00488	Myosin-9 Coagulation factor XIII A chain	MYH9 F13A1	312,240,000 309,550,000	3,676,700 38,304,000	19,015,000 144,670,000	0 49,351,000	0	289,550,000 12,444,000	0 64,783,000	14 11
		P16403	Histone H1.2	HIST1H1C	308,980,000	26,941,000	14,080,000	6,953,300	0	29,397,000	231,610,000	8
Yes	Yes	P05091 P31944	Aldehyde dehydrogenase, mitochondrial Caspase-14;Caspase-14 subunit p17, mature form	ALDH2 CASP14	295,420,000 292,460,000	0 41,450,000	295,420,000 20,154,000	0 92,287,000	0 47,890,000	0 24,225,000	0 66,452,000	13 5
Yes		P23141-3 Q13492-3	Liver carboxylesterase 1 Phosphatidylinositol-binding clathrin assembly protein	CES1 PICALM	287,760,000 280,250,000	0	275,240,000 13,085,000	0 54,721,000	0 40,016,000	12,513,000 68,106,000	0 104,330,000	8 2
Yes		P08263 P01709	Glutathione S-transferase A1 Io lambda chain V-II region MGC	GSTA1	276,080,000 272,320,000	0 194,040,000	276,080,000 27,482,000	0	0	0 20,496,000	0 30,296,000	6 1
Yes		K7EMS3 P32119	Keratin, type I cytoskeletal 19	KRT19 PRDX2	271,550,000	43,143,000	35,179,000	52,355,000 17,114,000	28,751,000	3,693,300	108,430,000	8
Yes		P11142	Peroxiredoxin-2 Heat shock cognate 71 kDa protein	HSPA8	264,970,000 256,440,000	10,440,000 21,135,000	64,536,000	39,021,000	0	28,665,000 87,034,000	44,712,000	7 12
Yes Yes		H3BQ34 M0QZK8	Pyruvate kinase;Pyruvate kinase PKM Gamma-glutamylcyclotransferase	PKM GGCT	253,600,000 252,790,000	157,610,000 23,067,000	12,316,000 23,773,000	26,633,000 53,047,000	7,716,200 57,290,000	41,154,000 26,710,000	8,175,000 68,899,000	4 3
		P62805 F8VV32	Histone H4 Lysozyme;Lysozyme C	HIST1H4A LYZ	247,550,000 237,840,000	32,165,000 25,942,000	44,025,000 54,297,000	57,166,000 24,124,000	32,274,000 46,944,000	24,152,000 38,336,000	57,770,000 48,197,000	3
Yes		A0A2R8YGD1	Tripeptidyl-peptidase 1	TPP1	228,720,000	59,580,000	36,930,000	40,003,000	12,722,000	48,382,000	31,107,000	2
Yes		A0A286YFJ8 P30086	lg gamma-4 chain C region Phosphatidylethanolamine-binding protein 1	IGHG4 PEBP1	221,300,000 220,410,000	21,901,000 0	25,795,000 220,410,000	0	48,084,000 0	94,876,000 0	30,645,000 0	9 6
Yes		Q8NDC0 E9PSB3	MAPK-interacting and spindle-stabilizing protein-like Eukaryotic translation initiation factor 3 Sub M	MAPK1IP1L EIF3M	219,790,000 204,390,000	0	0	74,677,000 204,390,000	0	55,083,000 0	90,029,000 0	1 1
Yes Yes		P00367 P01040	Glutamate dehydrogenase 1, mitochondrial Cystatin-A;Cystatin-A, N-terminally processed	GLUD1 CSTA	202,320,000 200,650,000	0 31,866,000	194,820,000 28,575,000	0 24,874,000	0 17,883,000	7,505,800	0 97,455,000	8 3
Yes		H0Y755	Low affinity immunoglobulin gamma Fc region receptor III-A	FCGR3A	200,010,000	96,729,000	0	76,577,000	15,235,000	0	11,468,000	2
Yes Yes		Q6UWP8 H0YH81	Suprabasin ATP synthase subunit beta,mitochondrial	SBSN ATP5B	199,090,000 192,440,000	23,686,000 0	5,567,100 150,240,000	53,784,000 11,186,000	11,163,000 0	9,392,600 26,174,000	95,502,000 4,835,000	7 3
Yes	Yes	P00738 P05109	Haptoglobin;Haptoglobin alpha chain Protein S100-A8;Protein S100-A8, N-terminally processed	HP \$100A8	191,600,000 188,970,000	0 15,112,000	83,217,000 51,461,000	0 6,955,600	0 7,752,500	105,830,000 102,410,000	2,547,800 5,286,800	8 4
		P10412 P30101	Histone H1.4 Protein disulfide-isomerase A3	HIST1H1E PDIA3	188,770,000 184,850,000	0 27,987,000	51,503,000 81,404,000	19,340,000 9,267,600	0	38,303,000 52,967,000	79,622,000 13,224,000	7
Yes		Q60FE5	Filamin-A	FLNA	176,900,000	17,314,000	62,222,000	4,156,600	0	93,211,000	0	14
	Yes	P59666 A0A7I2V4I6	Neutrophil defensin 3;HP 3-56;Neutrophil defensin 2 Heterogeneous nuclear ribonucleoproteins A2/B1	DEFA3 HNRNPA2B1	175,940,000 175,770,000	12,525,000 10,611,000	147,180,000 33,709,000	0 28,025,000	0 3,763,900	0 47,208,000	16,235,000 52,448,000	4 8
Yes		C9JZN1 E9PJX3	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 2 DC-STAMP domain-containing protein 1	GNB2 DCST1	167,230,000 165,830,000	0 165,830,000	32,409,000 0	0	114,540,000 0	0	20,285,000	3 1
Yes		Q93088	Betainehomocysteine S-methyltransferase 1	BHMT	156,930,000	0	156,930,000	0	0	0	0	5
Yes		Q08188 Q5JP53	Protein-glutamine gamma-glutamyltransferase E Tubulin beta chain;Tubulin beta-2B chain	TGM3 TUBB	151,040,000 148,810,000	19,454,000 0	14,749,000 39,759,000	30,930,000 10,457,000	27,901,000 5,418,600	11,456,000 93,172,000	46,554,000 0	6 3
Yes		P00352 A0A7I2V3H3	Retinal dehydrogenase 1 Putative elongation factor 1-alpha-like 3	ALDH1A1 EEF1A1	147,820,000 146,880,000	0 10,829,000	143,910,000 56,560,000	0 10,460,000	0 7,325,300	3,905,500 52,315,000	0 9,388,600	7 1
Yes		P29508-2 P47929	Galectin-7	SERPINB3 LGALS7	144,360,000 142,190,000	34,074,000 14,374,000	0	63,249,000 53,808,000	7,558,700	7,745,700 41,851,000	31,729,000 12,331,000	3
Yes		P02730	Band 3 anion transport protein	SLC4A1	137,560,000	0	122,820,000	6,434,500	0	0	8,304,400	6
Yes Yes		P25705-2 P09467	ATP synthase subunit alpha, mitochondrial Fructose-1,6-bisphosphatase 1	ATP5A1 FBP1	135,600,000 134,090,000	25,045,000 0	92,411,000 112,310,000	4,146,300 0	0	14,002,000 21,781,000	0	9 4
Yes		A0A6Q8PFK8 P14625	Heat shock protein beta-1 Endoplasmin	HSPB1 HSP90B1	129,770,000 128,220,000	6,293,600	23,017,000 87,804,000	23,662,000 12,003,000	14,009,000 1,880,000	27,850,000 22,276,000	34,937,000 4,253,300	3 6
		A0A5F9ZHX5	Chromodomain-helicase-DNA-binding protein 3	CHD3	126,410,000	72,151,000	0	0	0	0	54,262,000	1
Yes		D3YTK1 P07476	B-cell lymphoma/leukemia 11B Involucrin	BCL11B IVL	124,710,000 120,360,000	76,098,000 0	14,068,000 0	16,701,000 0	0	0 120,360,000	17,845,000 0	1 6
Yes		P00558-2 A0A0G2JRN3	Phosphoglycerate kinase 1 Alpha-1-antitrypsin;Short peptide from AAT	PGK1 SERPINA1	119,430,000 119,420,000	0	106,620,000 0	0	0	12,816,000 119,420,000	0	5 2
Yes		P10599-2 A0A087WVQ6	Thioredoxin Clathrin heavy chain;Clathrin heavy chain 1	TXN CLTC	119,320,000 118,860,000	32,992,000 7,694,400	7,421,500 39,319,000	15,014,000 4,351,100	6,942,900 5,094,400	38,357,000 27,799,000	18,590,000 34,607,000	3 5
			· · · ·				.,,	,,	.,,	,,		-

Yes		P11166 A0A0A0MSI0	Solute carrier family 2, facilitated glucose transporter member 1 Peroxiredoxin-1	SLC2A1 PRDX1	117,840,000 117,410,000	27,594,000 0	20,800,000 23,434,000	27,638,000 24,158,000	17,045,000 0	17,769,000 50,913,000	6,991,000 18,908,000	1 6
res		P04843	Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 1	RPN1	114,750,000	14,069,000	19,291,000	38,305,000	0	5,918,100	37,166,000	5
Yes		Q9BS26 P31040	Endoplasmic reticulum resident protein 44 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	ERP44 SDHA	114,410,000 110,870,000	0 21,023,000	19,792,000 29,762,000	0 5,004,900	57,777,000 6,511,700	15,611,000 7,760,200	21,226,000 40,805,000	2 5
Yes		E9PS23 P00918	Cofilin-1 Carbonic anhydrase 2	CFL1 CA2	105,680,000 103,530,000	0	47,412,000 103,530,000	6,922,800 0	6,769,200 0	42,374,000 0	2,206,100 0	2 6
Yes		P40926	Malate dehydrogenase, mitochondrial;Malate dehydrogenase	MDH2	102,110,000	0	102,110,000	0	0	0	0	6
Yes Yes		P09210 P09211	Glutathione S-transferase A2 Glutathione S-transferase P	GSTA2 GSTP1	101,640,000 101,360,000	0	101,640,000 24,528,000	0	0	0 76,833,000	0	6 2
Yes Yes		P00338-3 P30084	L-lactate dehydrogenase A chain Enovl-CoA hydratase, mitochondrial	LDHA ECHS1	101,020,000 100,510,000	0	67,486,000 100.510.000	0	0	33,536,000 0	0	4 5
Yes		P00326	Alcohol dehydrogenase 1C	ADH1C	99,362,000	0	99,362,000	0	0	0	0	12
Yes Yes		P11182 P60174	Lipoamide acyltransferase component of branched-chain α-keto acid Triosephosphate isomerase	DBT TPI1	98,020,000 96,410,000	2,429,500 0	0 96,410,000	88,425,000 0	7,165,200 0	0	0	6 6
Yes Yes		P31995-4 P81605-2	Low affinity immunoglobulin gamma Fc region receptor II-c Dermcidin;Survival-promoting peptide;DCD-1	FCGR2C DCD	95,150,000 94,948,000	0	0 17,310,000	21,613,000 24,755,000	16,029,000 14,705,000	0 27.485.000	57,508,000 10,693,000	2 8
Yes		A0A7I2V2R3	Heterogeneous nuclear ribonucleoprotein A3	HNRNPA3 CST6	94,476,000 90,006,000	0 23,842,000	0	40,480,000	18,442,000	11,950,000	23,604,000	5
Yes		Q15828 P04259	Cystatin-M Keratin, type II cytoskeletal 6B	KRT6B	89,853,000	0	3,936,600	12,469,000 12,262,000	11,616,000 4,134,500	14,124,000 69,520,000	27,955,000 0	56
Yes		K7EQ02 P08238	DAZ-associated protein 1 Heat shock protein HSP 90-beta	DAZAP1 HSP90AB1	88,043,000 87,486,000	0 9,004,500	4,283,400 43,177,000	36,199,000 0	21,232,000 0	26,328,000 26,031,000	0 9,274,000	2 8
Yes		Q13835-2 P16401	Plakophilin-1 Histone H1.5	PKP1 HIST1H1B	87,271,000 86,334,000	14,367,000	4,843,200	0	14,614,000	47,376,000	6,070,300	3 5
Yes		P21549	Serinepyruvate aminotransferase	AGXT	84,253,000	ō	84,253,000	0	ō	33,838,000 0	52,496,000 0	3
Yes Yes		E7EQR4 A8MW49	Ezrin Fatty acid-binding protein, liver	EZR FABP1	83,177,000 80,281,000	11,616,000 0	57,174,000 80,281,000	0	0	0	14,386,000 0	6 3
Yes Yes		Q09666 P06396-2	Neuroblast differentiation-associated protein AHNAK Gelsolin	AHNAK GSN	79,609,000 77,391,000	4,552,900 0	0	0	0	75,056,000 77,391,000	0	8 5
Yes		P08311	Cathepsin G	CTSG	75,345,000	0	64,752,000	0	0	10,593,000	0	3
Yes Yes		P07737 Q13867	Profilin-1 Bleomycin hydrolase	PFN1 BLMH	73,460,000 71,299,000	0 15,720,000	45,606,000 8,186,000	0 22,679,000	0	27,854,000 9,475,800	0 15,237,000	2 2
Yes Yes		A0A0G2JIW1 P25311	Heat shock 70 kDa protein 1A;Heat shock 70 kDa protein 1B Zinc-alpha-2-glycoprotein	HSPA1A AZGP1	70,838,000 70,437,000	0 17,679,000	40,124,000 10,057,000	9,828,700 36,466,000	0	14,307,000 0	6,577,900 6,235,100	7 6
		A0A7I2YQK6	60 kDa heat shock protein, mitochondrial	HSPD1	70,230,000	0	41,023,000	0	0	29,206,000	0	3
Yes Yes		P30041 P17066	Peroxiredoxin-6 Heat shock 70 kDa protein 6;Putative heat shock 70 kDa protein 7	PRDX6 HSPA6	70,214,000 69,823,000	0	70,214,000 31,296,000	0 5,901,700	0 4,534,000	0 18,897,000	0 9,194,300	2 4
	Yes	E9PHT9 P31025	Annexin;Annexin A5 Lipocalin-1:Putative lipocalin 1-like protein 1	ANXA5 LCN1	69,705,000 68,579,000	7,186,600 17,246,000	4,930,200 0	11,971,000 8,715,500	16,361,000 19,543,000	5,489,900 9 898 400	23,766,000 13,176,000	4 2
		P31930	Cytochrome b-c1 complex subunit 1, mitochondrial	UQCRC1	66,759,000	0	7,055,500	32,142,000	9,727,500	17,834,000	0	2
Yes Yes		P22735 Q6ZVX7	Protein-glutamine gamma-glutamyltransferase K F-box only protein 50	TGM1 NCCRP1	66,068,000 65,548,000	9,145,000 18,299,000	8,097,100 1,627,800	11,141,000 13,871,000	12,123,000 10,069,000	8,823,300 9,179,600	16,739,000 12,502,000	2
Yes		Q92637	High affinity immunoglobulin gamma Fc receptor IB	FCGR1B	65,085,000	14,808,000	24,911,000	0	0	0	25,367,000	2
		P31947-2 M0R3F1	14-3-3 protein sigma Heterogeneous nuclear ribonucleoprotein U-like protein 1	SFN HNRNPUL1	65,014,000 64,921,000	0 7,997,300	0 41,310,000	0 15,614,000	0	65,014,000 0	0	4 3
Yes		Q9HAU0-6 Q16822	Pleckstrin homology domain-6 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial	PLEKHA6 PCK2	64,712,000 63,356,000	0	0 63,356,000	0	35,710,000 0	13,996,000 0	15,006,000 0	1 6
Yes		P42765	3-ketoacyl-CoA thiolase, mitochondrial	ACAA2	63,130,000	0	63,130,000	0	0	0	ō	3
Yes Yes		V9GYC1 095954	Apolipoprotein A-II; Proapolipoprotein A-II; Truncated apolipoprotein A-II Formimidoyltransferase-cyclodeaminase	APOA2 FTCD	63,025,000 62,955,000	0	0 62,955,000	0	0	63,025,000 0	0	3
Yes		P01833 H3BUH7	Polymeric immunoglobulin receptor;Secretory component Fructose-bisphosphate aldolase;Fructose-bisphosphate aldolase A	PIGR ALDOA	62,780,000 61,547,000	55,565,000 0	0 30,590,000	7,215,700 0	0	0 30.957.000	0	2
Yes		I3NI03	Protein disulfide-isomerase	P4HB	61,057,000	5,594,500	24,393,000	6,481,000	4,107,900	14,479,000	6,001,800	1
Yes Yes		P04899-4 J3QS36	Guanine nucleotide-binding protein G(i) subunit alpha-2 L-xylulose reductase	GNAI2 DCXR	60,628,000 58,887,000	0	5,045,200 58,887,000	17,245,000 0	6,652,900 0	12,318,000 0	19,367,000 0	3 4
Yes		D6REM4 P01594	Casein kinase I isoform alpha;Casein kinase I isoform alpha-like	CSNK1A1 IGKV1D-33	58,574,000 58,512,000	58,574,000 35,985,000	0 4,295,800	0 2,809,900	0 3,517,000	0 4,290,800	0	1 1
		A0A0A0MSV6	lg kappa chain V-I region AU;Ig kappa chain V-I region AG Complement C1q subcomponent subunit B	C1QB	58,010,000	0	0	58,010,000	0	0	7,612,700 0	2
Yes Yes		P69891 Q5T6W2	Hemoglobin subunit gamma-1 Heterogeneous nuclear ribonucleoprotein K	HBG1 HNRNPK	57,351,000 56,797,000	0	0 9,694,800	20,525,000 10,343,000	11,885,000 0	0 20.754.000	24,940,000 16.006.000	11 1
Yes		Q6P0N6	Dystonin	DST	55,054,000	0	0	0	55,054,000	0	0	1
Yes Yes		P08559-3 P54868	Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial Hydroxymethylglutaryl-CoA synthase, mitochondrial	PDHA1 HMGCS2	54,649,000 54,294,000	0	0 54,294,000	36,915,000 0	17,733,000 0	0	0	2 3
Yes		K7EP41 A0A7I2V5R8	Glucose-6-phosphate isomerase Dipeptidyl peptidase 4 soluble form	GPI DPP4	51,787,000 49,250,000	0 16,947,000	28,093,000 0	0 6,971,900	0	23,693,000 0	0 25,332,000	1 3
Yes		P02745	Complement C1q subcomponent subunit A	C1QA	49,029,000	0	0	26,241,000	7,260,800	0	15,527,000	1
Yes Yes		H7C131 P14550	3-ketoacyl-CoA thiolase, peroxisomal Alcohol dehydrogenase [NADP(+)]	ACAA1 AKR1A1	49,012,000 48,970,000	0	39,040,000 48,970,000	0	0	9,971,800 0	0	2 3
Yes Yes		H7BYH4 075891-2	Superoxide dismutase [Cu-Zn]	SOD1 ALDH1L1	48,641,000 47,334,000	0	36,536,000 47,334,000	0	0	12,105,000	0	1
Yes		P16152	Cytosolic 10-formyltetrahydrofolate dehydrogenase Carbonyl reductase [NADPH] 1	CBR1	46,537,000	Ō	46,537,000	Ō	ō	ō	ō	3
Yes		Q16762 P98082-2	Thiosulfate sulfurtransferase Disabled homolog 2	TST DAB2	46,314,000 46,020,000	0 7,661,800	46,314,000 4,233,100	0 4,780,500	0 11,910,000	0 4,537,100	0 12,898,000	3 1
Yes		A0A2R8Y7L2	Peroxisomal multifunctional enzyme type 2;Enoyl-CoA hydratase 2	HSD17B4	44,462,000	0	44,462,000	0 27.748.000	0	0	0	3
Yes		F5H5P2 P07910	2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial Heterogeneous nuclear ribonucleoproteins C1/C2	BCKDHA HNRNPC	44,336,000 44,199,000	0	0	27,748,000 19,282,000	6,992,100 0	9,596,700 24,917,000	0	2 2
Yes		P01701 Q16610-2	lg lambda chain V-I region NEW Extracellular matrix protein 1	IGLV1-51 ECM1	43,260,000 43,164,000	43,260,000 16,073,000	0	0 4,679,200	0 16,017,000	0	0 6,394,400	1 3
Yes		P80748	Ig lambda chain V-III region LOI	IGLV3-9	39,938,000	39,938,000	Ó	0	0	ō	0	2
Yes Yes		P00480 P06727	Ornithine carbamoyltransferase, mitochondrial Apolipoprotein A-IV	OTC APOA4	38,811,000 38,730,000	0	38,811,000 0	0	0	0 38,730,000	0	3 4
	Yes	A0A3B3ISA6 C9J2I0	Complement C4-A;Complement C4 beta chain Arf-GAP domain and FG repeat-containing protein 1	C4B AGFG1	37,477,000 37,463,000	0	0 19,993,000	0	0 17,470,000	37,477,000 0	0	3 1
Yes		P62081	40S ribosomal protein S7	RPS7	36,563,000	Ō	0	0	0	36,563,000	0	1
Yes Yes		P00505 Q14669	Aspartate aminotransferase, mitochondrial E3 ubiquitin-protein ligase TRIP12	GOT2 TRIP12	36,173,000 35,387,000	0 5,063,600	36,173,000 0	0	0 1,274,500	0 7,478,400	0 21,571,000	1 2
Yes Yes		P00747 A0A5E97HD4	Plasminogen; Plasmin heavy chain A; Activation peptide; Angiostatin	PLG	35,204,000	0	18,546,000 34,864,000	0	0	16,658,000	0	2
Yes		P42357	Acetyl-CoA acetyltransferase, mitochondrial Histidine ammonia-lyase	ACAT1 HAL	34,864,000 34,798,000	3,023,300	5,789,400	4,315,200	4,655,100	0 3,693,900	13,321,000	1
Yes Yes		P08574 A0A7I2V2G2	Cytochrome c1, heme protein, mitochondrial Stress-70 protein, mitochondrial	CYC1 HSPA9	34,705,000 34,422,000	17,970,000 3,644,700	0 30,777,000	0	3,321,100 0	6,646,500 0	6,767,300 0	1 5
Yes		Q13151 Q00266	Heterogeneous nuclear ribonucleoprotein A0 S-adenosylmethionine synthase isoform type-1	HNRNPA0 MAT1A	34,332,000 34,266,000	9,337,700	8,802,000 34,266,000	6,967,600	9,225,100	0	0	1
		B4E1S2	Annexin;Annexin A4	ANXA4	34,107,000	Ō	23,248,000	7,248,900	ō	Ō	3,610,400	2
Yes Yes		E7EN95 Q15149-7	Filamin-B Plectin	FLNB PLEC	33,248,000 32,622,000	0	0	0	0	33,248,000 32,622,000	0	4 5
Yes		Q5T750 P29401	Skin-specific protein 32 Transketolase	XP32 TKT	32,441,000 32,236,000	14,229,000	12,308,000 25,916,000	0	5,905,100 0	0 6,320,100	0	1
Yes		R4GN49	Protein S100-A2	S100A2	32,039,000	0	0	0	0	32,039,000	0	2
Yes Yes		Q14574-2 P07900	Desmocollin-3 Heat shock protein HSP 90-alpha	DSC3 HSP90AA1	31,820,000 31,748,000	0	0	11,287,000 18,987,000	9,170,400 0	0 12,762,000	11,362,000 0	2 7
Yes		K7ESE1	Keratin, type I cytoskeletal 17	KRT17	31,444,000	0	0	0	0	31,444,000	0	6
Yes		H7BZJ3 A0A2R8YGX3	Protein disulfide-isomerase A3 Tropomyosin alpha-4 chain	PDIA3 TPM4	31,218,000 30,416,000	10,969,000 0	0	Ō	0	12,027,000 30,416,000	8,221,900 0	4
Yes		A0A1X7SBZ2 P68133	Probable ATP-dependent RNA helicase DDX17 Actin, alpha skeletal muscle; Actin, aortic smooth muscle	DDX17 ACTA1	30,189,000 28,542,000	11,040,000 0	12,105,000 0	0 22,625,000	0	7,044,500 5,916,600	0	1 11
Yes		P31151	Protein S100-A7	S100A7	28,377,000	16,068,000	Ó	0	3,923,400	5,362,900	3,022,700	1
Yes Yes		O75874 P63104	Isocitrate dehydrogenase [NADP] cytoplasmic 14-3-3 protein zeta/delta	IDH1 YWHAZ	27,456,000 26,529,000	0	27,456,000 0	0 3,983,100	0	0 11,736,000	0 10,810,000	3 3
Yes Yes		A0A7I2V3U0 C9JEH7	Aconitate hydratase, mitochondrial 40S ribosomal protein S4, X isoform	ACO2 RPS4Y1	26,341,000 26,072,000	0 26,072,000	7,668,600 0	3,421,200 0	0	7,748,000 0	7,503,500 0	2 3
Yes		D6RHJ7	Dihydropteridine reductase	QDPR	25,964,000	0	22,627,000	0	0	3,337,100	0	2
Yes	Yes	P21980 I3L1P8	Protein-glutamine gamma-glutamyltransferase 2 Mitochondrial 2-oxoglutarate/malate carrier protein	TGM2 SLC25A11	25,527,000 25,396,000	0	25,527,000 0	0 9,416,800	0	0 5,550,200	0 10,429,000	3 1
Yes Yes		E9PP21 P26641	Cysteine and glycine-rich protein 1 Elongation factor 1-gamma	CSRP1 EEF1G	25,181,000 25,062,000	0 8,120,000	19,963,000	5,218,000 0	0	0 16,942,000	0	1
Yes		Q99497	Protein deglycase DJ-1	PARK7	24,469,000	0	24,469,000	Ō	ō	0	ō	2
Yes		B4DK69 H3BTX9	Aldo-keto reductase family 1 member C2 Acyl-coenzyme A synthetase ACSM2B, mitochondrial	AKR1C2 ACSM2B	23,775,000 23,403,000	0	23,775,000 23,403,000	0	0	0	0	3 2
Yes		P17096 O43548	High mobility group protein HMG-I/HMG-Y	HMGA1 TGM5	23,239,000 22,931,000	0	0	0 5,106,200	0 3,459,400	0 5,197,500	23,239,000 9,168,100	1
Yes		A0A6E1W9L1	Protein-glutamine gamma-glutamyttransferase 5 Zinc finger and BTB domain-containing protein 3	ZBTB3	22,345,000	5,533,200	0	7,473,000	0	5,197,500 9,338,700	0	2
Yes Yes		P07099 A0A7I2YQ74	Epoxide hydrolase 1 UTPglucose-1-phosphate uridylyltransferase	EPHX1 UGP2	21,730,000 21,651,000	0	21,730,000 21,651,000	0	0	0	0	2 3
Yes		P34896-3	Serine hydroxymethyltransferase, cytosolic	SHMT1	21,544,000	0	21,544,000	0	ō	0	0	2
Yes Yes		P51857-2 H0YCY6	3-oxo-5-beta-steroid 4-dehydrogenase Bifunctional ATP-dependent dihydroxyacetone kinase; ATP-dependent	AKR1D1 TKFC	21,175,000 20,829,000	0	21,175,000 20,829,000	0	0	Ō	0	2 3
Yes Yes		F8VPF3 P01019	Myosin light polypeptide 6;Myosin light chain 6B Angiotensinogen;Angiotensin-1;Angiotensin-2;Angiotensin-3;Angiotensin-4	MYL6 AGT	20,561,000 20,374,000	0	0	0	0	20,561,000 20,374,000	0	1 2
			<ul> <li>g</li></ul>		_3,51-7,000	v	v	v	5	,0, 1,000	v	-

	P25325-2 A0A3B3ISY1	3-mercaptopyruvate sulfurtransferase;Sulfurtransferase Tissue factor pathway inhibitor 2	MPST TFPI2	19,789,000 19,686,000	0 8,176,900	19,789,000 0	0	0 8,803,000	0 2,706,500	0
	Q16698-2	2,4-dienoyl-CoA reductase, mitochondrial	DECR1	19,661,000	0,170,300	19,661,000	0	0,000,000	2,700,500	0
	C9JV37	Prothrombin;Activation peptide fragment 1	F2	19,349,000	ō	0	ō	ō	19,349,000	ō
	A0A6Q8PFC6	Glycine amidinotransferase, mitochondrial	GATM	18,900,000	0	18,900,000	0	0	0	-
	A0A075B6H9	Immunoglobulin lambda variable 4-69	IGLV4-69	18,184,000	18,184,000	0	ō	ō	ō	č
	V9GYG0	ADP/ATP translocase 3; ADP/ATP translocase 3, N-terminally processed	SLC25A4	17.956.000	0	ō	6.886.600	4.931.600	ō	6.137.900
	A0A1W2PP35	Heterogeneous nuclear ribonucleoprotein U	HNRNPU	17,783,000	0	0	17,783,000	0	0	(
	E5RGW4	Nucleophosmin	NPM1	17,763,000	0	0	0	0	17,763,000	(
	J3QRN2	Beta-2-glycoprotein 1	APOH	17,755,000	0	8,891,500	Ō	0	0	8,863,30
	E9PRN7	3 beta-hydroxysteroid dehydrogenase/Delta 5>4-isomerase type 2	HSD3B1	17,661,000	0	0	4,061,200	6,881,400	0	6,718,40
	P52758	Ribonuclease UK114	HRSP12	16,603,000	0	16,603,000	0	0	0	
	Q15084-3	Protein disulfide-isomerase A6	PDIA6	16,371,000	0	10,683,000	0	0	5,687,900	
	Q5TF55	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial	ALDH4A1	16,343,000	0	16,343,000	0	0	0	
	H0Y4K8	Fibronectin;Anastellin;Ugl-Y1;Ugl-Y2;Ugl-Y3	FN1	16,129,000	2,290,000	0	7,354,100	0	0	6,485,40
	A0A494C1T2	C-1-tetrahydrofolate synthase, cytoplasmic	MTHFD1	15,674,000	0	15,674,000	0	0	0	
	E7EPM6	Long-chain-fatty-acidCoA ligase 1	ACSL1	15,503,000	0	15,503,000	0	0	0	
	H0YJF9	Dihydrolipoyllysine-residue succinyltransferase/2-oxoglutarate dehydrogen	DLST	14,869,000	0	0	11,035,000	0	3,833,400	
	Q14134-2	Tripartite motif-containing protein 29	TRIM29	14,797,000	0	0	0	0	14,797,000	
	P18206-2	Vinculin	VCL	14,766,000	0	0	0	0	0	14,766,00
Yes	D6R9P3	Heterogeneous nuclear ribonucleoprotein A/B	HNRNPAB	14,544,000	0	0	14,544,000	0	0	
	P10696	Alkaline phosphatase, placental-like;Alkaline phosphatase, placental type	ALPPL2	14,464,000	14,464,000	0	0	0	0	
	H3BRG4	Cytochrome b-c1 complex subunit 2, mitochondrial	UQCRC2	14,346,000	0	14,346,000	0	0	0	
•	C9JRL4	Malate dehydrogenase;Malate dehydrogenase, cytoplasmic	MDH1	14,124,000	0	14,124,000	0	0	0	0 407 50
	P62258	14-3-3 protein epsilon	YWHAE	14,037,000	0	5,850,000	0	0	0	8,187,50
	D6RFG5	Annexin;Annexin A3	ANXA3	13,723,000	0	0	0	0	13,723,000	
	O60701-3	UDP-glucose 6-dehydrogenase	UGDH	13,415,000	0	13,415,000	0	0	0	
	B0YIW2	Apolipoprotein C-III	APOC3	13,244,000	0	0	0	0	13,244,000	
	A0A0G2JQH2	40S ribosomal protein S18	RPS18	13,172,000	0	0	0	0	13,172,000	
	P49189	4-trimethylaminobutyraldehyde dehydrogenase	ALDH9A1	13,161,000	0	13,161,000	0	0	0	
	P11277-3	Spectrin beta chain, erythrocytic	SPTB	13,077,000	0	13,077,000	0	0	0	
	Q9HC84 P46783	Mucin-5B 405 ribosomal protein \$10 Butativo 405 ribosomal protein \$10 liko	MUC5B	12,990,000 12,790.000	0	12,990,000	0	0	0 6,459,400	
	P46783 P04080	40S ribosomal protein S10;Putative 40S ribosomal protein S10-like Cvstatin-B	RPS10 CSTB			6,330,400 0		0	6,459,400 0	
	F6RED5	Cystatin-B Destrin	DSTN	12,717,000 12.619.000	7,164,000 0	0 12,619,000	5,552,700 0	0	0	
	P25786	Proteasome subunit alpha type-1;Proteasome subunit alpha type	PSMA1	12,242,000	0	8,949,000	3,292,900	0	0	
	P16157-14	Ankvrin-1	ANK1	12,242,000	0	12.173.000	3,292,900	0	0	
	A0A087WT59	Transthvretin	TTR	11,910,000	0	12,173,000	0	0	11,910,000	
	F9PK47	Alpha-1,4 glucan phosphorylase;Glycogen phosphorylase, liver form	PYGI	11.862.000	0	11,862,000	0	0	11,310,000	
	P02808	Statherin	STATH	11,823,000	11,823,000	11,002,000	0	0	0	
	P08246	Neutrophil elastase	FLANE	11.630.000	11,023,000	11,630,000	0	0	0	
	P52907	F-actin-capping protein subunit alpha-1	CAPZA1	11,591,000	0	0	0	ő	11,591,000	
	C9JA05	Immunoglobulin J chain	JCHAIN	11,558,000	0	ő	0	ő	11,558,000	
	Q9UG54	Mitogen-activated protein kinase kinase kinase 7	DKFZp586F0420	11,510,000	11,510,000	ő	ő	ŏ	0	
	P45954-2	Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial	ACADSB	11.392.000	0	11 392 000	ŏ	ő	ő	
	B5MD38	Trifunctional enzyme subunit beta, mitochondrial;3-ketoacyl-CoA thiolase	HADHB	11,328,000	ō	11.328.000	ō	ō	ō	
	P25815	Protein S100-P	\$100P	11.215.000	0	0	Ó	0	0	11.215.00
	P02549-2	Spectrin alpha chain, erythrocytic 1	SPTA1	10,654,000	0	10,654,000	0	0	0	
	H0YAG8	Alcohol dehydrogenase class-3	ADH5	10,551,000	0	10,551,000	0	0	0	
	A0A087WW87	Ig kappa chain V-II region FR;Ig kappa chain V-II region Cum	IGKV2-40	10,538,000	0	0	0	0	10,538,000	
	B1AKI5	Muscleblind-like protein 3;Muscleblind-like protein 2	MBNL3	10,394,000	0	10,394,000	0	0	0	
	B1AKQ8	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1	GNB1	10,354,000	0	0	0	0	0	10,354,00
	A0A0J9YXZ5	Ras GTPase-activating-like protein IQGAP1	IQGAP1	10,328,000	0	0	0	0	10,328,000	
	P13716-2	Delta-aminolevulinic acid dehydratase	ALAD	10,259,000	0	10,259,000	0	0	0	
	Q13404-8	Ubiquitin-conjugating enzyme E2 variant 1	UBE2V1	9,964,900	0	9,964,900	0	0	0	
	M0R0Y6	Heterogeneous nuclear ribonucleoprotein M	HNRNPM	9,627,300	0	0	0	0	9,627,300	
	A0A7I2V699	Nucleolin	NCL	9,473,600	0	0	0	0	9,473,600	
	P05387	60S acidic ribosomal protein P2	RPLP2	9,359,400	3,670,500	0	0	0	5,688,900	
	Q06520	Bile salt sulfotransferase	SULT2A1	9,347,800	0	9,347,800	0	0	0	
	P21399	Cytoplasmic aconitate hydratase	ACO1	9,273,300	0	9,273,300	0	0	0	
	P27824-3	Calnexin	CANX	9,232,100	0	0	0	0	9,232,100	
	A0A0C4DGA2	Encyl-CoA delta isomerase 2, mitochondrial	ECI2	9,217,600	0	9,217,600	0	0	0	
	A0A140TA58	Keratin-associated protein 9-9	KRTAP9-9	9,046,100	0	9,046,100	0	0	0	4 770 20
	J3KRG2 E5GZP6	Gasdermin-A	GSDMA PPEIBP1	8,582,300	0	3,803,000	0	0	0	4,779,30
	P32926	Liprin-beta-1 Desmoglein-3	DSG3	8,376,800	8,376,800 0	0	0	0	0 8,254,400	
	A0A0G2JMB2	Ig alpha-2 chain C region	IGHA2	8,254,400 7,976.600	0	7.976.600	0	0	8,254,400	
	M0QY85	Tubulin beta-4A chain;Tubulin beta-4B chain	TUBB4A	7,933,700	0	7,933,700	0	0	0	
	Q14117	Dihydropyrimidinase	DPYS	7,933,700	0	7,933,700	0	0	0	
	E9PE82	Short-chain specific acyl-CoA dehydrogenase, mitochondrial	ACADS	7,313,700	0	7,313,700	0	0	0	
	E3FE02	Selenium-binding protein 1	SELENBP1	6 229 500	0	6 229 500	0	0	0	
	Q13011	Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial	ECH1	5,760,800	0	5,760,800	0	0	0	
	Q9UBG3	Cornulin	CRNN	5 651 400	ő	0,700,000	5 651 400	0	0	
	Q08257-2	Quinone oxidoreductase	CRYZ	5,461,300	0	5,461,300	0,001,400	0	ő	
	P28838-2	Cytosol aminopeptidase	LAP3	5,135,200	0	5,135,200	0	0	0	
	A8MUD9	60S ribosomal protein L7	RPL7	4,984,000	4,984,000	0 0	0	0	0	
	E9PEB5	Far upstream element-binding protein 1	FUBP1	4,984,000	4,984,000	0	4,190,600	0	0	
	P09651	Heterogeneous nuclear ribonucleoprotein A1	HNRNPA1	3,752,800	3,752,800	0	4,190,000	0	0	
	P22314-2	Ubiquitin-like modifier-activating enzyme 1	UBA1	3,748,100	3,752,800	3 748 100	0	0	0	
	Q14032	Bile acid-CoA:amino acid N-acyltransferase	BAAT	3,451,500	0	3,451,500	0	0	ő	
	G3V5K1	Protein transport protein Sec23A	SEC23A	2.912.600	ő	0,401,000	0	ő	2,912,600	(
	H7C4C8	T-complex protein 1 subunit theta	CCT8	2,848,600	ŏ	2,848,600	ő	ŏ	2,012,000	Č

 Table 4

 Proteins identified in PICALM immunoprecipitations.

 Placental extracts U1, R4, Q1, Q4, O1, and N3 were immunoprecipitated in one experiment.

Majority protein ID	Protein	Gene	Total Intensity	Intensity PICALM	Intensity PICALM	Intensity PICALM	Intensity PICALM	Intensity PICALM	Intensity PICALM	Peptides
P01857	Ig gamma-1 chain C region	IGHG1	48 398 000 000	U1	R4 13,091,000,000	<b>Q1</b> 789,180,000	<b>Q4</b> 14,626,000,000	<b>O1</b> 12,977,000,000	N3 6 715 700 000	23
Q13492	Phosphatidylinositol-binding clathrin assembly prote	PICALM	18,858,000,000		5,271,000,000	657,650,000	3,743,800,000			35
P50995-2	Annexin A11	ANXA11	15,851,000,000		4,529,400,000	433,220,000	3,795,300,000	3,270,300,000		37
P20073-2	Annexin A7	ANXA7	9,130,600,000		2,765,200,000	238,940,000	1,535,100,000	2,049,900,000		32
A0A286YES1	Ig gamma-3 chain C region	IGHG3	4,336,300,000	33,112,000	1,106,600,000	53,173,000	927,810,000	812,970,000		20
A0A7I2V378 E7EVS6	Laminin subunit beta-1 Actin, cytoplasmic 1;Actin, cytoplasmic 1, N-termina	LAMB1 ACTB	3,056,100,000 2,600,000,000	0 74,816,000	3,056,100,000 1,747,800,000	0 140,870,000	0 230,680,000	0 217,870,000	0 187,980,000	1 19
P01834	Ig kappa chain C region	IGKC	2,165,500,000	19,359,000	221.050.000	1,391,900,000	195,150,000	232,100,000	105,920,000	9
A0A286YFJ8	Ig gamma-4 chain C region	IGHG4	1,609,600,000	0	218,830,000	22,468,000	138,990,000	428,050,000	801,270,000	17
P0DOY3	Immunoglobulin lambda constant 3	IGLC3	1,591,000,000	2,681,900	60,706,000	741,050,000	302,850,000	240,510,000	243,250,000	9
A0A286YEY1	Ig alpha-1 chain C region	IGHA1	1,335,500,000	23,359,000	584,930,000	130,660,000	252,550,000	139,020,000	204,990,000	14
Q9Y6R7	IgGFc-binding protein	FCGBP	1,098,700,000 1,060,200,000	9,162,000 0	128,730,000	9,654,400	38,684,000	824,150,000 205.020.000	88,293,000 0	30
P01624 P31943	Ig kappa chain V-III region POM Heterogeneous nuclear ribonucleoprotein H;Heterog	IGKV3D-15 HNRNPH1	1,047,700,000	10,293,000	124,770,000 217,040,000	613,850,000 24,254,000	116,590,000 289,540,000	295,340,000	211,190,000	2 11
P08670	Vimentin	VIM	951,490,000	6,378,400	298,510,000	5,089,400	72,211,000	358,520,000	210,780,000	26
H0YEF7	Phosphatidylinositol-binding clathrin assembly prote	PICALM	874,480,000	16,602,000	212,520,000	57,324,000	467,540,000	68,277,000	52,211,000	14
E9PQV5	Coiled-coil domain-containing protein 37	CCDC37	870,490,000	0	0	870,490,000	0	0	0	1
A0A4W8ZXM2	Immunoglobulin heavy variable 3-72	IGHV3-72	808,240,000	44,918,000	282,930,000	12,296,000	137,660,000	204,230,000	126,190,000	3
P05783 P07355	Keratin, type I cytoskeletal 18 Annexin A2;Annexin;Putative annexin A2-like protei	KRT18 ANXA2	760,020,000 742,370,000	0 6,496,700	231,740,000 256,760,000	8,635,500 55,166,000	185,390,000 54,726,000	187,570,000 196,500,000	146,680,000 172,720,000	17 15
P01871	Ig mu chain C region	IGHM		105,950,000	12,770,000	0	95,422,000	155,950,000	352,180,000	18
P31942-2	Heterogeneous nuclear ribonucleoprotein H3	HNRNPH3	681,640,000	0	133,900,000	68,508,000	133,680,000	231,950,000	113,610,000	9
Q8NDC0	MAPK-interacting and spindle-stabilizing protein-like	MAPK1IP1L	497,400,000	15,599,000	39,220,000	243,740,000	59,063,000	32,791,000	106,990,000	1
P51512-2	Matrix metalloproteinase-16	MMP16	429,540,000	0	178,440,000	27,390,000	0	223,720,000	0	1
H0Y8G5	Heterogeneous nuclear ribonucleoprotein D0	HNRNPD	409,120,000	0 5,970,500	31,290,000	27,715,000	95,052,000	151,740,000	103,320,000 110,760,000	5
E7ETU5 Q8WZ42	RNA-binding motif, single-stranded-interacting prote Titin	RBMS1 TTN	391,920,000 387,820,000	5,970,500	68,667,000 0	17,784,000 0	143,760,000 75,928,000	44,979,000 210,050,000	101,840,000	7 1
P02675	Fibrinogen beta chain; Fibrinopeptide B; Fibrinogen b	FGB	348,580,000	0	343,520,000	2,249,600	0,020,000	210,000,000	2,806,500	16
A0A0D9SF16	Methyl-CpG-binding domain protein 5	MBD5	346,080,000	0	0	0	346,080,000	0	0	1
O14979-3	Heterogeneous nuclear ribonucleoprotein D-like	HNRNPDL	334,140,000	4,097,000	84,425,000	6,682,100	92,722,000	38,095,000	108,120,000	6
P98082	Disabled homolog 2	DAB2	308,620,000	30,904,000	53,571,000	22,044,000	29,573,000	79,395,000	93,129,000	8
A0A286YEY4 P68871	Ig gamma-2 chain C region Hemoglobin subunit beta;LVV-hemorphin-7;Spinorp	IGHG2 HBB	295,690,000 289,630,000	3,630,700 17,601,000	140,820,000 25,216,000	13,340,000 58,392,000	30,486,000 73,808,000	32,731,000 70,816,000	74,683,000 43,798,000	15 4
P11021	78 kDa glucose-regulated protein	HSPA5	278,720,000	66,634,000	8,224,700	00,392,000	44,577,000	12,509,000	146,770,000	14
P04083	Annexin A1;Annexin	ANXA1	264,550,000	7,343,100	128,430,000	38,085,000	12,426,000	24,473,000	53,792,000	13
P01594	Ig kappa variable 1-33	IGKV1-33	258,450,000	2,181,900	6,309,800	167,650,000	34,900,000	29,177,000	18,233,000	2
O43866	CD5 antigen-like	CD5L	258,210,000	0	64,662,000	0	27,301,000	135,430,000	30,812,000	5
F8VV32	Lysozyme;Lysozyme C	LYZ	201,490,000	13,865,000	0	33,772,000 155,520,000	58,974,000 0	48,689,000	46,193,000 0	3 4
P21980-2 P01615	Protein-glutamine gamma-glutamyltransferase 2 Immunoglobulin kappa varibable 2D-28	TGM2 IGKV2D-28	182,780,000 157,840,000	21,051,000 0	6,206,000 0	56,727,000	2,124,500	1,244,100	97,746,000	4
Q5T749	Keratinocyte proline-rich protein	KPRP	156,670,000	0	14,536,000	42,583,000	12,523,000	41,980,000	45,045,000	8
Q5T7N2	LINE-1 type transposase domain-containing protein	L1TD1	147,570,000	0	33,515,000	51,668,000	0	0	62,386,000	2
A0A6Q8PGK1	Heat shock protein beta-1	HSPB1	140,170,000	5,102,400	5,175,100	116,740,000	0	9,140,400	4,009,100	4
Q02413	Desmoglein-1	DSG1	139,520,000	4,467,600	13,159,000	21,449,000	21,775,000	52,035,000	26,635,000	9
F8VVB9 A0A6Q8PFJ0	Tubulin alpha-1B chain;Tubulin alpha-1A chain;Tubu Prelamin-A/C;Lamin-A/C	TUBA1B LMNA	130,470,000 126,810,000	4,960,800 51,770,000	53,076,000 36,048,000	11,800,000 0	10,998,000 9,173,200	17,150,000 5,398,800	32,482,000 24,420,000	4 7
P69905	Hemoglobin subunit alpha	HBA1	120,580,000	8,819,100	32,928,000	0	19,697,000	31,037,000	28,103,000	3
P02671	Fibrinogen alpha chain;Fibrinopeptide A;Fibrinogen	FGA	119,010,000	5,765,800	89,186,000	13,712,000	0	1,589,500	8,753,800	6
A0A0B4J231	Immunoglobulin lambda-like polypeptide 5;lg lambd	IGLL5	113,780,000	0	823,960	0	51,884,000	45,566,000	15,503,000	7
Q9HAU0-6	Pleckstrin homology domain-6	PLEKHA6	100,890,000	0	9,826,200	91,063,000	0	0	0	1
Q92945	Far upstream element-binding protein 2	KHSRP	96,813,000	25,823,000	0	0	5,257,900	16,437,000	49,295,000	8
R4GNB1	Acyl-CoA synthetase family member 4	AASDH	94,959,000	0	6,802,400	6,567,300	14,507,000	47,725,000	19,358,000	1
C9JEU5	Fibrinogen gamma chain	FGG GAPDH	90,470,000	63,046,000	15,905,000	0	10,380,000	0	1,139,700	7 6
P04406 K7ERX7	Glyceraldehyde-3-phosphate dehydrogenase ATP synthase subunit alpha, mitochondrial	ATP5A1	89,398,000 87,648,000	4,504,400 0	74,117,000 49,222,000	3,593,000 0	1,898,700 0	5,284,800 20,992,000	0 17,434,000	5
E9PPG9	mRNA export factor	RAE1	87,447,000	0	40,222,000	ő	58,237,000	2,416,200	26,794,000	4
P30101	Protein disulfide-isomerase A3	PDIA3	86,682,000	0	34,607,000	0	0	17,446,000	34,628,000	8
K7EQ02	DAZ-associated protein 1	DAZAP1	83,974,000	0	11,234,000	0	42,826,000	23,140,000	6,774,000	2
Q01469	Fatty acid-binding protein, epidermal	FABP5	79,112,000	0	8,010,100	12,771,000	28,053,000	0	30,278,000	1
Q01085 P21397-2	Nucleolysin TIAR;Nucleolysin TIA-1 isoform p40 Amine oxidase [flavin-containing] A;Amine oxidase	TIAL1 MAOA	77,006,000 76,723,000	0	15,592,000 33,332,000	0 0	14,334,000 16,437,000	18,441,000 0	28,639,000 26,954,000	4 4
A6NHN2	Roquin-2	RC3H2	74,367,000	0	00,002,000	50,159,000	10,437,000	8,880,000	15,328,000	1
P14866	Heterogeneous nuclear ribonucleoprotein L	HNRNPL	68,836,000	0	0	0	0	0	68,836,000	7
Q5JPU3	Pyruvate dehydrogenase E1 component subunit alp	PDHA1	66,908,000	0	12,367,000	0	31,262,000	13,254,000	10,024,000	3
Q8IUC1	Keratin-associated protein 11-1	KRTAP11-1	65,493,000	0	18,492,000	28,950,000	0	18,051,000	0	3
Q5JP53	Tubulin beta chain	TUBB	64,164,000 59,976,000	3,856,400 4,759,100	37,532,000	2,310,200	7,223,200	4,449,300 18,719,000	8,792,800	3
C9J2I0 P19474	Arf-GAP domain and FG repeat-containing protein 1 E3 ubiguitin-protein ligase TRIM21	AGFG1 TRIM21	58,811,000	4,759,100	12,457,000 6,681,800	0	0	29,267,000	24,041,000 22,862,000	5
D6R9P3	Heterogeneous nuclear ribonucleoprotein A/B	HNRNPAB	58,548,000	0	7,571,700	2,186,500	9,640,700	28,004,000	11,145,000	4
Q5T1M5	FK506-binding protein 15	FKBP15	58,396,000	11,484,000	0	0	14,598,000	0	32,314,000	4
E9PGY2	Dynein assembly factor 5, axonemal	DNAAF5	56,016,000	0	0	0	20,626,000	25,326,000	10,064,000	1
P63261 Q9NZT1	Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-termina Calmodulin-like protein 5	ACTG1 CALML5	55,103,000 54,136,000	0	29,965,000 7,928,200	6,910,800 10,694,000	6,077,800 0	5,127,100 27,905,000	7,022,400 7,608,500	19 1
C9JZN1	Guanine nucleotide-binding protein G(I)/G(S)/G(T) s	GNB2	53,184,000	0	7,920,200	45,048,000	8,135,900	27,905,000	7,008,500	4
A0A7I2YQK6	60 kDa heat shock protein, mitochondrial	HSPD1	50,218,000	1,514,400	15,195,000	0	15,571,000	6,895,200	11,042,000	3
P31040-2	Succinate dehydrogenase [ubiquinone] flavoprotein	SDHA	49,094,000	0	23,561,000	0	3,205,300	15,958,000	6,369,600	5
A0A7I2V2R3	Heterogeneous nuclear ribonucleoprotein A3	HNRNPA3	48,903,000	0	15,655,000	0	7,296,200	11,237,000	14,714,000	2
Q8IWB6-3	Inactive serine/threonine-protein kinase TEX14	TEX14	48,249,000	0	0	0	0	21,743,000	26,507,000	1
P68371 H0YFX9	Tubulin beta-4B chain;Tubulin beta-4A chain Histone H2A;Histone H2A type 1-J;Histone H2A type	TUBB4B H2AFJ	48,032,000 45,901,000	0 12,453,000	39,150,000 7,861,100	0 20,288,000	4,137,600 0	0	4,744,800 5,298,900	3 1
Q8IUC0	Keratin-associated protein 13-1;Keratin-associated p	KRTAP13-1	44,512,000	12,433,000	7,315,500	7,365,500	0	29,831,000	3,230,300	1
A0A087WVQ6	Clathrin heavy chain;Clathrin heavy chain 1	CLTC	44,504,000	21,103,000	0	0	0	0	23,400,000	3
P63267	Actin, gamma-enteric smooth muscle;Actin, alpha s	ACTG2	44,025,000	0	23,112,000	0	0	8,310,000	12,603,000	12
H7BZJ3	Protein disulfide-isomerase A3	PDIA3	43,257,000	4,680,500	27,448,000	0	0	11,128,000	0	3
A0A0B4J1V1	Ig heavy chain V-III region JON;Ig heavy chain V-III	IGHV3-21	43,147,000	0	9,064,600	2,411,600	0	22,858,000	8,812,900 0	2 1
H7C582 Q9BYR6	Integrator complex subunit 1 Keratin-associated protein 3-3	INTS1 KRTAP3-3	42,661,000 40,458,000	0	0 40,458,000	42,661,000 0	0	0	0	1
Q13151	Heterogeneous nuclear ribonucleoprotein A0	HNRNPA0	39,870,000	0	40,430,000	5,577,800	21,067,000	9,442,300	3,783,300	1
H0Y6B2	Sushi domain-containing protein 1	SUSD1	38,095,000	0	0	22,678,000	8,950,800	6,466,400	0	1
A0A1B0GVP4	Ligand-dependent nuclear receptor corepressor	LCORL	36,335,000	0	16,645,000	0	9,411,000	0	10,278,000	1
P14923	Junction plakoglobin	JUP	35,503,000	0	0	4,915,000	0	21,240,000	9,347,600	6
P01023 A0A7I2V3H3	Alpha-2-macroglobulin Putative elongation factor 1-alpha-like 3;Elongation	A2M EEF1A1	35,281,000 34,691,000	0	0 20,615,000	0	18,291,000 0	0 6,899,500	16,990,000 7,176,500	2 3
I3L0W5	Putative elongation factor 1-alpha-like 3;Elongation 14-3-3 protein epsilon	YWHAE	34,691,000	0	4,124,200	0 16,649,000	3,202,500	4,882,900	5,292,400	3
P02787	Serotransferrin	TF	33,379,000	5,509,000	4,124,200	4,698,000	8,538,800	1,682,500	12,951,000	3
Q08554-2	Desmocollin-1	DSC1	31,458,000	0	0	2,709,100	0	22,304,000	6,444,900	2
E5RGE1	14-3-3 protein zeta/delta	YWHAZ	31,118,000	0	0	31,118,000	0	0	0	2
P06576 P17931	ATP synthase subunit beta, mitochondrial;ATP synt Galectin-3;Galectin	ATP5B LGALS3	31,113,000 30,883,000	0	31,113,000 0	0 30,883,000	0	0	0	3 3
C9JA05	Immunoglobulin J chain	JCHAIN	29,005,000	6,597,900	8,495,000	8,405,600	0	0	5,506,600	1
							-	-		

A0A0G2JRN3	Alpha-1-antitrypsin;Short peptide from AAT	SERPINA1	28,649,000	1,644,400	2,510,900	10.667.000	8,084,300	1,831,300	3,911,300	2
P31025	Lipocalin-1;Putative lipocalin 1-like protein 1	LCN1	28,552,000	0	0	2,845,200	0	6,027,100	19,679,000	2
P07237	Protein disulfide-isomerase	P4HB	28,383,000	0	18,574,000	0	0	4,970,100	4,837,900	3
H0Y5H6	Ubiquitin-associated protein 2-like	UBAP2L	25,709,000	0	0	0	0	8,179,400	17,530,000	1
Q96CBB S4R460	Integrator complex subunit 12 Ig heavy chain V-III region BRO region DOB	INTS12 IGHV30R16-9	25,627,000 24,932,000	0	0 13,396,000	0	0	25,627,000 6,415,600	0 5,120,200	1 3
Q5JTQ6	Alpha-catulin	CTNNAL1	23,896,000	ů 0	10,000,000	17,301,000	0	6,594,900	0,120,200	1
P07910	Heterogeneous nuclear ribonucleoproteins C1/C2	HNRNPC	23,699,000	0	15,502,000	0	8,197,000	0	0	2
E9PEB5	Far upstream element-binding protein 1	FUBP1	23,687,000	0	0	0	0	20,589,000	3,098,200	3
Q07065	Cytoskeleton-associated protein 4	CKAP4	23,211,000	0	10,484,000	0	0	7,232,200	5,495,600	5
Q9UBG3	Cornulin	CRNN IGHV1-18	23,063,000	0	0	23,063,000 0	0	0 8 305 300	6 214 900	3 2
A0A0C4DH31 P04843	Ig heavy chain V-I region V35 Dolichyl-diphosphooligosaccharideprotein glycosyl	RPN1	22,114,000 21,647,000	0	7,494,400 6,872,300	0	2,481,300	8,305,200 3,898,300	6,314,800 8,395,600	2
A0A0G2JIW1	Heat shock 70 kDa protein 1A;Heat shock 70 kDa pr	HSPA1A	21,113,000	1,946,300	16,283,000	0	2,101,000	2,883,300	0,000,000	4
P11142-2	Heat shock cognate 71 kDa protein	HSPA8	20,977,000	14,054,000	0	1,367,200	1,373,400	4,182,300	0	6
Q15365	Poly(rC)-binding protein 1;Poly(rC)-binding protein 3	PCBP1	19,851,000	0	8,243,700	0	0	7,620,100	3,987,300	4
P29401	Transketolase	TKT	19,791,000	2,617,800 0	17,173,000	0	0	0	0	3
P11166 M0R3F1	Solute carrier family 2, facilitated glucose transporte Heterogeneous nuclear ribonucleoprotein U-like pro	SLC2A1 HNRNPUL1	19,512,000 19,055,000	0	19,512,000 0	0	0	0	19,055,000	1 4
P69892	Hemoglobin subunit gamma-2;Hemoglobin subunit g	HBG2	18,869,000	8,500,000	10,370,000	0	0	0	19,000,000	4
A0A7I2V4I6	Heterogeneous nuclear ribonucleoproteins A2/B1	HNRNPA2B1	18,704,000	0	0	0	0	12,162,000	6,541,300	4
A0A5F9ZH78	Arginase-1	ARG1	17,366,000	0	4,850,200	0	0	5,206,700	7,309,200	2
J3KPS3	Fructose-bisphosphate aldolase;Fructose-bisphosph	ALDOA	16,868,000	0	16,868,000	0	0	0	0	3
A0A7I2YQY2 Q9BYQ3	Heterogeneous nuclear ribonucleoprotein A1;Heterc Keratin-associated protein 9-3	HNRNPA1 KRTAP9-3	16,360,000 16,191,000	2,149,600 0	2,573,000 16,191,000	0 0	7,993,500 0	3,644,300 0	0	1 2
Q9BS26	Endoplasmic reticulum resident protein 44	ERP44	16,007,000	0 0	7,136,300	0 0	0	7,435,300	1,435,800	3
P15924-2	Desmoplakin	DSP	15,924,000	0	0	6,126,800	0	9,797,400	0	5
P05109	Protein S100-A8; Protein S100-A8, N-terminally proc	S100A8	15,760,000	828,670	4,227,300	10,704,000	0	0	0	1
E9PMZ8	T-lymphoma invasion and metastasis-inducing prote	TIAM2	15,463,000	0	0	15,463,000	0	0	0	1
P01833 H3BQZ7	Polymeric immunoglobulin receptor;Secretory comp Heterogeneous nuclear ribonucleoprotein U-like pro		15,458,000 15,173,000	0 1,669,300	11,036,000 0	0	0	3,208,000	1,214,700 13,503,000	3 1
P55795	Heterogeneous nuclear ribonucleoprotein U-like pro	HNRNPH2	14,987,000	1,009,300	4,489,200	0	1,825,300	5,079,900	3,592,900	5
A0A0G2JPP1	Keratin-associated protein 4-8	KRTAP4-8	14,521,000	0	14,521,000	0	0	0	0	1
E9PHT9	Annexin;Annexin A5	ANXA5	12,946,000	0	0	12,946,000	0	0	0	2
A0A6Q8PF87	Apoptosis-inducing factor 1, mitochondrial	AIFM1	12,539,000	Ő	12,539,000	0	Ő	0	Ő	1
M0R1R1	Serine/threonine-protein kinase PAK 4	PAK4	12,509,000	0	0	0	0	0	12,509,000	1
P04040	Catalase	CAT	12,392,000	0	3,717,800	1,498,500	0	3,932,900	3,243,300	1
A0A140TA58	Keratin-associated protein 9-9;Keratin-associated pr	KRTAP9-9	12,125,000	0	12,125,000	0	0	0	0	2
A0A0A0MS98 P0DP03	Band 3 anion transport protein Ig heavy chain V-III region CAM;Ig heavy chain V-II	SLC4A1 IGHV3-23	12,063,000 11,962,000	2,108,100 0	0	0	3,363,800 0	0 7,237,200	6,591,400 4,724,800	1 1
P81605	Dermcidin;Survival-promoting peptide;DCD-1	DCD	11,727,000	0	ő	7,387,600	0	4,338,900	4,724,000	2
H0YFA4	Cysteine-rich protein 2	CRIP2	11,648,000	0	0	7,587,800	4,060,200	0	0	2
A0A3B3ITD8	Nuclear pore complex protein Nup98-Nup96;Nuclea	NUP98	11,301,000	0	0	0	11,301,000	0	0	2
P14625	Endoplasmin	HSP90B1	11,207,000	11,207,000	0	0	0	0	0	4
Q96PK6 E7ENL6	RNA-binding protein 14 Collagen alpha-3(VI) chain	RBM14 COL6A3	11,150,000 10,671,000	0 10,671,000	0	0	7,074,900 0	0	4,075,400	1 3
F8WBE5	Transferrin receptor protein 1;Transferrin receptor p	TFRC	10,642,000	3,853,100	0	0	0	0	6,788,600	1
A0A0G2JMB2	Ig alpha-2 chain C region	IGHA2	10,360,000	0	5,177,500	0	0	2,870,900	2,311,700	9
A0A7I2YQJ0	Transitional endoplasmic reticulum ATPase	VCP	10,078,000	10,078,000	0	0	0	0	0	2
B3KVK2	Guanine nucleotide-binding protein G(I)/G(S)/G(T) s	GNB1	9,941,900	0	0	6,870,800	0	3,071,100	0	1
Q9BYR3 P52597	Keratin-associated protein 4-4 Heterogeneous nuclear ribonucleoprotein F;Heterog	KRTAP4-4 HNRNPF	9,925,900 9,850,000	0	9,925,900 3,857,200	0	0	0	0 5,992,800	1 3
P01024	Complement C3;Complement C3 beta chain;C3-bet	C3	9,848,400	0	9,848,400	0	0	0	5,992,600	2
P80723-2	Brain acid soluble protein 1	BASP1	9,527,100	0	0	Ō	0	0	9,527,100	2
F8W1T6	RNA-binding motif, single-stranded-interacting prote	RBMS2	9,438,700	0	0	0	0	0	9,438,700	4
P31944	Caspase-14;Caspase-14 subunit p17, mature form;(	CASP14	9,239,700	0	0	5,161,200	0	0	4,078,600	1
P0DP08 H3BU13	Ig heavy chain V-II region NEWM;Ig heavy chain V- Pyruvate kinase;Pyruvate kinase PKM	IGHV4-4 PKM	9,180,400 9,106,300	0	0 9,106,300	0	0	5,589,100 0	3,591,300 0	1 1
F8WEU2	ATP-dependent 6-phosphofructokinase, liver type	PFKL	9,083,300	9,083,300	9,100,300	0	0	0	0	1
A0A0C4DH25	Immunoglobulin kappa variable 3D-20	IGKV3D-20	8,934,800	0	0	0	0	0	8,934,800	1
P52907	F-actin-capping protein subunit alpha-1	CAPZA1	8,912,600	0	8,912,600	0	0	0	0	1
I3L1P8	Mitochondrial 2-oxoglutarate/malate carrier protein	SLC25A11	8,767,800	0	0	8,767,800	0	0	0	1
B4E3S0 F8W6D9	Coronin;Coronin-1C Sentrin-specific protease 6	CORO1C SENP6	8,702,200 8,679,600	0	4,567,500 0	0 0	0	4,134,700 0	0 8,679,600	1 2
P36957-2	Dihydrolipoyllysine-residue succinyltransferase com	DLST	8,276,700	0	5,934,900	0	0	0	2,341,800	1
P31930	Cytochrome b-c1 complex subunit 1, mitochondrial	UQCRC1	8,234,200	Ő	3,957,100	õ	Ő	0	4,277,000	2
P02808	Statherin	STATH	8,064,100	0	0	8,064,100	0	0	0	1
P16403	Histone H1.2;Histone H1.3	HIST1H1C	7,889,100	0	2,483,600	5,405,500	0	0	0	3
K7EMF8	Very long-chain specific acyl-CoA dehydrogenase, r	ACADVL	7,844,000	0	7,844,000	0	0	0	0	1
C9JP00 A0A6I8PIN8	Muscleblind-like protein 1 F-actin-capping protein subunit beta	MBNL1 CAPZB	7,830,800 7,662,300	0	0 0	0 6,785,600	0	2,369,000 876,710	5,461,800 0	1 1
095205	Muscleblind-like protein 2	MBLL	7,485,300	ů 0	Ő	0,700,000	0	1,647,200	5,838,000	1
A0A590UK99	Deleted in malignant brain tumors 1 protein	DMBT1	7,481,500	1,749,100	0	0	3,277,000	0	2,455,300	1
P01766	Ig heavy chain V-III region BRO	IGHV3-13	6,767,800	0	0	0	0	4,376,000	2,391,900	2
J3KSH9 P55268	Integrin beta-4	ITGB4	6,700,000	0	0	0	0	0	6,700,000	1
P55268 P47929	Laminin subunit beta-2 Galectin-7	LAMB2 LGALS7	6,456,200 6,362,600	6,456,200 0	0	0 1,822,500	0	0	0 4,540,100	2 1
E9PFG7	2-oxoglutarate dehydrogenase, mitochondrial	OGDH	6,288,400	6,288,400	0	1,822,500	0	0	4,540,100	1
E5RK69	Annexin;Annexin A6	ANXA6	6,072,900	0	0	0	0	0	6,072,900	2
E7EQB2	Lactotransferrin;Lactoferricin-H;Kaliocin-1;Lactoferre	LTF	6,032,800	0	3,762,400	2,270,400	0	0	0	3
E9PRN7	3 beta-hydroxysteroid dehydrogenase/Delta 5>4-is	HSD3B1	5,960,500	0	5,960,500	0	0	0	0	1
P17661 A0A087X0S5	Desmin Collagen alpha-1(VI) chain	DES COL6A1	5,939,400 5,903,600	0 5,903,600	5,939,400 0	0 0	0	0	0	5 2
P0DP09	Immunoglobulin kappa variable 1-13	IGKV1D-13	5,730,000	0	0	5,730,000	0	0	0	1
P62805	Histone H4	HIST1H4A	5,728,200	0	2,222,200	0	0	3,506,000	0	2
Q8WVV4	Protein POF1B	POF1B	5,534,300	0	0	0	0	5,534,300	0	1
A0A1W2PP22	Heterogeneous nuclear ribonucleoprotein U	HNRNPU	5,391,800	0	0	0	0	0	5,391,800	1
Q9BW30 P08572	Tubulin polymerization-promoting protein family me Collagen alpha-2(IV) chain;Canstatin	TPPP3 COL4A2	5,092,600 5,034,400	5,092,600 5,034,400	0 0	0	0	0	0	1 1
A0A075B6K5	Ig lambda chain V-III region LOI	IGLV3-9	5,034,400	5,034,400 0	0	2,660,600	0	0	2,364,600	1
H0YJL6	Ena/VASP-like protein	EVL	4,998,300	0	Ő	4,998,300	Ő	Ő	2,001,000	1
P59666	Neutrophil defensin 3;HP 3-56;Neutrophil defensin 2	DEFA3	4,545,800	0	0	0	0	4,545,800	0	1
Q9NQP5	Coagulation factor XIII A chain	F13A1	4,473,400	4,473,400	0	0	0	0	0	2
E9PS23 B4DU11	Cofilin-1 Estradiol 17-beta-dehydrogenase 1	CFL1 HSD17B1	4,289,600 4,274,500	0	2,251,300 2,367,500	0 1,907,000	2,038,300	0	0	2 1
C9J9S3	Estradioi 17-beta-denydrogenase 1 Serine/threonine-protein phosphatase;Serine/threon	PPP1CB	4,274,500 4,214,000	0	2,367,500	1,907,000	0	0	2,297,500	1
C9JHS9	Vigilin	HDLBP	4,198,300	0	0	1,910,400	1,536,900	0	2,297,300	1
P05187	Alkaline phosphatase, placental type;Alkaline phosp	ALPP	4,169,700	0	0	0	0	0	4,169,700	2
F8WEW2	Actin-related protein 3	ACTR3	4,132,700	0	4,132,700	0	0	0	0	1
Q9ULV0	Unconventional myosin-Vb	MYO5B	4,073,000	2,220,100	0	0	1,853,000	0	2 756 400	2
J3QSA3 B8ZZ51	Ubiquitin-40S ribosomal protein S27a;Ubiquitin;40S Malate dehydrogenase, cytoplasmic	UBB MDH1	4,045,100 4,029,700	1,288,700 0	0	0 4,029,700	0	0	2,756,400 0	1 1
E9PQ34	Serpin H1	SERPINH1	4,029,700	0	4,018,600	4,029,700	0	0	0	1
13L245	Nuclear pore complex protein Nup88	NUP88	3,921,000	0	0	Ő	0	0	3,921,000	1
Q13263-2	Transcription intermediary factor 1-beta	TRIM28	3,569,200	3,569,200	0	0	0	0	0	1
Q9HD89	Resistin	RETN	3,487,400	0	0	2,254,600	0	1,232,800	0	1
Q9GZM7-3	Tubulointerstitial nephritis antigen-like	TINAGL1	3,481,600	0	3,481,600	0	0	0	0	1

P27824-3	Calnexin	CANX	3,444,400	0	0	0	0	0	3,444,400	1
A0A3B3ISA6	Complement C4-A;Complement C4 beta chain;Com	C4B	3,381,500	0	0	0	0	0	3,381,500	1
A6NCI4-3	von Willebrand factor A domain-containing protein 3	VWA3A	3,185,200	0	0	0	3,185,200	0	0	1
Q8WV48-5	Coiled-coil domain-containing protein 107	CCDC107	3,057,000	0	0	3,057,000	0	0	0	1
Q00013-2	55 kDa erythrocyte membrane protein	MPP1	2,911,300	0	2,911,300	0	0	0	0	1
Q14677	Clathrin interactor 1	CLINT1	2,901,400	0	0	0	0	2,901,400	0	1
A6NHR2	39S ribosomal protein L37, mitochondrial	MRPL37	2,898,500	0	0	0	0	2,898,500	0	1
P82663-3	8S ribosomal protein S25, mitochondrial	MRPS25	2,580,800	0	0	0	0	0	2,580,800	1
H7C4C8	T-complex protein 1 subunit theta	CCT8	2,560,000	0	2,560,000	0	0	0	0	1
P16401	Histone H1.5	HIST1H1B	2,527,600	0	0	2,527,600	0	0	0	1
A0A3B3ITI4	Stress-70 protein, mitochondrial	HSPA9	2,413,000	2,413,000	0	0	0	0	0	1
Q8TE68	Epidermal growth factor receptor kinase substrate 8	EPS8L1	2,165,700	2,165,700	0	0	0	0	0	1
Q8TDL5	BPI fold-containing family B member 1	BPIFB1	2,146,600	0	0	0	0	1,170,700	975,880	1
P31146	Coronin-1A	CORO1A	2,123,800	0	0	0	0	2,123,800	0	1
E9PSE0	MAP kinase-interacting S/T-protein kinase 1	MKNK1	1,976,500	0	0	0	1,976,500	0	0	1
A0A1X7SBZ2	Probable ATP-dependent RNA helicase DDX17	DDX17	1,903,300	0	0	0	1,903,300	0	0	1
M0R1B5	Acetolactate synthase-like protein	ILVBL	1,702,000	0	1,702,000	0	0	0	0	1
M0QX10	Nuclear pore glycoprotein p62	NUP62	1,380,100	0	0	0	0	0	1,380,100	1
P09525-2	Annexin A4	ANXA4	1,341,500	0	0	1,341,500	0	0	0	1
O15400-2	Syntaxin-7	STX7	1,329,200	1,329,200	0	0	0	0	0	1
H3BS21	Haptoglobin;Haptoglobin alpha chain;Haptoglobin b	HP	1,311,500	0	1,311,500	0	0	0	0	2
U3KQK0	Histone H2B;Histone H2B type 1-L;Histone H2B typ	HIST1H2BN	1,266,700	0	1,266,700	0	0	0	0	1
K7EJ44	Profilin-1	PFN1	1,249,400	0	0	0	0	1,249,400	0	1
K7EK06	PhenylalaninetRNA ligase alpha subunit	FARSA	1,246,700	0	1,246,700	0	0	0	0	1
P10412	Histone H1.4	HIST1H1E	1,033,200	0	0	1,033,200	0	0	0	3
A0A087WUX6	Proteasomal ubiquitin receptor ADRM1	ADRM1	993,900	0	993,900	0	0	0	0	1
B1AUU8	Epidermal growth factor receptor substrate 15	EPS15	797,470	797,470	0	0	0	0	0	1
O76041	Nebulette	NEBL	651,720	0	0	0	0	0	651,720	1

Table 5 Protein levels of MDMX (A), PICALM (B), OT-R (C) and V1aR (D) in 44 placental extracts. MDIXX and PICALM values are relative to extract D1, and OT-R and V1aR values relative to sample V1. Replicate and mean values are shown.

Patient				% of Q1				MEAN
H1		128.4	116.9	116.5	78.2	116.9	141.1	116.3
H2			19.1	60.8	32.5	18.9	16.0	29.5
H3			8.3	9.0	26.3	17.4	4.2	13.0
1-1		128.8	209.0	114.6	222.2	102.8	146.1	153.9
1-2				57.1	75.4	106.7	51.6	72.7
1-3		123.6	72.5	77.1	84.1	37.8	71.7	77.8
1-4	136.6	88.3	135.7	81.5	58.6	133.1	103.0	94.1
J-1					118.1	130.2	119.1	122.5
J-2					92.9	56.5	58.9	69.5
J-3					84.0	60.8	66.2	70.3
L1			46.6	61.1	72.0	35.8	41.9	51.5
L2					46.3	55.2	31.0	44.2
L3					72.1	69.1	47.5	62.9
L4				11.9	23.9	16.2	8.9	16.3
M1				57.2	57.5	29.7	62.4	51.7
M3						76.8	37.2	57.0
M4				60.1	40.8	42.1	68.7	52.9
N1		60.1	40.8	42.1	68.7	101.6	101.6	115.5
N2		10.2	31.0	45.5	58.0	58.2	6.6	34.9
N3			75.3	167.8	85.8	80.4	68.0	95.5
N4				55.9	52.5	60.4	48.7	54.4
01			57.5	34.5	46.1	101.6	49.8	57.9
02				78.4	82.8	34.4	85.6	70.3
03		77.3	58.3	22.3	42.5	11.0	8.6	36.7
04			72.9	24.9	34.5	25.4	111.4	53.8
O5					244.4	229.0	145.1	206.1
07					167.2	179.6	163.3	170.0
Q1	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Q2		199.7	169.8	211.0	205.4	156.5	144.9	181.2
Q3		90.9	90.1	76.0	75.8	74.2	88.5	82.6
Q4		50.5	86.2	28.6	45.5	62.7	31.5	50.8
R3		28.2	99.6	57.5	20.0	60.2	77.0	54.5
R4			126.7	116.9	93.8	58.6	109.0	101.3
R5					33.6	79.8	48.8	54.1
S1					207.4	128.9	151.4	162.6
S2					202.5	107.1	110.4	140.0
T1				124.8	161.9	155.5	124.5	141.7
T2					115.0	91.3	82.9	96.4
U1					119.7	87.7	103.7	103.7
U2					163.0	175.0	122.9	153.6
V1					75.4	71.1	21.0	55.9
V2					92.8	72.9	99.0	88.2
W1		1		1	99.2	72.4 197.7	84.0	85.2

Patient				% of Q1				MEAN
H1					21.3	31.8	34.7	29.3
H2					32.8	31.2	55.6	39.9
H3				126.3	114.0	164.0	120.6	131.2
1.1				120.0	114.0	59.9	77.3	68.6
1.2						64.9	78.8	71.8
1.3					31.5	28.4	10.5	23.4
1-4			15.7	14.2	2.0	7.1	2.9	84
J-1	85.4	122.8	105.8	72.0	126.2	127.1	103.0	106.0
J-2				30.9	21.9	21.6	41.0	28.8
J-3			93.6	118.5	113.6	166.7	101.5	118.8
L1				95.2	122.6	227.4	127.2	143.1
L2					60.2	58.9	91.8	70.3
L3				100.2	102.2	142.1	94.5	109.7
L4					77.4	92.1	115.4	95.0
M1				167.9	156.1	131.4	159.8	153.8
M3					4.6	4.3	4.2	4.4
M4					106.1	78.3	104.0	96.1
N1					42.5	34.5	80.1	52.4
N2				50.7	49.6	87.1	62.5	62.5
N3					72.7	69.7	77.3	73.2
N4				45.2	42.4	43.5	51.3	45.6
01				41.5	43.8	35.3	11.4	33.0
02				96.6	42.9	109.5	117.3	91.6
03				53.7	66.5	45.6	151.3	79.3
04				157.1	63.8	54.9	188.3	116.0
05						153.7	134.3	144.0
07						142.0	216.5	179.2
Q1	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Q2			166.3	186.0	176.6	138.0	140.5	161.5
Q3					115.3	138.5	138.3	130.7
Q4						198.8	188.6	193.7
R3					95.8	208.0	244.3	182.7
R4					83.7	64.9	42.0	63.5
R5 S1				150.9	115.3	205.3 97.3	274.9	240.1 137.6
S1 S2				150.9	115.3	97.3	186.9 216.2	206.0
52 T1				192.9	101.9			206.0
11 T2				226.5	181.1	173.3	169.2 219.4	171.3
U1				220.0	101.1	165.3	219.4	169.5
U2					104.2	165.3	217.6	162.3
V1					119.8	207.3	218.0	214.1
V1 V2					225.3	207.3	251.0	214.1 230.4
V2 W1				129.3	225.3	215.0	251.0	230.4
W2				149.3	125.9	125.7	152.0	145.4

Patient			***	T-R fV1			MEAN
H1		-		31.9	32.6	34.9	33.1
H2				44.6	47.5	54.3	48.8
H2 H3			52.7	53.5	66.5	64.1	40.0
1-1			32.1	45.9	44.5	43.4	44.6
1.2	56.0	64.8	43.0	40.5	51.5	35.1	44.0
1-2	36.0	04.0	43.3	40.3	29.3	32.2	36.9
1-4			43.3	24.3	25.3	18.2	22.3
J-1			78.0	66.2	80.9	83.8	77.2
.1.2			78.0	64.8	55.1	44.8	54.9
J-3		74.2	64.0	62.4	73.1	87.1	72.2
L1		1.4.5	04.0	02.4	85.6	77.4	81.5
L2			84.2	80.5	86.5	93.2	86.1
L3			77.8	72.1	61.6	81.6	73.3
14			79.0	70.5	82.2	82.3	78.5
M1				43.2	37.9	41.8	41.0
M3			22.0	22.3	21.1	18.9	21.1
M4			22.0	57.8	42.3	45.7	48.6
N1			73.6	61.4	84.1	88.0	76.8
N2				75.7	80.6	78.6	78.3
N3				102.2	95.9	108.0	102.0
N4			56.3	55.7	76.5	55.9	61.1
01			40.0	61.6	46.1	43.1	47.7
02				81.7	85.7	90.1	85.8
03			67.0	77.0	90.8	93.7	82.1
04		80.5	81.2	84.9	93.8	97.9	87.7
05			100.2	85.9	89.7	95.0	92.7
07				67.1	71.1	79.1	72.4
Q1			83.6	76.2	85.0	99.4	86.1
Q2			93.4	102.4	103.9	119.0	104.7
Q3	69.1	65.4	91.4	67.6	71.4	74.1	73.2
Q4	_			77.3	70.4	82.6	76.8
R3	_			117.8	101.2	107.9	109.0
R4	_		87.2	75.4	84.6	97.8	86.2
R5	_		80.3	79.4	83.4	122.1	91.3
S1	_		108.7	99.1	116.1	118.3	110.6
S2		102.9	89.2	116.9	119.2	116.5	108.9
T1		120.1	104.1	113.7	129.4	119.7	117.4
T2			118.7	112.9	127.8	122.0	120.4
U1		84.5	66.8	75.1	126.9	103.6	91.4
U2			107.0	101.2	117.9	112.0	109.5
V1	100.0	100.0	100.0	100.0	100.0	100.0	100.0
V2		111.0	100.6	104.7	117.9	114.4	109.7
W1			102.0	113.8	121.5	118.2	113.9

D							
Patient				1aR fV1			MEAN
H1		-	740		27.0	46.7	36.9
H2				51.5	62.7	70.4	61.5
H3				01.0	73.0	73.8	73.4
1-1				77.8	61.7	72.6	70.7
1-2				11.0	51.4	56.5	53.9
1-3					58.5	69.7	64.1
1-4					56.4	67.2	61.8
J-1			41.2	43.3	54.9	67.6	51.7
J-2					55.3	42.6	48.9
J-3				56.8	61.7	75.2	64.5
L1			43.6	57.5	63.6	67.0	57.9
L2				80.4	76.0	91.4	82.6
L3				87.9	87.8	98.6	91.5
L4				87.2	68.3	75.9	77.1
M1				76.4	90.0	87.7	84.7
M3				118.5	80.7	108.1	102.4
M4			43.9	60.7	66.4	63.1	58.5
N1				67.4	79.6	76.5	74.5
N2			65.5	58.4	72.5	81.7	69.5
N3				71.8	70.9	85.2	75.9
N4		30.3	16.9	46.6	46.1	31.8	34.3
01				83.8	60.3	76.4	73.5
02				75.0	72.3	77.4	74.9
03				74.5	72.2	79.3	75.3
04				69.9	51.4	70.2	63.8
05		49.8	93.2	68.2	85.9	73.6	74.2
07				83.8	73.3	88.3	81.8
Q1			98.8	62.7	98.3	79.8	84.9
Q2 Q3		91.1	77.3	102.2	99.7	100.8	94.2
Q3 Q4	68.5	60.6	96.9	71.5	62.4 73.7	66.2 82.9	66.7
Q4 R3	68.5	33.1	96.9	76.0	51.4	74.6	76.7
R3 R4		33.1	98.1	74.7 81.9	92.3	103.7	94.0
R5			96.1	42.8	92.3	68.6	62.7
ко S1			00.0	42.8	105.6	93.2	98.0
\$2				78.4	86.0	99.7	88.0
32 T1		129.5	91.3	102.2	77.7	100.1	100.2
T2		69.6	73.3	93.1	84.7	95.1	83.2
U1			63.1	51.1	77.3	65.0	64.1
U2				78.1	79.5	87.6	81.7
V1	100.0	100.0	100.0	100.0	100.0	100.0	100.0
V2				93.0	98.1	107.1	99.4
W1			105.0	94.9	91.2	92.2	95.8
W2		111.0	62.2	103.1	99.2	75.4	90.2

#### Table 6

### Regression coefficients from univariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

	Regression	
Covariate	Coefficient (95% CI)	P-value
Age	1.94 (-0.79, 4.67)	0.17
Gravidity	9.66 (3.59, 15.70)	3x10 <sup>-3</sup>
Gestational Age	-1.79 (-12.40, 8.86)	0.74
Body Mass Index in Labor and Delivery		
Suite	0.97 (-0.18, 2.13)	0.11
Race		
White	(REF)	
Black	22.20 (-14.85, 59.26)	0.24
Asian	-32.49 (-133.62, 68.64)	0.53
Unknown	-3.74 (-77.21, 69.73)	0.92
Hispanic	-0.66 (-37.72, 36.39)	0.97
Preeclampsia		
No	(REF)	-
Yes	-44.13 (-71.63, -16.64)	3x10 <sup>-3</sup>
Diabetes		
No	(REF)	
Туре II	47.63 (14.27, 90.00)	8x10 <sup>-3</sup>
GDM	47.91 (5.51, 90.32)	0.03
Mode of Delivery		
SVD	(REF)	-
CD prior to onset of Labor	56.16 (24.13, 88.18)	1x10 <sup>-3</sup>
CD after onset of Labor	34.80 (-4.46, 74.07)	0.09
VBAC	5.55 (-85.70, 96.79)	0.91
Neonate Sex		
Female	(REF)	
Male	5.04 (-24.35, 34.43)	0.74
Neonatal Weight (g)	0.03 (0.01, 0.06)	3x10 <sup>-3</sup>

#### Table 7

### Regression coefficients from univariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

Covariate	Regression Coefficient (95% CI)	P-value
Age	3.68 (0.28, 7.08)	0.04
Gravidity	7.64 (-0.68, 15.95)	0.08
Gestational Age	6.88 (-6.62, 20.37)	0.32
Body Mass Index in Labor and Delivery		
Suite	2.06 (0.66, 3.45)	6x10 <sup>-3</sup>
Race		
White	(REF)	
Black	17.33 (-24.11, 60.77)	0.44
Asian	17.49 (-101.07, 136.05)	0.77
Unknown	-75.81 (-161.94, 10.32)	0.09
Hispanic	-46.39 (-89.82, -2.95)	0.04
Preeclampsia		
No	(REF)	
Yes	-35.60 (-73.25, 2.04)	0.07
Diabetes		
No	(REF)	
Type II	23.28 (-23.57, 70.13)	0.34
GDM	38.05 (-21.50, 97.60)	0.22
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	59.96 (19.24, 100.68)	6x10 <sup>-3</sup>
CD after onset of Labor	5.69 (-44.23, 55.62)	0.82
VBAC	-50.27 (-166.29, 65.75)	0.40
Neonate Sex		
Female	(REF)	
Male	19.10 (-18.16, 56.37)	0.32
Neonatal Weight (g)	0.03 (7x10 <sup>-7</sup> , 0.06)	0.06

### Table 8

### Regression coefficients from univariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

Covariate	Regression	P-value
	Coefficient (95% CI)	
Age	1.56 (0.13, 2.99)	0.04
Gravidity	1.02 (-2.60, 4.64)	0.58
Gestational Age	1.73 (-4.00, 7.45)	0.56
Body Mass Index in Labor and Delivery		
Suite	0.55 (-0.07, 1.17)	0.09
Race		
White	REF	REF
Black	-10.77 (-30.15, 8.61)	0.28
Asian	-6.04 (-58.92, 46.85)	0.82
Unknown	-27.94 (-66.36, 10.49)	0.16
Hispanic	-19.53 (-38.90, -0.15)	0.06
Preeclampsia		
No	REF	REF
Yes	-15.28 (-31.12, 0.54)	0.07
Diabetes		
No	REF	REF
Туре 2	24.16 (5.47, 42.85)	0.02
GDM	15.32 (-8.44, 39.07)	0.21
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	21.82 (4.09, 39.55)	0.02
CD after onset of Labor	0.55 (-21.19, 22.29)	0.96
VBAC	-19.308 (-69.60, 31.44)	0.46
Neonatal Sex		
Female	REF	REF
Male	8.56 (-7.11, 24.23)	0.29
Neonatal Weight (g)	0.01 (8.36x10 <sup>-4</sup> , 0.03)	0.04

#### Table 9

# Regression coefficients from univariable analysis of V1aR protein band intensity (relative to internal reference individual T1)

	,	
Covariate	Regression Coefficient (95% CI)	P-value
Age	0.63 (-0.30, 1.56)	0.19
Gravidity	1.84 (-0.38, 4.07)	0.11
Gestational Age	-0.72 (-4.34, 2.90)	0.70
Body Mass Index in Labor and Delivery		
Suite	0.20 (-0.20, 0.60)	0.34
Race		
White	REF	REF
Black	7.77 (-4.51, 20.04)	0.22
Asian	-15.55 (-49.05, 17.94)	0.37
Unknown	-13.74 (-38.07, 10.60)	0.28
Hispanic	-0.24 (-12.52, 12.03)	0.97
Preeclampsia		
No	REF	REF
Yes	-5.17 (-15.46, 5.12)	0.33
Diabetes		
No	REF	REF
Туре 2	11.84 (-0.34, 24.03)	0.06
GDM	7.67 (-7.82, 23.16)	0.34
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	20.36 (10.58, 30.13)	6x10 <sup>-3</sup>
CD after onset of Labor	-1.05 (-13.04, 10.93)	0.86
VBAC	-9.60 (-18.26, 37.44)	0.50
Neonatal Sex		
Female	REF	REF
Male	-4.53 (-14.46, 5.40)	0.38
Neonatal Weight (g)	5x10 <sup>-3</sup> (-3.00x 10 <sup>-3</sup> , 0.013)	0.23

#### Table 10

### Regression coefficients from multivariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

Covariate	Regression Coefficient (95% CI)	P-value
Gravidity	7.19 (1.24, 13.14)	0.02
Preeclampsia		
No	(REF)	
Yes	-40.61 (-66.18, -15.04)	3x10 <sup>-3</sup>
Diabetes		
No	(REF)	
Туре II	20.10 (-16.80, 57.00)	0.29
GDM	31.20 (-8.81, 71.22)	0.14
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	9.05 (-26.72, 44.83)	0.62
CD after onset of Labor	27.22 (-8.08, 62.52)	0.14
VBAC	-15.92 (-93.98, 62.13)	0.69
Neonatal Weight (g)	0.01 (-0.01, 0.04)	0.37

### Table 11

### Regression coefficients from multivariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

Covariate	Regression Coefficient (95% CI)	P-value
Age	1.73 (-1.64, 5.09)	0.32
Body Mass Index in Labor and Delivery		
Suite	1.35 (-0.07, 2.77)	0.07
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	40.00 (-3.85, 83.85)	0.08
CD after onset of Labor	0.82 (-48.29, 49.93)	0.97
VBAC	-37.87 (-151.23, 75.48)	0.52

### Table 12

### Regression coefficients from multivariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

Covariate	Regression Coefficient (95% CI)	P-value
Age	0.71 (-0.83, 2.35)	0.39
Diabetes		
No	REF	REF
Туре 2	14.0 (-11.14, 37.70)	0.27
GDM	5.64 (-21.43, 32.00)	0.68
Mode of Delivery		
SVD	REF	REF
CD prior to onset of Labor	13.25 (-7.83, 34.33)	0.23
CD after onset of Labor	-1.04 (-23.92, 21.84)	0.93
VBAC	-0.17 (-68.44, 34.32)	0.52
Neonatal Weight (g)	4.05x 10 <sup>-4</sup> (-0.02, 0.02)	0.96

#### Table 13

### Regression coefficients from bootstrapped replicates of univariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

	(95% quantiles of point	Percentage of replicates
Covariate	estimate from bootstrapped	<0.05 (95% quantiles of P-
Covariate	replicates)	value)
	• • •	/
Age	(0.43, 2.90)	1.7% (0.05, 0.77)
Gravidity	(6.82, 12.15)	95.5% (8x10 <sup>-4</sup> , 0.06)
Gestational Age	(-6.88, 1.78)	0% (0.25, 0.97)
Body Mass Index in Labor		
and Delivery Suite	(0.60, 1.50)	12.6% (0.03, 0.34)
Race		
White	(REF)	
Black	(5.10, 39.4)	0.9% (0.07, 0.80)
Asian	(-53.55, -6.43)	0% (0.33, 0.91)
Unknown	(-30.86, 17.09)	0% (0.46, 0.99)
Hispanic	(-19.69, 13.18)	0% (0.32, 0.99)
Preeclampsia		
No	(REF)	
Yes	(-54.91, -28.15)	91.2% (9x10 <sup>-4</sup> , 0.08)
Diabetes		
No	(REF)	
Type II	(24.47, 60.41)	60% (2x10 <sup>-3</sup> , 0.23)
GDM	(24.83, 67.47)	44.8% (7x10 <sup>-3</sup> ,0.30)
Mode of Delivery		
SVD	(REF)	
CD prior to onset of Labor	(38.96, 67.36)	98.6% (5x10 <sup>-4</sup> , 0.04)
CD after onset of Labor	(17.16, 55.75)	15.5% (0.18, 0.46)
VBAC	(-25.22, 55.19)	0% (0.28, 0.99)
Neonate Sex		
Female	(REF)	
Male	(-10.62, 15.81)	0% (0.32, 0.99)
Neonatal Weight (g)	(0.02, 0.05)	85.8% (3x10 <sup>-4</sup> , 0.14)

#### Table 14

### Regression coefficients from bootstrapped replicates of univariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

FICALM protein band intensity (relative to internal reference individual QT)				
	(95% quantiles of point	Percentage of replicates		
Covariate	estimate from	<0.05 (95% quantiles of P-		
	bootstrapped replicates)	value)		
Age	(2.19, 5.17)	41% (7.1x10 <sup>-3</sup> , 0.27)		
Gravidity	(3.42, 11.80)	22% (0.01, 0.46)		
Gestational Age	(1.82, 11.72)	0.1% (0.11, 0.82)		
Body Mass Index in Labor				
and Delivery Suite	(1.41, 2.66)	90% (8x10 <sup>-4</sup> , 0.09)		
Race				
White	(REF)			
Black	(-7.10, 40.07)	0% (0.12, 0.97)		
Asian	(-40.69,111.00)	0% (0.9, 0.99)		
Unknown	(-96.07, -53.30)	2% (0.05, 0.28)		
Hispanic	(-64.85, -29.39)	40% (0.01, 0.24)		
Preeclampsia				
No	(REF)			
Yes	(-52.30, -18.88)	20.3% (0.01, 0.37)		
Diabetes				
No	(REF)			
Туре II	(2.82, 45.52)	0.6% (0.08, 0.91)		
GDM	(23.35, 56.54)	0.6% (0.08, 0.51)		
Mode of Delivery				
SVD	(REF)			
CD prior to onset of Labor	(41.39, 79.89)	88.5% (9x10 <sup>-4</sup> , 0.08)		
CD after onset of Labor	(-17.08, 31.02)	0% (0.26, 0.99)		
VBAC	(-82.60, -27.18)	0% (0.22, 0.67)		
Neonate Sex				
Female	(REF)			
Male	(3.42, 35.19)	0.3% (0.10, 0.84)		
Neonatal Weight (g)	(0.01, 0.05)	35.1% (3x10-3, 0.40)		

#### Table 15

# Regression coefficients from bootstrapped replicates of univariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

OT-K protein band intensity (relative to internal relefence individual 11)				
	(95% quantiles of point	Percentage of replicates		
Covariate	estimate from	<0.05 (95% quantiles of P-		
	bootstrapped replicates)	value)		
Age	(1.17, 2.01)	54.7% (0.01, 0.14)		
Gravidity	(0.15, 2.08)	0% (0.29, 0.93)		
Gestational Age	(-0.00, 3.40)	0% (0.26, 0.96)		
Body Mass Index in Labor				
and Delivery Suite	(0.34, 0.77) 15% (0.02, 0.3			
Race				
White	REF	REF		
Black	(-17.36, -3.71)	0% (0.09, 0.74)		
Asian	(-13.48, 1.09)	0% (0.62, 0.99)		
Unknown	(-33.74, -21.97)	0% (0.10, 0.30)		
Hispanic	(-24.88, -14.18)	32% (0.02, 0.18)		
Preeclampsia				
No	REF	REF		
Yes	(-20.16, -10.62)	24% (0.02, 0.22)		
Diabetes				
No	REF	REF		
Туре 2	(17.21, 31.63)	84% (0.00, 0.10)		
GDM	(8.96, 22.63)	1% (0.07, 0.48)		
Mode of Delivery				
SVD	REF	REF		
CD prior to onset of Labor	(16.54, 27.71)	83% (0.01, 0.09)		
CD after onset of Labor	(-5.28, 6.19)	0% (0.57, 0.99)		
VBAC	(-29.34, -2.46)	0% (0.27, 0.93)		
Neonatal Sex				
Female	REF	REF		
Male	(4.20, 13.13)	0% (0.11, 0.62)		
Neonatal Weight (g)	(0.01, 0.02)	49% (0.01, 0.17)		

#### Table 16

# Regression coefficients from bootstrapped replicates of univariable analysis of V1aR protein band intensity (relative to internal reference individual T1)

viak protein band intensity (relative to internal reference individual 11)				
	(95% quantiles of point	Percentage of replicates		
Covariate	estimate from	<0.05 (95% quantiles of P-		
	bootstrapped replicates)	value)		
Age	(0.17, 1.12)	6% (0.03, 0.74)		
Gravidity	(0.48, 3.04)	14% (0.02, 0.71)		
Gestational Age	(-2.20, 0.98)	0% (0.30, 0.98)		
Body Mass Index in Labor				
and Delivery Suite	(-0.03, 0.43) 2% (0.07, 0.93			
Race				
White	REF	REF		
Black	(1.07, 14.58)	3% (0.04, 0.88)		
Asian	(-32.74, -3.26)	0% (0.09, 0.87)		
Unknown	(-24.28, -1.85)	0% (0.09, 0.89)		
Hispanic	(-7.10, 7.06)	0% (0.26, 0.99)		
Preeclampsia				
No	REF	REF		
Yes	(-11.01, 0.40)	2% (0.07, 0.94)		
Diabetes				
No	REF	REF		
Туре 2	(5.78, 19.09)	23% (9x10 <sup>-3</sup> , 0.41)		
GDM	(-4.01, 18.40)	4% (0.04, 0.95)		
Mode of Delivery				
SVD	REF	REF		
CD prior to onset of Labor	(14.50, 26.60)	100% (4x10 <sup>-5</sup> , 2x10 <sup>-2</sup> )		
CD after onset of Labor	(-7.93, 5.70)	0% (0.26, 0.99)		
VBAC	(-7.09, 23.62)	0% (0.16, 0.97)		
Neonatal Sex				
Female	REF	REF		
Male	(-9.92, 0.86)	0% (0.11, 0.93)		
Neonatal Weight (g)	(1.0x 10 <sup>-3</sup> , 9.0x 10 <sup>-3</sup> )	2% (0.05, 0.82)		

#### Table 17

### Regression coefficients from bootstrapped replicates of multivariable analysis of MDMX protein band intensity (relative to internal reference individual Q1)

(95% quantiles of point	Percentage of replicates
estimate from	<0.05 (95% quantiles of P-
bootstrapped replicates)	value)
(4.17, 9.81)	44% (0.01, 0.28)
REF	
(-54.42, -22.05)	80% (1x10 <sup>-3</sup> , 0.17)
(REF)	
(-7.15, 35.26)	1% (0.10, 0.97)
(7.02, 50.01)	5% (0.04, 0.78)
(REF)	
(-7.87, 27.66)	0% (0.22, 0.98)
(7.62, 49.52)	8% (0.03, 0.69)
(-45.98, 36.55)	0% (0.32, 0.86)
(-0.002, 0.03)	2% (0.07, 0.96)
	estimate from bootstrapped replicates) (4.17, 9.81) REF (-54.42, -22.05) (REF) (-7.15, 35.26) (7.02, 50.01) (REF) (-7.87, 27.66) (7.62, 49.52) (-45.98, 36.55)

#### Table 18

### Regression coefficients from bootstrapped replicates of multivariable analysis of PICALM protein band intensity (relative to internal reference individual Q1)

· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		
Covariate	(95% quantiles of point estimate from	Percentage of replicates <0.05 (95% quantiles of P-	
Cevaliate			
	bootstrapped replicates)	value)	
Age	(0.09, 3.35)	1% (0.07, 0.93)	
Body Mass Index in Labor			
and Delivery Suite	(0.55, 2.11)	26% (0.008, 0.54)	
Mode of Delivery			
SVD	REF		
CD prior to onset of Labor	(17.36, 62.80)	20% (0.02, 0.48)	
CD after onset of Labor	(-23.42, 26.23)	0% (0.31, 0.99)	
VBAC	(-70.17, -12.72)	0% (0.29, 0.84)	

#### Table 19

### Regression coefficients from bootstrapped replicates of multivariable analysis of OT-R protein band intensity (relative to internal reference individual T1)

(95% quantiles of point	Percentage of replicates
estimate from	<0.05 (95% quantiles of P-
bootstrapped replicates)	value)
(0.27, 1.17)	0% (0.17, 0.76)
REF	REF
(6.09, 21.30)	0% (0.10, 0.65)
(-1.66, 14.21)	0% (0.32, 0.99)
REF	REF
(7.33, 19.97)	0% (0.09, 0.51)
(-6.97, 4.89)	0% (0.55, 0.99)
(-27.20, -0.44)	0% (0.32, 0.98)
(-4x 10 <sup>-3</sup> , 5x 10 <sup>-3</sup> )	0% (0.52, 0.99)
	estimate from bootstrapped replicates) (0.27, 1.17) REF (6.09, 21.30) (-1.66, 14.21) REF (7.33, 19.97) (-6.97, 4.89) (-27.20, -0.44)

Table 20

Table 20

Autoantigens listed by Neiman et al. among the proteins in VEGFR2, MDMX, and PICALM immunoprecipitations (IP).

	Uniprot	Gene	Protein name	Autoimmune disease
VEGFR2 IP	P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M)	Sjögren's syndrome
	E7EVS6	ACTB	Actin, cytoplasmic 1 (Beta-actin)	Autoimmune hemolytic anemia
	P07355		Annexin A2 (Annexin II) (Annexin-2)	Antiphospholipid syndrome
	P08758	ANXA5	Annexin A5 (Anchorin CII)	Antiphospholipid syndrome
	P11182	DBT	Lipoamide acyltransferase BCOADC-E2	Primary biliary cholangitis
	P17661	DES	Desmin	Sjögren's syndrome
	P10515	DLAT	PDC-E2	Primary biliary cirrhosis
	Q02413	DSG1	Desmoglein-1	Pemphigus foliaceus
	P19474		E3 ubiquitin-protein ligase TRIM21	Sjögren's syndrome; Systemic Lupus Erythematosus
	Q8WZ42	TTN	Titin	Myasthenia gravis
	P08670	VIM	Vimentin	Rheumatoid arthritis
MDMX IP	P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M)	Sjögren's syndrome
	P68133	ACTA1	Actin, alpha skeletal muscle	Autoimmune hemolytic anemia; myashenia gravis
	P07355	ANXA2	Annexin A2 (Annexin II) (Annexin-2)	Antiphospholipid syndrome
	P08758	ANXA5	Annexin 5	Antiphospholipid syndrome
	P11182	DBT	Lipoamide acyltransferase BCOADC-E2	Primary biliary cirrhosis
	Q6P0N6	DST	Dystonin	Bollous pemphigoid
	P06733	ENO1	α-Enolase	Multiple sclerosis
	P35579	MYH9	Myosin-9	Multiple sclerosis
	P08559	PDHA1	Pyruvate dehydrogenase E1-A type 1	Primary biliary cholangitis
	P21980	TGM2	Isopeptidase TGM2	Celiac's disease
	Q08188	TGM3	Transglutaminase-3	Dermatitis herpetiformis
	P29401	TKT	Transketolase	Multiple sclerosis
	P19474	TRIM21	E3 ubiquitin-protein ligase TRIM21	Sjögren's syndrome; Systemic Lupus Erythematosus
	P18206	VCL	Vinculin	Myasthenia gravis
PICALM IP	P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M)	Sjögren's syndrome
	E7EVS6	ACTB	Actin, cytoplasmic 1 (Beta-actin)	Autoimmune hemolytic anemia
	P63261	ACTG1	Actin, cytoplasmic 2/γ-actin	Autoimmune hemolytic anemia; myashenia gravis
	P63267	ACTG2	Alpha-actin-2	Autoimmune hemolytic anemia; myashenia gravis
	P07355	ANXA2	Annexin A2 (Annexin II) (Annexin-2)	Antiphospholipid syndrome
	P08758	ANXA5	Annexin A5 (Anchorin CII)	Antiphospholipid syndrome
	P17661	DES	Desmin	Sjögren's syndrome
	P36957	DLST	2-oxoglutarate dehydrogenase E2	Pernicuous anemia
	Q08554	DSC1	Desmocollin-1	IgA pemphigus
	Q02413	DSG1	Desmoglein-1	Pemphigus foliaceus
	Q9Y285	FARSA	Phenylalanyl-tRNA synthetase α-subunit	Schizophrenia
	Q02218	OGDH	2-oxoglutarate dehydrogenase E1	Pernicuous anemia
	Q5JPU3	PDHA1	Pyruvate dehydrogenase E1-A type 1	Primary biliary cholangitis
	P21980	TGM2	Isopeptidase TGM2	Celiac's disease
	P29401	ткт	Transketolase	Multiple sclerosis
	P19474		E3 ubiquitin-protein ligase TRIM21	sjögren's syndrome; Systemic Lupus Erythematosus
	Q13263		E3 SUMO-protein ligase TRIM28	Myositis
	Q8WZ42	TTN	Titin	Myasthenia gravis
	P08670	VIM	Vimentin	Rheumatoid arthritis

#### Table 21

Patient demographics

Clinical characteristics	Study subjects (n=44)	% of n
Maternal Age		
18-34	40	91%
≥35	4	9%
BMI		
Underweight (<18.5)	0	0%
Normal (18.5-24.9)	3	7%
Overweight (25-29.9)	9	20%
Obesity I (30-34.9)	12	27%
Obesity II (35-35.9)	5	11%
Extreme Obesity (≥40)	15	34%
Parity		
Nulliparous	11	25%
Multiparous	33	75%
Gestational Age at Delivery		
< 37 weeks	4	9%
≥ 37 weeks	40	91%
Race		
White	17	39%
African American	12	27%
Hispanic	12	27%
Other	3	7%
Diabetes	14	32%
Type 1	0	0%
Туре 2	9	20%
Gestational	5	11%
Chronic Hypertension	6	14%
Normotensive	28	64%
Preeclampsia	16	36%
Preeclampsia and Diabetes	4	9%